書籍詳細

序章

P.2 掲載の参考文献

• 1) 浅野 泰:臨床医学の展望―腎臓病学,日本医事新報4006:6-13,2001

• 2) 高久史麿:21世紀の医学医療,日本人間ドック学会誌15:316.322,2001

• 3) 高久史麿:ポストゲノム時代の生命倫理,最新医学56:98-102,2001

P.6 掲載の参考文献

• 1) Clinical trial data base:JGene Med Feb 1,2001インターネットで利用可(Http://.www.WILEY.co.uk/ genetherapy)

• 2) Gansbacher B et al:Clinical protocol:Apilot study of immunization with interleukin-2 secreting allogenic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma, Human Gene Ther 3:691,1992

• 3) 谷憲三朗:癌に対する遺伝子治療,日外会誌 101:618,2000

• 4) Tstljie M, Isaka Y, Nakamura H et al:Prolonged transgene expression in glomeruliusing an Epstein-Barr virus replicon vector system combined with AVE type HVJ liposome, Kidney Int 59:1390,2001

• 5) Tsujie M, Isaka Y, Nakamura H et al:Electroporation mediated gene transfer targeting glomeruli, J Am Soc Nephrol,12:949, 2001

• 6) Tsujie M, Isaka Y, Ando Y et al:Gene transfer targeting interstitial fibroblasts by the artificial viral envelope-type hemagglutinating virus of Japan liposome method, Kideny Int 57:1973,2000

• 7) Isaka Y, Tsujie M, Ando Y et al:Transforming growth factorβ-1 antisense oligodeoxynucleotides into renal interstitial fibroblasts blocks interstitial fibrosis in unilateral obstruction, Kidney Int 58:1885, 2000

• 8) Isaka, Y, Brees DK, Ikegaya K et al:Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney, Nat Med 2:418,1996
  pubmed

• 9) Isaka Y et al:Gene therapy by transforming growth factor-β-receprtor-IgG Fc chimera inhibited extracellular matrix accumulation in experimental glomerulonephritis, Kidney Int 55:465,1999

• 10) Isaka Y, M Tsujie, Y Kaneda, A Yamauchi, Y Orita, N Ueda, E Imai and M Hori:Gene therapy by TGFbRII/IgGFc chimera manipulated early manifestations in diabetic nephropathy, J Am Soc Nephrol 9:3229A,1998

• 11) Kitamura M et al:Transfer of genetically engineered macrophages into the glomenllus, Kidney Int 51:1274-9,1997
  pubmed

• 12) Kluth DC et al:Macphages transfected with adeno-virus to expres Ilr4 reduce lnflammation ln experimental glomerulonephritis, J Immunol 166:4728, 2001

• 13) Yokoo T et al:Prophylaxis of antibody-induced acute glomerulonephritis With genetically modified bone marrow-derived vehicle cells, Human Gene Ther 10:2673-2678,1999
  pubmed

• 14) Noiri E et al:In vivo targeting of Inducible NO synthase with oligodeoxynucleotides protects rat kidney against Ischemia, J Clin Invest 97:237,1996

• 15) Oberbauer R et al:Renal uptake of an 18-mer phosphorothioate ohgonucleotides, Kidney Int 48:1226, 1995

• 16) Hellar H et al:Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat, Kidney Int 50:473,1996

• 17) Lai L, D Chan, R Erickson, S Hsu and Y Uen:Correction of renal tubular acidosis in carbonic anhydrase II-dencient mice with gene theraphy, J Clin Invest 101:1320-1325,1999

• 18) Verkrnen AS:Lessons on renal physiology from transgenic mice lacking aquaporin water chaimels, J Am Soc Nephrol 10:1126,1999
  pubmed

• 19) Azuma H:Effect of hepatocyte growth factor on chronic rejection in rat renal allografts, Transplant Proc 31:854-5,1999
  pubmed

P.14 掲載の参考文献

• 1) Prochkop DJ:Marrow stromal cells as stem cells for nonhematopoitic tissues, Science 276:697-698, 1999

• 2) Makino S, Fukuda K, Miyoshi S et al:Cardiomyocytes can be generated from marrow stromal cells in vitro, J Clin Invest 103:697-705,1999
  pubmed

• 3) Asahara T, Murohara T, SUIIivan A et al:Isolation of progenitor endothehal cells for angiogenesis, Science 275:964-967,1997

• 4) Saiura A, Sata M, Hirata Y et al:Circulating smooth muscle progenitor cells contribute to atherosclerosis, Nature Med 7:382-383,2001
  pubmed

• 5) Bjorklund A, Svendsen C:Stem cells. Breakng the brain-blood barrier, Nature 397:569,1999
  pubmed

• 6) Ramiya VK, Maraist M, Arfors KE et al:Reversal of insulin-dependent diabetes using islet generated invitro from pancreatic stem cells, Nature Med 6:278-282,2000

• 7) Kanwar YS, Carone FA, Kumar A, Wada J, Ota K, and Wallner EI Role of extracellular matrix, growth factors artd prot-oncogenes in metanephric development, Kidney Int 52:589-606,1997

• 8) Lipschutz M:Molecular development of the kidney:areview of the results of gene disruption studies. Am J Kidney Dis 31(3) :383-397,1998

• 9) Schuchardt A, D'Agati V, Larsson-Blombery L et al:Defects in enteric nervous system of mice lacking the tyrosine kinase receptor Ret, Nature 367:380-383,1994

• 10) Schuchardt A, Pachnis V, Constantini F:Renal agenesis and hypodysplasia in ret-K mutant mice results from defects in ureteric duct development, Development 122:1919-1929,1996

• 11) liu ZZ, Wada J, Kumar A et al:Comparative role of phosphotyrosine knase domains of c-ros and c-ret protooncogenes in metanephric development with respect to growth factors and matrix morphogens, Dev Biol 1178:133-148,1996

• 12) Moore MW, Klein RD, Farinas I et al:Renal and neuronal abnormalities in mice lackng GDNF, Nature 382:76-79,1996

• 13) Pichel JG, Shen L, Sheng HZ et al:Defects in enteric innervation and kidney development in mice lackmg GDNF, Nature 383:73-75,1996

• 14) Rogers SA, Ryan G, Purchio AF et al:Metanepkmc transforming growth factor-β1 regulates nephrogenesis in vitro, Am J Physiol 264:F 996-1002,1993

• 15) Kulkami AB, Karlsson S:Transforming growth factor-β1knockout mice:amutation in one cyto-kmne gene Causes a daramatic inflammatory, Am J Pathol 143:3-9,1993

• 16) Piscione TD, yager TD, Gupta IR et al:BMP-2 and OP-l exert dlirect and opposite effects on renal branching morphogenesis, Am J Physiol 273:F 961-F 975,1997

• 17) Dudley AT, Lyons KM, Robertson EJ:Arequirement for bone morphogenic protein-7 during development of the mammalian kidney and eye, Genes Dev 9:2795-2807,1995

• 18) Luo GC, Hofmann C, Bronckers AL et al:BMP-7 is an inducer of nephrogenesis and is also required fbr eye development and skeletal pattering, Genes Dev 9:2808-2802,1995

• 19) Dum NR, Winnier G, Hargett K et al:Haploinsufficient phenotypes in Bmp4 heterozygous null mice modification by mutations in GU 3 and Alx4, Dev Biol 188:235-247,1997

• 20) Woolf AS, Kolatsi-Joannou M, Hardman P et al:Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros, J Cell Biol l 28:171-184,1995

• 21) Uehara Y, Minowa O, Mori K et al:Placental defect and embryonic lethality in mice lackmg hepatocyte growth factor/scatter factor, Nature 373:702-705, 1995

• 22) Liu ZZ, Kumar A, Wallner EI et al:Trophic effect of insulin-like growth factor-I on metanephric development:relationship to proteoglycans, Eur J Cell Biol 65:378-391,1994
  pubmed

• 23) Wada J, Liu ZZ, Alvares K et al:Cloning of cDNA for the a-subunit of mouse insulin-like growth factor I receptor and the role of the receptor in metanephric development, Proc Natl Acad Sci U.SA 90:10360-10364,1993

• 24) Karavanova I, Dove LF, Resau JH et al:Conditioned medium from rat ereteric bud cell line in combination with bFGF induces complete differentiation of isolated metanephric mesenchyme, Development 122:4159-4167,1996
  pubmed

• 25) Barasch J, Qiao J, McWilliams G et al:Ureteric bud cells secrete multiple factors, including bFGE which rescue renal progenitors from apoptosis, Am J Physiol 273:F 757-F 767,1997

• 26) Rotherpieler UW, Dressler GR:Pax-2 is required for mesenchyme-to-epithelium conversion during lddney development, Development 119:711-795, 1993

• 27) Torres M, Gomez-Pardo, E, Dressler R et al:Pax-2 controls multiple steps of urogenital development, Development 121:4057-4065,1995

• 28) Kispert A, Vainio S, McMahon Ap:Wnt-4 is a mesenchymal signal for epithelial transformation of metanephnc mesenchyme in the developing kidney, Development l 25:4225-4234,1998

• 29) Stark K, Vainio G, Vassileva G et al:Epithelial transformation of metanephric mesenchyme in the developing kidney is regulated by Wnt-4, Nature 372:679-683,1994

• 30) Kreidberg JA, Sariola H, Lotkmg M et al:WT-1 is required for early kidney development, Cell 174:679-691,1993

• 31) Miyamoto N, Ybshida M, Kuratani S et al:Defects of urogenital development in mice lackng Emx2, Development 124:1653-1664,1997

• 32) George EL, Georges-Labouesse EN, Patel-King RS et al:Defects in mesoderm, neural tube and vascular development in mouse emblyos lacking frbronectin. Development 119:1079-1091,1993
  pubmed

• 33) Saga Y, Yagi T, lkawa Y et al:Mice develop normany without tenasckm, Genes Dev 6:1821-1831,1992

• 34) Noakes PG, Miner JH, Gautam M et al:The renal glomerulus of mice lacking s-lamin/laminin β 2:nephrosis despite molecular compensation by laminin β1, Nat Genet 10(4) :400-406,1995

• 35) Bullock SL, Fletcher JM, Beddington RS et al:Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase, Genes Dev 12(12) :1894-906,1998
  pubmed

• 36) Cosgrove D, Meehan DT, Grunkemeyer JA et al:Collagen COL4A3 knockout:a mouse model for autosomal Alport syndrome, Genes Dev 10(23) :2981-2992,1996
  pubmed

• 37) Kanwar YS, Ota K, Yang Q et al:Isolation of rat fibrillin-1 cDNA and its relevance in metanephric development, Am J Physiol 275(5 PT 2) :F 710-723, 1998

• 38) Kumar A, Ota K, Wada J, Wallner EI, Charonis AS, Carone FA, and Kanwar YS:Developmental regulation and partial-length cloning of tubulointerstitial nephritis antigen of murine metanephros, Kidney Int 52:620-627,1997
  pubmed

• 39) Kanwar YS, Kumar A, Yang Q et al:Tubulointerstitial nephritis antigen:an extracellular matric protein that selectively regulates tubulogenesis vs. glomerulogenesis during mammalian renal development, Proc Natl Acad Sci USA 96:11323-11328, 1999

• 40) Wada J, Kanwar YS:Identification and characterization of galectin-9, a novel β-galacoside-binding mammalian lectin, J Biol Chem 272:6078-6086, 1997

• 41) Wada J, Ota K, Kumar A et al:Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin, J Clin Invest 99:2451-2461,1997

• 42) Tsuchiyama Y, Wada J, Zhang H et al:Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats, Kidney Int 58:1941-1952,2000
  pubmed

• 43) Bullock SL, Johnson TM, Bao Q et al:Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney, J Am Soc Nephrol 12:515-523,2001

• 44) Ota K, Stetler-Stevenson WG, Yang Q et al:Cloning of murine membrane-type-1-matrix metalloproteinase(MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor, Kidney Int 54(1) :131-142,1998
  pubmed

• 45) Kanwar YS, Ota, Yang Q et al:Roel of membrane-type matrix metalloproteinase 1 (MT-1-MMP) , MMP-2, and its inhibitor in nephrogenesis, Am J Physiol 277:F 934-947,1999

• 46) Barasch J, Yang J, Qiao J et al:Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros, J Clin Invest 103:1299-1307,1999
  pubmed

• 47) Georges-Labouesse E, Messaddeq N, Yehia G, Cadalbert L, Dierich A, Le Meur M:Absence of integrin α 6 leads to epidermolysis bullosa and neonatal death in mice, Nat Genet 13(3) :370-373,1996

• 48) Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, Jaenisch R:α3β1 integrin has a crucial role in kidney and lung organo-genesis, Development 122(11) :3537-3547,1996

• 49) Muller U, Wang D, Denda S, Meneses JJ, Pedersen RA, Reichrdt LF:Integrin α8β1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis, Cell 88(5) :603-613, 1997

• 50) Stephens LE, Sutherland AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, Damsky CH:Deletion of β1 integrins in mice results in inner cell mass failure and peri-implantation lethality, Genes Dev 9(15) :1883-95, 1995

• 51) Fassler, R, Meyer M:Consequences of lack of β1 integrin gene expression in mice. Genes Dev 9(15) :1896-908,1995

• 52) Fassler R, Pfaff M, Murphy J, Noegel AA, Johansson S, Timpl R, Albrecht R:Lack ofβ1 integrin gene in embryonic stem cells affects morphology, adhesion, and migration but not integration into the inner cell mass of blastocysts, J Cell Biol 128 (5) :978-988,1995

• 53) Hirsch E, Iglesias A, Potocnik AJ, Hartmann U, Fassler R:Impaired migration but not differentiation of haematopoietic stem cells in the absence of, β1 integrins, Nature 380(6570) :171-5,1996

• 54) Wada J, Kumar A, Liu ZZ, Ruoslahti E, Reichardt L, Marvaldi J, Kanwar YS:Cloning of mouse integrin αvcDNA and role of the α v-related matrix receptors in metanephric development, J Cell Biol 132 (6) :1161-1176, 1996

• 55) Arend LJ, Smart AM, Briggs JP:Mouse β6 integrin sequence, pattern of expression, and role in kidney development, J Am Soc Nephrol 11:2297-2305, 2000

• 56) Bader BL, Rayburn H, Crowley D, Hynes RO:Extensive vasculogenesis, angiogenesis, and organogenesis precide lethality in mice lacking all αv integrins, Cell 95:507-519,1998

• 57) Kitamoto Y, Tokunaga H, Tomita K:Vascular endothelial growth factor is an essential molecule for mouse kidney development:glomerulogenesis and nephrogenesis, J Clin Invest 99:2351-2357,1997
  pubmed

• 58) Robert B, Xhao X, Abrahamson DR:Coexpression of neurophilin-1, F1k1, and VEGF164 in developing and mature mouse kidney glomeruli, Am J Physiol Renal Physiol 279:F 275-F 282,2000

• 59) Tufro A, Norwood VF, Carey RM et al:Vascular endothelial growth factor induces nephrogenesis and vasculogenesis, J Am Soc Nephrol 10:2125-2134, 1999
  pubmed

• 60) Oliver JA, Al-Awqati Q:An endothelial growth factor involved in rat renal development, J Clin Invest 102:1028-1219,1998

• 61) Malacinski GM, Ariizumi T, Asashima M:Work in progress:the Renaissance in amphibian embryology, Comp Biochem Physiol B 126:179-187,2000
  pubmed

• 62) Ariizumi T, Asashima M:In vitro induction systems for analyses of amphibian organogenesis and body patterning, Int J Dev Biol 45:273-279,2001
  pubmed

• 63) Koseki C, Herzlinger D, Al-Awqati:Integration of embryonic nephrogenic cells carrying a reporter gene into functioning nephrons, Am J Physiol 261:C 550-554,1991

• 64) Hammerman MR:New developments in kidney development, Nephron 81:131-135,1999
  pubmed

• 65) Barasch J, Yang J, Ware CB et al:Mesenchymal to epithelial conversion in rat metanephros is induced by LIF, Cell 99:377-386,1999
  pubmed

• 66) Qui L, Escalante CR, Aggarwal AK et al:Monomeric midkine induces tumor cell proliferation in the absence of cell-surface proteoglycan binding, Biochemistry 39:5977-5987,2000

• 67) Wada J, Zhang H, Tsuchiyama Y et al:Gene expression profile in streptozotocin-induced mice kidneys undergoing glomerulosclerosis, Kidney Int 59:1363-1373,2001
  pubmed

P.22 掲載の参考文献

• 1) Yasuda Y, Miyata T, Nangaku M et al:Functional quantitative analysis of the genome in cultured human mesangial cells, Kidney lnt 53:154-158,1998

• 2) Matsubara K, Okubo K:cDNA analysis in the human genome project, Gene 135:265-274,1993
  pubmed

• 3) Okubo K, Hori N, Matoba R et al:Large scale cDNA sequencing for analysis of quantitative and quantitative aspects of gene expression, Nature Gene 2:173-179,1992

• 4) Miyata T, Nangaku M, Suzuki D et al:A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy, J Clin Invest 102:828-836,1998

• 5) Eitsman DT, McCoy RD, Zheng X et al:Bleomycininduced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene, J Clin Invest 97:232-237,1996

• 6) Kruithof EKO, Baker MS, Bunn CL:Biological and clinical aspects of plasminogen activator inhibitor type 2, Blood 86:4007-4024,1995

• 7) Bachmann F:The enigma PAI-2:Gene expression, evolutionary and functional aspects, Thromb Haemostasis 74:172-179,1995

• 8) Tsujimoto M, Tsuruoka N, Ishida N et al:Purification, cDNA cloning and characterization of anew serpin with megakaryocyte maturation activity, J Biol Chem 272:15373-15380,1997

• 9) Bird PI:Serpins and regulation of cell death, Results Probl Cell Differ 24:63-89,1998
  pubmed

• 10) Potempa J, Korzus E, Travis J:The serpin superfamily of proteinase inhibitors:structure, function, and regulation, J Biol Chem 269:15957-15960,1994
  pubmed

• 11) Suzuki D, Miyata T, Nangaku M et al:Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases, J Am Soc Nephrol 10:2606-2613,1999
  pubmed

• 12) Nangaku M, Miyata T, Suzuki D et al:Cloning of rodent megsin revealed its upregulation in mesangioproliferative nephritis, Kidney Int"in press"

• 13) Wada T, Miyata T, Inagi R et al:Cloning and characterization of a novel subunit of protein serin/threonine phosphatase 4 from human mesangial cells, J Am Soc Nephrol"in press"

P.28 掲載の参考文献

• 1) 大島伸一,小野佳成,絹川常郎ほか:生体腎移植 50例の検討―生存率の向上について―,日泌会誌 74:765-769,1983

• 2) 腎移植臨床登録集計報告(1994,中間報告) ,移植 30:427-449,1995

• 3) UNOS OPTN. Registry Data,2001

• 4) Cecka J M:The UNOS scientific renal transplant registry. In:Cecka and Terasaki, editors. Clinical Transplants 1998. Los Angeles, UCLA Tissue Typing Laboratory:p 1-16,1998

• 5) 小野佳成,大島伸一:慢性拒絶反応の克服,医学のあゆみ13:991-994,2001

• 6) Solez K, Axelsen Roy A, Benediktsson H et al:Kidney International 44:411-422,1993

• 7) Yamada S, Ono Y, Katoh N et al:Patients receiving kidneys from non-heart-beating donors in the cycolosporin era:factors influensing long-term results, Transplant Proc 26(4) :2013-2015,1994
  pubmed

• 8) Brenner B M, Milford EL:Nephron underdosing:a programmed cause of chronic renal allograft failure, Am J Kidney Dis 21:66-72,1993
  pubmed

• 9) 小野佳成:移植腎に生ずる非免疫学的障害 Annual Review 腎臓 2000, pp 169-174,2000

• 10) Mizutani K, Ono Y, Hattori R et al:Use of marginal orgaus from non-heart beating cadaveric kidney donors Transplantation, in press, 2001

• 11) Opelz G, Wujciak T, Ritz E:Assosiation of chronic kidney graft failure with recipient blood pressure, Kidney 53:217-222,1998

• 12) Hattori R, Ohshima S, Ono Y et al:Long-term outcome of kidney transplants from non-heart beating donor:multivariate analysis of factors affecting the graft survival, Transplant Proc 31:2847-2850,1999
  pubmed

• 13) Opelz G, Wujciak T:Transplant Proc 27:93-99,1995
  pubmed

• 14) Preliminary international figures on 1999 organ donation & transplantation activities, Oragns and Tissues 3:73-78,2000

• 15) Gjertson D W, Cecka J M, Terasaki P I:The relative effects of FK506 and cyclosporine on short-and long-term kidney graft survival, Transplant 60:1384-1388,1995

• 16) Shapiro R, L Jordan M, P Scantlebury V et al:A Prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/rednisone/mycophenolate mofetil in renal transplant recipienats, Transplantation 67:411-415,1999

• 17) Vanrenterghem Y, Squifflet J P, Forsythe J et al:Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients, Transplant Proc 30:1291-1291,1998

• 18) Nashn B et al:Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients, Lancet 350:1193-1198, 1997

P.33 掲載の参考文献

• 1) Kolff WJ, Berk HThJ:The artificial Kidney:a dialyzer with great area, Acta Med Scand 117:121-134, 1944

• 2) Quinton W, Dillard D, Scribner BH:Cannulation of blood vessels for prolonged hemodialysis, Trans Am Soc Artif Intern Organs 6:104-113,1960
  pubmed

• 3) Survey of end-stage renal failure by Fresenius Medical Care Co.

• 4) 日本透析医学会統計調査委員会:わが国の慢性維 持透析療法の現況,1999年12月31日現在,日本透析医学会,2000

• 5) Babb AL, Popovich RP, Christopher TG, Scribner BH:The genesis of the square meter-hour hypothesis, Trans Am Soc Artif Intern Organs 17:81-90, 1971
  pubmed

• 6) Henderson LW, Besarab A, Michaels A et al:Blood purification by ultra-filtration and fluid replacement(Diafiltration) ,Trans Am Soc Artif Intern Organs 13:216-226,1967

• 7) Quelhorst E, Rieger J, Doht B et al:Treatment of chronic uremia by an ultra-filtration kidney-first clinical experience, Proc Eur Dial Transplant Assoc 13:314-317,1976

• 8) 斎藤 明,小川洋史,高木豊巳,鄭 大基:Protein-Losing hemoilter の臨床と濾過液の中高分子量物質の分析,人工臓器10:907-910,1981

• 9) 斎藤 明,小川洋史,高木豊巳,鄭 大基:Protein-permeating hemodiafiltration の長期臨床評価,人工臓器 13:643-646,1984

• 10) 斎藤 明:Protein-permeable hemofilters の除去性能糸球体濾過へのアプローチ―,人工臓器13:1303-1313,1984

• 11) Gejyo E Yamada T, Odani S et al:A new form of amyloid protein associated with hemodialysis was identified as β2-microglobulin, Biochem Biophys Res Commun 129:701-706,1985

• 12) von Sengbusch G, Baurmeister U, Vienken J:Adaptation of cellulosic membranes to different biocompatibility parameters. Contr Nephrol vol.59, p 126-133, Kager, Basel,1987

• 13) Akizawa T, Kitaoka T, Koshikawa S et al:Deveopment of a regenerated cellulose non-complement activating membrane for hemodialysis, Trans Am Soc Artif Intern Organs 32:76-80,1986

• 14) 佐々木正富:一般的なセルロース膜とビタミンE 改質セルロース膜,竹沢真吾,編:血液透析スタッフのための新しいハイパフォーマンスダイアライザー,東京医学社 P 13-27,1998

• 15) 山川 真,山本忠司ほか:アセテート代謝と透析不快症状,透析開始 14:147,1981

• 16) 阿部富彌:バイカーボネイト透析液の歴史,透析フロンティヤ2:2-8,1992

• 17) Chertow GM, Burke SK, Lazarus JM et al:Poly[al-kylamine hydrochloride]ReaGel:Anoncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure, Am J Kidney Dis 31:66-71,1997

• 18) Wada M, Ishii H, Fumya Y et al:NPS R-568 halts or reverses osteitis fibrosa in uremic rats, Kidney Int 53:1998
  pubmed

• 19) Radtke HW, Rege AB, Lamarche MB et al:Identification of spermine as an inhibitor of erythropoeisis in patients with chronic renal failure, J Clin Invest 67:1623-1629,1981

• 20) Eschbach JW:Recombinant human erythropoietin in anemic patients with end stage renal diseases, Ann Intem Med 111:992-1000,1989

• 21) 平沢由平:リコンビナントエリスロポエチンによる腎性貧血治療ガイドライン,厚生科学研究, 平成2年腎不全医療研究班報告書,p 59-62,1990

• 22) National Kidney Foundation anemia work group:NKF-DOQI(Dialysis Outcome Quality Initiative) clinical practice guidelines for the treatment of anemia of chronic renal failure, Am J Kidney Dis 30 (suppl.3) :S 192-S 240,1997

• 23) European best practice guideline for the management of anemia in patients With chronic renal failure, Nephrol Dial Transplant 14(Suppl.5) :1999

• 24) 山上征二:透析液安全基準策定報告,透析会誌28:1487-1493,1995

• 25) 松山玲子,井上聖人,津波古幸彦ほか:水処理設備改善によるエリスルポエチンの減量,透析会誌 31(Suppl.1) :567,1998

• 26) Schwalbe S, Holzhauer M, Schaeffer J et al:Beta 2-microglobulin associated Amyloidosis:avanishing complication of long-term hemodialysis?Kidney Int 52:1077-1083,1997
  pubmed

• 27) Owen WF, Lowrie EG:C-reactive potein as an outcome predictor for maintenance hemodialysis patients, Kidney Int 54:627-636,1998

• 28) Unpublished data
  Medical*Online

• 29) Buoncristiani U et al:Daily recycled bicarbonate dialysis with polyacrylonitrile, Trans Am Soc Intern Aritf Organs 29:669-672,1983
  pubmed

• 30) Buoncristiani U, Quintaliani G, Cozzari M et al:Daily dialysis:long-term clinical metabolic results, Kidney Int 33(Suppl.24) :S 137-S 140,1988

• 31) Pierratos A, Ouwendyk M, Francoeur R et al:Nocturnal hemodialysis:three-year experience, J Am Soc Nephrol 9:859-868,1998
  pubmed

• 32) Sakai A, Takesawa S, Kumano K et al:Can recovered protein from the CAPD patients own dialysis effluent substitute for dextrose?Adv Perit Dial 14:40-43,1998

• 33) Mineshima M, Watanuki M, Yamagata K et al:Development of continuous recirculating Peritoneal dialysis using a double lumen catheter, ASAIO Jounal 38:M337-M340,1992

• 34) Saito A, Takagi T, Sugiura K et al:Maintaining low concentration of plasma β2-microglobulin through continuous slow hemofiltration, Nephrol Dial Transplant 10(Suppl.3) :52-56,1995

• 35) Saito A, Suzuki H, Bomsztyk K et al:Regeneration of peritoneal effluent by Madin-Darby canine kidney cells-lined hollow fibers, Mater Sci&Eng C 6:221-226,1998

• 36) Yerashima M, Fujita Y, Sugano K et al:Evaluation of water and electrolyte transport of tubular epithelial cells under osmotic and hydraulic pressure for development of bioartificial tubules, Artif Organs 25:209-212,2001

• 37) Fajita Y, Kakuta T, Asano M et al:Evaluation of active transport and morphological changes for bioartificial renal tubule device using MDCK cells. Tissue Eng 2001 (in press)

• 38) Ariizumi T, Asashima M:In vitro control of organo-genesis and fundamental embryonic form by the peptide growth factor activin, J Artif Organs 2:117-123,1999

P.38 掲載の参考文献

• 1) Stein BS:Laser-tissue interaction. in Smith JA ed:Lasers in urologic surgery, St. Louis, Mosby, pp 10-25,1994

• 2) Webb DR et al:The versaPulse holmium surgical laser in clinical urology:a pilot study, Minim Inv Therapy 2:23-26,1993

• 3) Geshwind HJ et al:Holmium YAG coronary angioplasty with multifiber catherters, J Interv Carciol 4:171-179,1991

• 4) Grasso M et al:Teckmiques in endoscopic lithotripsy using the pulsed-dye laser, Urology 3:138-144,1991
  pubmed

• 5) Grasso M:Ureteropyeloscopic treatment of ureteral and intrarenal calculi, Urol Clin North Am 27:623-631,2000
  pubmed

• 6) Matsuoka K et al:Holmium:yttrium-aluminum-garnet laser for endoscopic lithotripsy, Urology 45:947-952,1995
  pubmed

• 7) Engelmayer EI and Bells JA:Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract, Techn Urol 2:113-116,1996

• 8) Elliott DS et al:0ngterm follow-up of endocsopically treated upper urinary tract transitional cell carcinoma, Urology 47:819-822,1996
  pubmed

• 9) Clark PE, Streem SB, Geisinger MA:Ureteroscopic treatment and surveillance of upper tract transitional cell carcinoma, J Urol 161:157-161,1999

• 10) Savage SJ and Streem SB:Techniques in endourology;Ureteroscopic approach to upper-tract urothelial tumors, J Endourol 14:275-279,2000

• 11) Johnson DE:Use of the holmium:YAG(Ho:YAG) laser for treatment of superficial bladder carcinoma, Lasers Surg Med 14:213-218,1994
  pubmed

• 12) Razvi HA et al:Soft-tissue applications of the holmium:YAG laser in urology. J Endourol 9:387-390, 1995
  pubmed

• 13) Erhard M and Bagley DH:Urologic application of the holmium laser:preliminary experience, J Endourol 9:383-386,1995
  pubmed

• 14) Keeley FX Jr, Bibbo M and Bagley DH:Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma, J Urol 157:1560-1565,1997
  pubmed

• 15) Grasso M, Fraiman M and Levine M:Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies, Urology 54:240-246, 1999
  pubmed

• 16) Mugiya S et al:Endoscopic management of upper urinary tract disease using a 200-μm holmium laser fiber:initial experience in Japan, Urology 53:60-64,1999

• 17) Janetschek G et al:Laparoscopic nephron sparing surgery for small renal cell carcinoma, J Urol 159:1152-1155,1998
  pubmed

• 18) Kozlowski PM and Winfield HN:Laparoscopic partial nephrectomy and wedge resection, J Endourol 14:865-870,2000
  pubmed

P.43 掲載の参考文献

• 1) Sackett DL et al:Evidence-basedmedicine:what it is and what is isnt. BMJ 312:71-72,1996

• 2) 福井次矢編集:EBM実践ガイド,1996

• 3) Boissel JL, Fouque D, Laville M et al:Establishing a Cochrane Conaborative Review Group in Nephrology, Jnephron 9:34,1996

• 4) Jewis EJ, Hunsicker LG, Bain RP et al:The effect of angiotensin-converting-enzyme inhibition on iabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20) :1456-1462,1993

• 5) Maschio G, Alberti D, Janin G, et al:Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotenshin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Nengl J Med:334(15) :939-945,1996

• 6) Peterson J, Adler S, Burkart J et al:Blood Pressure Control, Proteinuria, and the Progression of Renal Disease.-The Modification of Diet in Renal Disease Study. American College of Physicians 123:754-762,1995

• 7) Ruggenenti P, Perna A, Gaspari F et al:Renal Function and requirement for dialysis in chronic nephropathy patients on long-term ramipril:REIN follow-up trial, Group Italiano di Studi Epidemiologici in Nefrologia(GISEN) .Ramipril Efficacy in Nephropathy. Lancet 352(9136) :1252-1256,1998

• 8) UK Prospective Diabetes Study(UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) .The Lancet 352:837-853,1998

• 9) Ohkubo Y, Kishikawa H, Araki E et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract 28(2) :103-117,1995
  pubmed

• 10) Ruilope LM, Salvetti A, Jamerson K et al:Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment(HOT) study. J Am Nephron 12(2) :218-225,2001

• 11) Nosadini B, Velussi M, Brocco E et al:Course of Renal Function in Type 2 Diabetic Patients With Abnormalities of Albumin Ecretion Rate. Diabetes 49:476-484,2000

• 12) Uzu T, Lnoue T, Fujii T et al:Prevalence and predictors of renal artery stenosis in patients with myocardial infarction. Am J Kidney Dis 29(5) :733-738

• 13) Valabhji J, Robinson S, Poulter C et al:Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension 23(4) :539-543, 2000
  pubmed

• 14) Plouin PF, Chatellier G, Dame B et al:Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis:a randomized trial. Essai Multi-centrique Medicaments vs Angioplastie(EMMA) Study Group. Hypertension 31:823-829,1998

• 15) Van Jaarsveld BC, Krijnen P, Pieterman H et al:The effect of balloon angioplasty on hypertension in athrosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 342:1007-1014,2000

第2章 腎臓病の分子生物学-病態解明に向けて-

P.50 掲載の参考文献

• 1) Granville DJ et al:Apoptosis:Molecular aspects of cell death and disease, Lab Invest 78:893-913,1998

• 2) Thompson CB:Apoptosis in the pathogenesis and treatment of disease, Science 267:1456-1462,1995
  pubmed

• 3) アポトーシスの最前線と疾患,最新医学54:823-930,1999

• 4) Majno G, Joris I:Apoptosis, oncosis, and necrosis:An overview of cell death, Am J Pathol 146:3-15, 1995
  pubmed

• 5) アポトーシスを操る役者たち:次々と登場する新規分子とその役割,細胞工学 18:1760-1804,1999

• 6) Savill JS, Mooney AF, Hughes J:Apoptosis in acute renal inflammation, Neilson EG, Couser WG eds:Immunologic renal disease, Lippincott-Raven, Philadelphia, p 309-329,1996

• 7) Ortiz A:Apoptotic regulatory proteins in renal injury, Kidney Int 58:467-485,2000
  pubmed

• 8) Kashihara N, Sugiyama H, Makino H:Mechanisms for induction of apoptosis and glomerular disease, Nephrol Dial Transplant 14(suple 1) :52-54,1999

• 9) 清水 章,山中宣昭:腎炎とアポトーシス,長沢 俊彦,河邊香月,伊藤克己,浅野 泰,遠藤 仁 編集:Annual Review腎臓1996,中外医学社,東京, p 88-94,1996

• 10) 腎とアポトーシス,清水不二雄 編集:別冊医学のあゆみ,医歯薬出版,東京,p 1-102,1997

• 11) Shimizu A et al:Recovery of damaged glomerular capillary network with endothelial cell apoptosis in experimental proliferative glomerulonephritis, Nephron 79:206-214,1998
  pubmed

• 12) Shimizu A et al:Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis, Am J Pathol 151:1231-1239,1997
  pubmed

• 13) Yamanaka N, Shimizu A:Role of glomerular endothelial cell damage in progressive renal disease, Kidney Blood Ress Res 22:13-20,1999

• 14) Masuda Y et al:Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally-induced glomerulonephritis, Am J Pathol (in press)

• 15) Kitamura H et al:Apoptosis in glomerular endothelial cells during the development of glomerular sclerosis in the remnant-kidney model, Exp Nephrol 6:328-336,1998
  pubmed

• 16) Shiiki H et al:Cell proliferation and apoptosis of the glomerular epithelial cells in rats with puromycin aminonucleoside nephrosis, Pathobiology 66:221-229,1998
  pubmed

• 17) 大橋隆治,山中宣昭:腎障害の進展とperitubular capillary,伊藤克己,浅野 泰,遠藤 仁,御手洗 哲也,東原英二 編集:Armual Review腎臓2001中外医学社,東京,p 88-93,2001

• 18) Yang B et al:Apoptosis and caspase-3 in experimental anti-glomerular basement membrane nephritis, J Am Soc Nephrol 12:485-495,2001
  pubmed

• 19) Doherty PC:Cell-mediated cytotoxicity, Cell 75:607-612,1993
  pubmed

• 20) Shimizu A et al:Complement-mediated killing of mesangial cells in experimental glomemlonephritis:Cell death by a combination of apoptosis and necrosis, Nephron 86:152-160,2000
  pubmed

• 21) Nagata S, Suda T:Fas and Fas ligand:lpr and gld mutations, lmmunol Today 16:39-43,1995
  pubmed

• 22) Ueda N, Kaushal GP, Shah SV:Apoptotic mechanisms in acute renal failure, Am J Med 108:403-415,2000
  pubmed

• 23) 清水 章:急性腎不全の基礎,腎臓22:82-90,1999

• 24) Daemen MARC et al:Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation, J Clin Invest 104:541-549,1999

• 25) Schelling JR, Cleveland RP:Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure, Kidney Int 56:1313-1316,1999
  pubmed

• 26) Gobe G, Schoch E, Leighton J:Molecular controls of radiation-induced apoptosis in the neonatal rat kidney, Kidney Int 56:1305-1309,1999
  pubmed

• 27) Lin HH et al:Bcl-2 0verexpression prevents apoptosis-induced Madin-Darby canine kidney simple epithelial cyst formation, Kidney lnt 55:168-178,1999

• 28) Nagata M et al:Apoptosis during art early stage of nephrogenesis induces renal hypoplasia in bcl-2-deficient mice, Am J Pathol 148:1601-1611,1996

• 29) Kabelitz D:Apoptosis, graft rejection, and transplantation tolerance,Transplantation 65:869-875, 1998
  pubmed

• 30) Shimizu A et al:The acceptance reaction:lntragraft events associated with tolerance to renal allografts in miniature swine, J Am Soc Nephrol 11:2371-2380,2000
  pubmed

• 31) Shimizu A et al:Intragraft events preceding chronic renal allograft rejection in a modified tolerance protocol, Kidney Int 58:2546-2558,2000

• 32) Woodle ES, Kulkarni S:Programmed cell death, Transplantation 66:681-691,1998
  pubmed

• 33) June CH et al:The B7 and CD28 receptor families, Immunol Today 15:321-331,1994
  pubmed

• 34) Haunstetter A, Izumo S:Toward antiapoptosis as a new treatment modality, Circ Res 86:371-376,2000
  pubmed

P.58 掲載の参考文献

• 1) Zimmerman JL et al:Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome, Crit care Med 3:3149-3154,2000
  pubmed

• 2) Mizuno M et al:Functional inhibition of a membrane complement regulatory protein induces lethal shock in rats primed with trace levels of lipopolysaccharide, J lmmunol 162:5477-5482, 1999

• 3) Kondo C et al:The Role of C5a in The Development of Thrombotic Glomerulonephritis in Rats, Clin Exp Immunol(in press)

• 4) Nishikawa et al:Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase, J Immunol 156:1182-1188,1996
  pubmed

• 5) Nomura A et al:Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement, J Clin Invest 96:2348-2356,1995
  pubmed

• 6) MiZuno M et al:The effects of functional supression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats, Arthritis Rheum 40:527-533,1997

• 7) Matsuo S et al:In vivo effects of monoclonal anti-bodies that functionally inhibit complement regulatory proteins in rats, J Exp Med 180:1619-1627, 1994

• 8) Watanabe Met al:CD59 protects kidneys from complement mediated injury in collaboration with Crry in rats, Kidney Int 58:1569-1579,2000

• 9) 水野正司ほか:慢性炎症性関節炎モデル(CIA) を用いた,関節炎の進展に伴う膜補体制御因子の分布の変化およびその役割を検討,補体シンポジウム会誌2000

• 10) Xu C et al:A critical role for murine complement regulator crry in fetomaternal tolerance, Science 287:498-501,2000

• 11) Nishikage H et al:The role of a complement regulatory protein in rat mesangial glomerulonephritis, J Am Soc Nephrol 6:234-242,1995
  pubmed

• 12) Hatanaka Y et al:Role of a rat membrane inhibitor of complement in anti-basement membrane antibody-induced renal injury, Kidney Int 48:1728-1738,1995
  pubmed

• 13) Nomura A et al:Role of complement in acute tubulointerstitial injury rats with aminonucleoside nephritis, Am J Pathol 151:539-547,1997

• 14) Morita Y et al:The role of complement in the pathogenesis of tubulointerstitial lesions in rat mesangial proliferative glomerulonephritis, J Am Soc Nephrol 8:1363-1372,1997
  pubmed

• 15) Morita Y et al:Complement activation products in the urine from proteinuric patients, J Am Soc Nephrol 11:700-707,2000
  pubmed

• 16) Pinter C et al:Presence of autoantibodies against complement regulatory proteins In relapsing-remitting multiple sclerosis, J Neurovirol 6:S 42-S 46, 2000

• 17) Hill J et al:Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat, J Immunol 149:1723-1728,1992

• 18) Quigg RJ et al:Blockade of antibody-induced glomerulonephntis With Crry-Ig, a soluble murine complement inhibitor, J Immunol 160:4553-4560,1998
  pubmed

• 19) Czermak BJ et al:Protective effects of C5a blockade In sepsis, Nature Med 5:788-792,1999
  pubmed

• 20) van den Berg CW et al:Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells, Transplant 70:667-673,2000
  pubmed

P.62 掲載の参考文献

• 1) 藤乗嗣泰,木村健二郎:腎とNOSのmolecular biology,腎と透析 45(臨時増刊号) :185-195,1998

• 2) Kakoki M et al:Effects of tetrahydrobiopterin on endothelial dysfunction in rats with ischemic acute renal failure, J Am Soc Nephrol 11:301-309,2000
  pubmed

• 3) Tojo A, Bredt DS, Wilcox CS:Distribution of postsynaptic density proteins in rat kidney:Relationship to neuronal nitric oxide synthase, Kidney Int 55:1384-1394,1999
  pubmed

• 4) Tojo A, Welch WJ, Bremer V et al:Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney, Kidney Int 52:1593-1601,1997
  pubmed

• 5) Griendling KK, Sorescu D, Ushio-Fukai M:NADPH oxidase:Role in cardiovascular biology and disease, Circ Res 86:494-501,2000
  pubmed

• 6) Jones SA, Hancock JT, Jones OT et al:The expression of NADPH oxidase components in human glomerular mesangial cells:detection of protein and mRNA for p 47phox, p67phox, and p22phox, J Am Soc Nephrol 5:1483-1491,1995

• 7) Bachmann S, Ramasubbu K:Immunohistochemical colocalization of the α-subunit of neutrophil NADPH oxidase and ecto-5-nucleotidase in kidney and liver, Kidney Int 51:479-482,1997

• 8) Geiszt M, Kopp JB, Vamai P et al:Identification of renox, an NAD(P) Hoxidase in kidney, Proc Natl Acad Sci USA 97:8010-8014,2000

• 9) Rajagopalan S, Kurz S, Munzel T et al:Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone, J Clin Invest 97:1916-1923,1996

• 10) Pagano PJ, Clark JK, Cifuentes-Pagano ME et al:Localization of a constitutively active, phagocytelike NADPH oxidase in rabbit aortic adventitia:Enhancedment by angiotensin II, Proc Natl Acad Sci USA 94:14483-14488,1997
  pubmed

• 11) Welch WJ, Tojo A, Lee JU et al:Nitric oxide synthase in the JGA of the SHR:expression and role in tubuloglomerular feedback, Am J Physol 277:F 130-F 138,1999

• 12) Welch WJ, Tojo A, Wilcox CS:Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR, Am J Physiol 278:F 769-F 776,2000

• 13) Schnackenberg CG, Welch WJ, Wilcox CS:Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic:role of nitric oxide, Hypertension 32:59-64,1998
  pubmed

• 14) Tojo A, Kimoto M, Wilcox CS:Renal expression of constitutive NOS and DDAH:separate effects of salt intake and angiotensin, Kidney Int 58(5) :2075-83,2000
  pubmed

• 15) Bremer V, Tojo A, Kimura K et al:Role of nitric oxide in rat nephrotoxic nephritis:comparison between inducible and constitutive nitric oxide synthase, J Am Soc Nephrol 8:1712-1721,1997
  pubmed

• 16) Kaushal GP, Shah SV:Proteases and oxidants in glomerular injury. Immunologic Renal Diseases ed. Neilson EG and Couser WG, Lippincott-Raven, Philadelphia, p 397-415,1997

• 17) Onozato ML, Tojo A, Wilcox CS et al:Effect of ACE inhibitor and Angiotensin II receptor blocker on NADPH oxidase and NO synthase in diabetic nephropathy, J Am Soc Nephrol 11:649A,2000 (abstract)

• 18) Wardle EN:Oxidative processes in glomerulonephritides:Additional Facts, Nephrol 85:103-106,2000

P.69 掲載の参考文献

• 1) Wada T, YOkoyama H, Kobayashi K et al:Chemokines in renal diseases, Int linmunopharmacol 1:637-645,2001
  pubmed

• 2) Romagnani P, Beltrame C, Annuziato F et al:Role for interactions between IP-10/MIG and CXCR3 in proliferative glomerulonephritis, J Am Soc Nephrol 10:2518-2526,1999

• 3) Banasa B, Luckow B, Moeller M et al:Chemokine and chemokine receptor expression in a novel human mesangial cell line, J Am Soc Nephrol 10:2314-2322,1999

• 4) Wada T, Yokoyama H, Tomosugi N et al:Detection of interleukin-8 in glomerular diseases, Kidney Int 46:455-460,1994
  pubmed

• 5) Yokoyama H, Wada T, Furuichi K et al:Urinary levels of monocyte chemotactic and activating factor and interleukin-8 reflect different disease activity of IgA nephropathy, J Leuko Biol 63:493-499,1998

• 6) Segerer S, Nelson PJ, Schlondorff D:Chemokines, chemokine receptors, and renal disease:From basic science to pathophysiologic and therapeutic studies, J Am Soc Nephrol 11:152-176,2000
  pubmed

• 7) Wada T, Yokoyama H, Su SB et al:Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis, Kidney Int 49:761-767,1996
  pubmed

• 8) Wada T, Furuichi K, Sakai N et al:Up-regulation of MCP-1 in tubulointerstitial lesions of human diabetic nephropathy, Kidney Int 58:1492-1498,2000
  pubmed

• 9) Luo Yloyd C, Gutierrez-Ramos JC et al:Chemokine amplification in mesangial cells, J Immunol 163:3985-3992,1999

• 10) Holdsworth SR, Kitching AR, Tipping PG et al:Th1 and Th2 T helper cell subsets affect pattems of injury and outcomes in glomerulonephritis, Kidney Int 55:1198-1216,1999

• 11) Wada T,Furuichi K, Segawa C et al:MIP-1αand MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis, Kidney Int 56:995-1003,1999

• 12) Furuichi K, Wada T, Sakai N et al:Distinct expression of CCRI and CCR5 in glomerular and intersitial lesions of human crescentic glomerulonephritis, Am J Nephrol 20:291-299,2000

• 13) Moore KJ, Wada T, Barbee S et al:RANTES is expresssed prior to renal disease in autoimmune MRL-Fas kidneys and incites renal injury, Kidney Int 53:1631-1641,1998

• 14) Wada T, Tomosugi N, Naito T et al:Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis, J Exp Med 180:1135-1140,1994
  pubmed

• 15) Wada T, Yokoyama H, Furuichi K et al:Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1) ,FASEB J 10:1418-1425,1996
  pubmed

• 16) Egashira K, Koyamagi M, Kitamoto S et al:Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats:blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis, FASEB J 14:1974-1978,2000

• 17) Ou ZL, Nakayama K, Natori Y et al:Effective methylprednisolone dose in experimetal crescentic glomerulonephritis, Am J Kidney Dis 37:411-417, 2001

第3章 原因遺伝子の解明と治療の新しいコンセプト

P.75 掲載の参考文献

• 1) 堅村信介:Dr. Alportとロンドン,日本腎臓学会誌 40:235-239,1998

• 2) 堅村信介ほか:Alport症候群.最新内科学大系,プログレスシリーズ 10,腎泌尿器疾患,冨田公夫編集,井村裕生ほか監修,中山書店,東京,135-150, 1999

• 3) Sado Y et al:Expression of collagen lV genes and Goodpasture antigens, in Ninomiya Y et al eds:Extracellular Matrix-Cellular Interaction;Molecules to Diseases. Japan Sci Soc Press, Tokyo/S Karger, Basel, p 235-260,1998

• 4) Ninomiya Y et al:Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal anti-bodies, J Cell Biol 130:1219-1229,1995

• 5) Barker DF et al:Identification of mutations in the COL4A5 collagen genes in Alport syndrome, Science 248:1224-1227,1990
  pubmed

• 6) Mochizuki T et al:Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome, Nat Genet 8:77-81,1994
  pubmed

• 7) Naito I et al:relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome, Kidney Int 50:304-311,1996
  pubmed

• 8) Kagawa M et al:Epitope-defined monoclonal anti-bodies against type IV collagen for diagnosis of Alports syndrome, Nephrol Dial Transplantation 12:1238-1241,1997

• 9) Jais JP et al:X-1inked Alport syndrome:Natural History in 195 Families and Genotype-Phenotype Correlations in Males. J Am Soc Nephrol 11:649-657, 2000

• 10) Rigden SPA et al:Report on management of renal failure in Europe,XXVI,1995. The child-adult interface:a report on Alports syndrome,1975-1993. The ERA-EDTA Registry. Nephrol Dial Transplant 11 Suppl 7:21-27,1996

• 11) Callis L et al:Long-term effects of cyclosporine A in Alports syndrome, Kidney Int 55:1051-1056, 1999
  pubmed

P.78 掲載の参考文献

• 1) Kestila M et al:Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome, Molecular Cell 1:575-582, 1998

• 2) Tryggvason K:Unraveling the mechanisms of glomerular ultrafiltration:Nephrin, a key component of the slit diaphragm, J Am Soc Nephrol 10:2440-2445,1999
  pubmed

• 3) Putaala H et al:Primary structure of mouse and rat nephrin cDNA and structure and expression of the mouse gene, J Am Soc Nephrol 11:991-1001,2000

• 4) Furness PN et al:Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome, Nephrol Dial Transplant 14:1234-1237,1999
  pubmed

• 5) Solin ML et al:Mitochondral dysfunction in congenital nephrotic syndrome, Lab Invest 80:1227-1232,2000

• 6) Aya K, Tanaka H, Seino Y:Novel mutation in the nephrin gene of a Japanese patient with congenital nephrotic syndrome of the Finnish type, Kidney Int 57:401-404,2000
  pubmed

• 7) Patrakka J et al:Congenital nephrotic syndrome (NPHS 1) :Features resulting from different mutations in Finnish patients, Kidney Int 58:972-980, 2000

• 8) Orikasa M et al:Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody, J lmmunol 141:807-814,1988
  pubmed

• 9) Kawachi H et al:Cloning of rat nephrin:expression in developing glomeruli and in proteinuric states, Kidney Int 57:1949-1961,2000
  pubmed

• 10) Topham PS et al:Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin, J Clin Invest 104:1559-1566,1999
  pubmed

• 11) Kawachi H et al:Slit diaphragm-reactive nephritogenic MAb 5-1-6 alters expression of ZO-1 in rat podocytes, Am J Physiol 273:F 984-993,1997

• 12) Macconi D et al:Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats, J Am Soc Nephrol 11:477-489,2000
  pubmed

• 13) Shin NY et al:Congenital nephrotic syndrome in mice lackng CD2-associated protein, Science 286:312-315,1999

• 14) Inoue T et al:FAT is a component of glomerular slit (diaphragms, Kidney Int 2001(in press)

• 15) 服部元史,鈴木俊明,伊藤克己:先天性乳児ネフローゼ症候群の治療,腎と透析 50:341-345,2001

• 16) Savage JM et al:Improved prognosis for congenital nephrotic syndrome of the Finnish type in Irish families, Arch Dis Child 80:466-469,1999
  pubmed

• 17) Kawachi H, Shimizu F:Molecular composition and function of the slit diaphragm:nephrin, the molecule responsible for proteinuria, Clin Exp Nephrol 4:161-172,2000

• 18) 清水不二雄,折笠道昭:糸球体濾過障壁の構造と機能,腎と透析50:283-288,2001

P.82 掲載の参考文献

• 1) Ichikawa I, Fogo A:Focal segmental glomerulosclerosis, Pediatr Nephrol 10:374-391,1996
  pubmed

• 2) Tejani A, Nicastri A, Phadke K et al:Familial focal segmental glomerulosclerosis, Int J Pediatr Nephrol 4:231-234,1983
  pubmed

• 3) McCurdy FA, Butera PJ, Wilson R:The familial occurrence of focal segmental glomerular sclerosis, Am J Kidney Dis 10:467-469,1987
  pubmed

• 4) Savin VJ, Shama R, Sharma M et al:Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis, N Engl J Med 4;334:878-883, 1996

• 5) Kaplan JM, Kim SH, North KN et al:Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomemlosclerosis, Nat Genet 24:251-256,2000

• 6) Boute N, Gribouval O, Roselli S et al:NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome, Nat Genet 24:349-354,2000
  pubmed

• 7) Somlo S, Mundel P:Getting a foothold in nephrotic syndrome, Nat Genet 24:333-335,2000
  pubmed

• 8) Barbaux S, Niaudet P, Gubler MC et al:Donor splice-site mutations in WTI are responsible for Frasier syndrome, Nat Genet 17:467-470,1997

• 9) Kambham N, Tanji N, Seigle RL et al:Congenital focal segmental glomerulosclerosis associated with β4 integrin mutation and epidermolysis bunosa, Am J Kidney Dis 36:190-196,2000

• 10) Conlon PJ, Lynn K, Winn MP et al:Spectrum of disease in familial focal and segmental glomerulosclerosis, Kidney Int 56:1863-1871,1999
  pubmed

• 11) Honda K, Yamada T, Endo R et al:Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion, J Cell Biol 23;140:1383-1393, 1998

• 12) Djinovic-Carugo K, Young P, Gautel M, Saraste M:Structure of the alpha-actinin rod:molecular basis for cross-linking of actin filaments, Cell 98:537-546,1999
  pubmed

• 13) Mathis BJ, Kim SH, Calabrese K et al:A locus for inherited focal segmental glomerulosclerosis maps to chromosome l9q13, Kidney Int 53:282-286,1998
  pubmed

• 14) Vats A, Nayak A, Ellis D et al:Familial nephrotic Syndrome:clinical spectrum and linkage to chromosome 19q13, Kidney Int 57:875-881,2000
  pubmed

• 15) Winn MP, Conlon PJ, Lynn KL et al:Clinical and genetic heterogeneity in familial focal segmental glomerulosclerosis, Kidney Int 55:1241-1246,1999
  pubmed

• 16) Winn MP, Conlon PJ, Lynn KL et a:Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity, Genomics 58:113-120, 1999
  pubmed

• 17) Fuchshuber A, Jean G, Gribouval O et al:Mapping agene(SRN1) to chromosome 1q25-q31 in idiopathic nephrotic syndrome confims a distinct entity of autosomal recessive nephrosis, Hum Mol Genet 4:2155-2158,1995

• 18) Snyers L, Umlauf E, Prohaska R:Ohgomeric nature of the integral membrane protein stomatin, J Biol Chem 273:17221-17226,1998
  pubmed

• 19) Tavemarakis N, Driscoll M:Molecular modeling of mechanotransduction in the nematode Caenorhabditis elegans, Annu Rev Physiol 59:659-689,1997

• 20) Tsukaguchi H, Yager H, Dawbom J et al:Alocus for adolescent and adult onset familial focal segmental glomerulosclerosis on chromosome 1q25-31, J Am Soc Nephrol 11:1674-1680,2000

P.85 掲載の参考文献

• 1) Choi JY, Shah M, Lee MG et al:Novel amiloride-sensitive sodium-dependent proton secretion in the mouse proximal convoluted tubule, J Clin Invest 105:1141-1146,2000
  pubmed

• 2) Romero ME Hediger MF, Boulpaep EL et al:Expression cloning and characterization of a renal electrogenic Na+/HCO3-cotransporter, Nature 387:409-413,1997

• 3) Burnham CE, Amlal H, Wang Z et al:Cloning and functional expression of a human kidney Na+ /HCO3 cotransporter, J Biol Chem 272:19111-19114,1997
  pubmed

• 4) Abuladze N, Lee I, Newman D et al:Molecular cloning, chromosomal localization, tissue distribution,and functional expression of the human pancreatic sodium bicarbonate cotransporter, J Biol Chem 273:17689-17695,1998

• 5) Abuladze N, Song M, Pushkin A et al:Structural organization of the human NBC1gene:kNBC1 is transcribed from an altemative promoter in intron 3,Gene 251:109-122,2000

• 6) Donckerwolcke RA, Van Stekelenburg GJ, Tiddens HA:Acase of bicarbonate-losing renal tubular acodosis with defective carbonic anhydrase activity,Arch Dis Child 45:769-773,1970

• 7) Winsnes A, Monn E, Stokke O, Feyling T:Congenital, persistent proximal type of renal tubular acidosis in two brothers,Acta Paediatr Scand 60:861-868,1979

• 8) Igarashi T, Inatomi J, Sekine T et al:Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities, Nat Genet 23:264-266,1999
  pubmed

• 9) Usui T, Seki G, Amano S et al:Functional and molecular evidence for Na+-HCO3. cotransporter in human corneal endothelial cells, Pfluegers Arch 438:458-462,1999

• 10) Usui T, Hara M, Satoh H et al:Molecular basis of ocular abnormalities associated with proximal renal tubular acidosis, J Clin Invest (in press)

• 11) Igarashi T, Inatomi J, Sekine T et al:A novel ninsense mutation in the Na+/HCO3, cotransporter gene(SLC4A4) in a patient with permanent isolated proximal renal tubular acidosis and bilateral glaucoma,J Am Soc Nephrol 12:713-718,2001

• 12) Rodriguez-Soriano J:New insights into the pathogenesis of renal tubular acidosis-from functional to molecular studies,Pediatr Nephrol 14:1121-1136, 2000
  pubmed

• 13) Schulties PJ, Clarke LL, Meneton P et al:Renal and intestinal absorption defects in mice lacking the NHE3 Na+/H+ exchanger,Nat Genet 19:282-285, 1998

• 14) Sly WS, Whyte MP, Sundaram V et al:Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification, N Engl J Med 313:139-145,1985
  pubmed

• 15) Hu PY, Roth DE, Skaaga LA et al:A splice mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arab countries, Hum Mutat 1:288-292,1992

P.90 掲載の参考文献

• 1) SW Emmons, S Somlo:Signal transduction. Mating, channels and kidney cysts, Nature 401:339-340,1999

• 2) Jim H, Christopher JW, Richard A et al:Identification of a humam homologue of the sea urchin receptor for egg jelly:a polycystic kidney disease-like protein, Hum Mol Genet 8:543-549,1999

• 3) Qian E Germino FJ, Cai Y et al:PKDl interacts with PKD2 through a probable coiled-coil domain, Nat Genet 16:179-183,1997

• 4) Nauta J, Goedbloed MA, van der Ouweland AM et al:Immunological detection of polycystin-1 in human kidney, Histochem Cell Biol 113:303-311,2000

• 5) Lu W, Peissel B, Babakhanlou H et al:Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkdl mutation, Nat Genet 17:179-181,1997

• 6) Barr MM, Stemberg PW:Apolycystic kidney-disease gene homologue required for male mating behavior in C. Elegans, Nature 401:386-389,1999

• 7) Boletta A, Qian F, Onuchic L F et al:Polycystin-1, the Gene Product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells, Mol Cell 6:1267-1273,2000
  pubmed

• 8) Cai Y, Maeda Y, Cedzich A et al:Identification and characterization of polycystin-2, the PKD2 gene product, J Biol Chem 274:28557-28565,1999
  pubmed

• 9) Gallagher AR, Cedzich A, Gretz N et al:The polycystic kidney disease protein PKD2 interacts with Hax-1,a protein associated with the actin cytoskeleton, Proc Natl Acad Sci USA 97:4017-4022,2000
  pubmed

• 10) Wu G, Markowitz G, Li L, D'Agati V et al:Cardiac defects and renal failure in mice With targeted mutation in Pkd2, Nat. Genet 24:75-78,2000

• 11) Chen XZ, Vassilev PM, Basora N et al:Polycystin-L is a calcium-regulated cation channel permeable to calcium ions, Nature 401:383-386,1999

• 12) Guo L, Schreiber TH, Weremowicz S et al:Identification and characterization of a novel polycystin family member polycystin-L2, in mouse and human:sequence, expression, altenative splicing, and chromosomal localization, Genomics 64:241-251,2000

• 13) Hanaoka K, Qian E Boletta A et al:Co-assembly of polycystin-1 and-2 produces umique cation-permeable currents, Nature 408:990-994,2000

• 14) Vandorpe DH, Chemova MN, Jiang L et al:The cytoplasmic C-terminal fragment of polycystin-1 regulates a Ca2+-permeable cation channel, J Biol Chem 276:4093-4101,2001

• 15) Gonzalez-Perrett S, Kim K, Ibarra C et al:Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD) ,is a Ca2+-permeable nonselective cation channel, Proc Natl Acad Sci USA 98:1182-1187,2001
  pubmed

• 16) Pei Y, Watnick T, He N et al:Somatic PKD2 mutations in individual kidney and liver cysts support a"two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease, J Am Soc Nephrol 10:1524-1529,1999
  pubmed

• 17) Ecder T and Schrier RW:Hypertension in autosoma1-dominant polycystic kidney disease:early occurrence and unique aspects, J Am Soc Nephrol 12:194-200,2001
  pubmed

• 18) Ecder T, Chapman AB, Brosnahan GM et al:Effect of Antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease, Am J Kidney Dis 35:427-432,2000

• 19) Ubara Y, Katori H, Tagami T et al:Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease, Am J Kidney Dis,34:926-931,1999
  pubmed

P.95 掲載の参考文献

• 1) Bartter FC, Pronove P, Gill JR et al:Hyperplasia of the juxtaglomemlar complex with hyperaldosteronism and hypokalemic alkalosis, Am J Med 33:811-828,1962
  pubmed

• 2) Gitelman BH, Graham JB, Welt G:A new familial disorder characterized by hypokalemia and hypomagnesemia, Trans Assoc Am Phys 79:221-235, 1966

• 3) Stein JH:The pathogenetic spectrum of Barters syndrome, Kidney Int 28:85-93,1985

• 4) Simon DB, Bindra RS, Mansfield TA et al:Mutations im the chloride charmel gene, CLCNKB, cause Bartters syndrome type III Nature Genet 17:171-178

• 5) Konrad M, Vollmem M, Lemmink HH et al:Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome, J Am Soc Neph-roll 11:1449-1459,2000

• 6) Jeck N, Konrad M, Peters M et al:Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype, Pediatr Res 48:754-758,2000
  pubmed

• 7) Simon DB, Karet FE, Hamdan JM et al:Bartters syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl co-transporter(NKCC2) , Nature Genet 1 3:183-188, 1996

• 8) Jamison RL, Ross JC, Kempson RL et al:Surreptitious diuretic ingestion and pseudo-Bartters syndrome, Am J Med 73:142-147,1982
  pubmed

• 9) Simon DB, Karet FE, Rodriguez-Soriano J et al:Genetic heterogeneity of Bartters syndrome revealed by mutations in the K+channel, ROMK, Nature Genet 14:152-156,1996

• 10) Takahashi N, Chemavvsky DR, Gomez RA et al:Uncompensated polyuria in a mouse model of Bartters syndrome, Proc Natl Acd Sci USA 97:5434-5439,2000

• 11) Betinelli A, Bianchetti MG, Girardin E et al:Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis:Bartter and Gitelman syndrome, J Pediatr 120:38-43,1992
  pubmed

• 12) Tsukarnoto T, Kobayashi T, Kawamoto K et al:Possible discrimination of Gitelmans syndrome from Bartters syndrome by renal clearance study:report of two cases, Am J Kidney Dis 25:637-641, 1995

• 13) Simon DB, Nelson-Williams, Bia MJ et al:Gitelmans variant of Bartters syndrome, inherited hypokalaemic alkalosis, is caused by mnutations in the thiazide-sensitive Na-Cl cotransporter, Nature genet 12:24-30,1996

• 14) Takeuchi K, Kure K, Kato T et al:Association of a mutation in thiazide-sensitive Na-Cl cotransporter with familial Gitelmans syndrome, J Clin Endocrinol Metab 81:4496-4499,1996

• 15) Monkawa T, Kurihara I, Kobayashi K et al:Novel mutations in thiazide-sensitive Na-Cl cotransporter gene of patients with Gitelmans syndrome, J Am Soc Nephrol 11:65-70,2000

• 16) Schultheis PJ, Lorenz JN, Meneton P et al:Phenotype resembling Gitelmarts syndrome in mice lacking the apical Na+-Cl-cotransporter of the distal convoluted tubule, J Biol Chem 273:29150-29155, 199817)

• 17) Komhoff M, Jeck NDM, Seyberth HW et al:cycloocygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome, Kidney lnt 58:2420-2424,2000

• 18) Kleta R, Basoglu C, Kuwertz-Broking:New treatment options for Bartters syndrome, New Engl Med 343:661-662,2000
  pubmed

P.101 掲載の参考文献

• 1) Liddle GW, Bledsoe T, Coppage WS Jr:A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion, Trans Assoc Am Physicians 76:199-213,19634

• 2) Botero-Velez M, Curtis J, Wamock DG:Liddles syndrome revisited:a disorder of sodium reabsorption in the distal tubule, N Engl J Med 330:178-181,1994

• 3) Canessa, CM, Horisberger JD, Rossier BC:Epithelial sodium channel related to proteins involved in neurodegeneration, Nature 361:467-470,1993
  pubmed

• 4) Canessa CM, Schild L, Buell G et al:Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits, Nature 367:463-467,1994
  pubmed

• 5) Shimkets RA, Warnock DG, Bositis CM et al:Liddles syndrome:heritable human hypertension caused by mutations in the b subunit of the epithelial sodium channel, Cell 79:407-414,1994

• 6) Schild L, Canessa CM, Shimkets RA et al:Amutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system, Proc Natl Acad Sci USA 92:5699-5703,1995

• 7) Hansson, JH, Nelson-Williams C, Suzuki H et al:Hypertension caused by a truncated epithelial sodium channelγ subunit:genetic heterogeneity of liddle syndrome, Nature Genet 11:76-82,1995

• 8) Hansson, JH, Schild L, Lu Y et al:A de novo missense mutation of the βsubunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity, Proc Natl Acad Sci 92:11495-11499,1995

• 9) Tamura H, Schild L, Enomoto N et al:Liddle disease caused by a missense mutation of β subunit of the epithelial sodium channel gene, J Clin lnvest 97:1780-1784,1996

• 10) Jeunemaitre X, Bassilana E Persu A et al:Genotype-phenotype analysis of a newly discovered family with Liddles syndrome, J Hypertension 15:1091-1100,1997

• 11) Inoue J, Iwaoka T, Tokunaga H et al:A family with Liddles syndrome caused by a new missense mutation in the β subunit of the epithelial sodium channel, J Clin Endocr Metab 83:2210-2213,1998

• 12) Jackson SN, Williams B, Houtman P et al:The diagnosis of Liddle syndrome by identification of a mutation in the βsubunit of the epithelial sodium channel, J Med Genet 35:510-512,1998

• 13) Inoue T, Okauchi Y, Matsuzaki Y et al:Identification of a single cytosine base insertion mutation at Arg-597 of the β subunit of the human epithelial sodium channel in a family with Liddle's disease, Eur J Endocrinol 138:691-697,1998

• 14) Uehara Y, Sasaguri M, Kinoshita A et al:Genetic analysis of the epithelial sodium channel in Liddle's syndrome, J Hypertens 16:1131-1135,1998

• 15) Yamashita Y, Koga M, Takeda Y et al:Two sporadic cases of Liddle's syndrome caused by De novo ENaC mutations, Am J Kidney Dis 37:499-504,2001

• 16) Snyder PM, Price MP, McDonald FJ et al:Mechanism by which Liddles syndrome mutations increase activity of a human epithelial Na+ channel, Cell 83:969-978,1995

• 17) Firsov D, Schild L, Gautschi I et al:Cell surface expression of the epithelial Na+ channel and a mutant causing Liddle syndrome:aquantitative approach, Proc Natl Acad Sci 93:15370-15375,1996

• 18) Staub O, Dho S, Henry P et al:WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddles syndrome, EMBO J 15:2371-2380,1996

• 19) Staub O, Gautschi I, Ishikawa T et al:Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination, EMBO J 16:6325-6336, 1997
  pubmed

• 20) Kellenberger S, Gautschi I, Rossier BC et al:Mutations causing Liddle syndrome reduce sodium-dependent downregulation of the epithelial sodium channel in the Xenopus oocyte expression system, J Clin lnvest 101:2741-2750,1998

P.106 掲載の参考文献

• 1) Suzuki Y, Okada T, Higuchi A et al:The low molecular weight of protein components in children urine, Acta Pediatr Jpn 22:1-5,1980

• 2) Wrong OM, Norden AGW, Feest TG:Dent's disease:a familial renal tubular syndrome with hypercalciuria, tubular proteinuria, rickets, nephrocalcinosis and eventual renal failure, Q J Med 77:1086-1087, 1990

• 3) Igarashi T, Hayakawa H, Shiraga H et al:Hypercalciuria and nephrocalcinosis in patients with idiopathic low-molecular-weight proteinuria in Japan:is the disease identical to Dent's disease in United Kingdom?Nephron 69:242-247,1995

• 4) Fisher SE, Van Bakel I, Lloyd SE et al:Cloning and characterization of CLCN5, the human kidney chloride channel gene implicated in Dent disease(an X-linked hereditary nephrolithiasis) Genomics 29:598-606,1995

• 5) Lloyd SE, Pearse SHS, Fisher SE et al:A common molecular basis for three inherited kidney stone diseases, Nature 379:445-449,1996

• 6) Akuta N, Llloyd SE, Igarashi T et al:Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis, Kidney Int 52:911-916,1997

• 7) Igarashi T, Gunter W, Sekine T et al:Functional characterization of renal chloride charmel, CLCN5, mutations associated with Dent's Japan disease, Kidney Inter 54:1850-1856,1998

• 8) Igarashi T, Inatomi J, Ohara T et al:Clinical and genetic studies of CLCN5 mutations in Japanese families with Dent's disease, Kidney Int 58:520-527, 2000

• 9) Takemura T, Hino S, Ikeda M, T et al:Identification of two novel mutations in the CLCN5 gene in Japanese patients with familial low molecular weight proteinuria(Japanese Dent's disease) ,Am J Kidney Dis 37:138-143,2001

• 10) Obermuler N, Grez N, Kriz W et al:The swelling-activated chloride channel CIC-2, the chloride channel ClC-3, and ClC-5, a chloride channel mutated in kidney stone disease, are expressed in distinct sub-populations of renal epithelial cells, J Clin Invest 101:635-642,1988

• 11) Devuyst O, Christie PT, Courtoy PJ et al:Intra-renal subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease, Hum Mol Genet 8:247-257,1999

• 12) Piwon N, Gunter W, Schwake M et al:ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease, Nature 408:369-373,2000

• 13) Lloyd SE, Gunter W, Pearse SHS et al:Characterization of renal chloride channel, CLCN5, mutations in hypercalciuric nephrocalcinosis (kidney stone) disorders, Hum Mol Genet 6:1233-1997

P.110 掲載の参考文献

• 1) Arthus MF, Lonergan M, Crumley MJ et al:Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus, J Am Soc Nephrol 11:1044-1054,2000
  pubmed

• 2) 佐々木 成:先天性腎疾患8腎性尿崩症,医学のあゆみ 193巻1号:43-46,2001

• 3) Peter MT Deen, Namette Marr, Erik-Jan Kamsteeg et al:Nephrogenic diabetes insipidus, Curr Opin Nephrol Hypertens 9:591-595,2000

• 4) Gamba G et al:Molecular cloning, priinary structure, and characterization of two members of themammalian electroneutral sodium-(potassium) -chloride cotransporter family expressed in kidney, JBiol Chem 269:17713-17722,1994

第4章 糸球体疾患の最新治療

P.114 掲載の参考文献

• 1) Brouhard BH, Travis LB:Acute postinfectious glomerulonephritis. In:Pediatric Kidney Disease (Edelmann CM Jr ed) , 2nd ed, Little, Brown and Company,Boston/Toronto/London, p 1199-1221,1992

• 2) 伊藤克己,服部元史:急性腎炎症候群,医学と薬学 41:7-12,1999
  Medical*Online

• 3) Ybshizawa N, Suzuki Y, Oshima S et al:Asymptomatic acute poststreptococcal glomerulonephritis following upper respiratory tract infections caused by group A streptococci, Clin Nephrol 46:296-301, 1996

• 4) 腎疾患患者の生活指導食事療法に関するガイドライン,日腎会誌39:1-37,1997

• 5) 服部元史,伊藤克己:腎性高血圧,小児科診療 62 (増刊号) :429-431,1999

• 6) Cleper R, Davidvitz M, Halevi R et al:Renal functional reserve after acute poststreptococcal glomerulonephritis, Pediatr Nephrol 11:473-476,1997

• 7) Ybshizawa N, Oshima S, Sagel I et al:Role of a streptococcal antigen in the pathogenesis acute streptococcal acute glomerulonephntis. Characterization of the antigen and a proposed mechanism for the disease, J Immunol 148:3110-3116, 1992

• 8) Johnston KH, Zabriskie JB:Purification and partial characterization of the nephritis strain-associated protein from streptococcus pyogenes, J Exp Med 163:697-712,1986
  pubmed

• 9) Vogt A, Batsford S, Rodriguez-Iturbe B et al:Cationic antigens in poststreptococcal glomerulonephntis, Clin Nephrol 20:271-279,1983
  pubmed

• 10) 尾田高志,吉澤信行:,急性腎炎症候群別冊医学のあゆみ腎疾患-state of arts(Ver.2) (成清卓二,浅野泰編) ,医歯薬出版,東京,p 244-248,1997

• 11) Ohsawa I, Ohi H, Endo M et al:Evidence of lectin complement pathway activation in poststreptococcal glomerulonephritis, Kidney Int 56:1158-1160, 1999
  pubmed

• 12) Schulze K, Medina E, Talay SR et al:Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response, Infection and Immunity 69:622-625,2001
  pubmed

• 13) 南学正臣,山田耕永,堀 雄-:補体調節蛋白と腎炎治療,腎と透析 48:215-218,2000

• 14) 大井洋之:補体と補体制御蛋白,腎と透析 48:27-31,2000

• 15) Couser WG, Johnson RJ, Young BA et al:The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomeruonephritis, J Am Soc Nephrol 15:1888-1894,1995

P.121 掲載の参考文献

• 1) 小山哲夫ほか:RPGNの早期発見 早期治療に関する研究-指針治療法の試案-.厚生省特定疾患進行性腎障害調査研究班平成11年度研究業績 66-88,2000

• 2) Churg J, Sobin LH:Classification of glomerulonephritis. In:Churg J, Bernstein J, Glassock RJ, eds. Renal Diesease. Classification and Atlas of Glomerular diseases. Tokyo, Igaku-Shoin, p 3-19. 1995

• 3) Davies DJ et al:Segmental necrotising glomemlonephrits with antineutrophil antibody:possible arbovirus aetiology?BMJ 285:606,1982
  pubmed

• 4) 吉田雅治,長澤俊彦:血管炎症候群,とくにWegener肉芽腫症の好中球細胞質に対する自己抗体,医学の歩み145:649-650,1988

• 5) Falk RJ, Jemette JC:Anti-neutrophic cytoplasmic autoantibodies with specificity for myeloperoxydase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis, N Engl JMed 318:1651-1657,1988

• 6) Hogan SL et al:Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis, J Am Soc Nephrol 7:23-32,1996
  pubmed

• 7) Westman KW et al:Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement, J Am Soc Nephrol 9:842-52,1998
  pubmed

• 8) Franssen CFM et al:Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificities:distinct differences between patients with anti-proteinase 3 and anti-myeloper-oxidase autoantibodies, J Intem Med 244:209-216, 1998

• 9) Fauci AS et al:Cyclophosphamide therapy of severe systemic necrotizing vasculitis, N Engl J Med 301:235-8,1979
  pubmed

• 10) Couser WG:Idiopathic rapidly progressive glomerulonephritis, Am J Nephrol 2:57-69,1982
  pubmed

• 11) Nachnan PH et al:Treatment response and relapse in antineutrophil cytoplasnic autoantibody-associated microscopic polyangiitis and glomerulonephritis, J Am Soc Nephrol 7:33-9,1996
  pubmed

• 12) De La Torre M et al:Monthly cyclophosphamide pulses in the treatment of crescentic glomerulonephritis, transplant Proc 30:3952-4,1998
  pubmed

• 13) Nowack R et al:Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis:a pilot study in 11 patients with renal involvement, J Am Soc Nephrol 10:1965-71,1999

• 14) Jindal KK:Management of idiopathic crescentic and diffuse proliferative glomerulonephritis:evidence-based recommendations, Kidney Int. Suppl;70:S 33-40,1999

• 15) Jayne DRW, Rasmussen N:Treatment of antineutro-phil cytoplasm autoantibody-associated systemic vasculitis:Initiatives of the Europian community systemic vasculitis clinical study group, Mayo Clin Proc 72:737-747,1997

P.126 掲載の参考文献

• 1) Imai H, Hamai K, Komatsuda A et al:IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis, Kidney Int 51:270-276,1997
  pubmed

• 2) Oliveira DB:Membranous nephropathy:an IgG4-mediated disease, Lancet 351:670-671,1998
  pubmed

• 3) Tencer J, Torffvit O, Thysell II et al:Urine IgG2/IgG4-ratio indicates the significance of the charge selective properties of the glomerular capillary wall for the macromolecular transport in glomemlar disease, Nephrol Dial Transplant 14:1425-1429,1999

• 4) Holdsworth SR, Kitching AR, Tipping PG:Th1 and Th2 helper cell subsets affect patterns of injury and outcomes in glomerulonephritis, Kidney Int 55:1198-1216,1999
  pubmed

• 5) Leenaerts PL, Hall BM, Van Damme BJ et al:Active Heymann nephritis in complement component C6 deficient rats, Kidney Int 47:1604-1614,1995
  pubmed

• 6) Montinaro V, Lopez A, Monno R et al:Renal C3 synthesis in idiopathic membranous nephropathy:correlation to urinary C5b-9 excretion, Kidney Int 57:137-146,2000
  pubmed

• 7) Takano T, Cybulsky AV:Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells. Role of cyclooxygenese-1 and-2, Am J Pathol 156:2091-2101,2000

• 8) Cybulsky AV, Takano T, Papillon J et al:Complement-induced phospholipase A2 activation in experimental membranous nephropathy, Kidney Int 57:1052-1062,2000
  pubmed

• 9) Saito A, Yamazaki H, Rader K et al:Mapping rat megalin:The second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis, Proc Natl Acad Sci USA 93:8601-8605,1996
  pubmed

• 10) 今井裕一,大谷 浩,涌井秀樹:膜性腎症の治療 戦略.副腎皮質ステロイド薬について腎と透析 50:151-157,2001

• 11) Erwin DT, Donadio JV Jr, Holley KE:The clinical course of idiopathic membranous nephropathy, Mayo Clinic Proceeding 48:697-712,1972

• 12) Donasio JV Jr, Torres VE, Velosa JA et al:Idiopathic membranous nephropathy:The natural history of untreated patients, Kidney Int 33:708-715, 1988

• 13) Cattran DC, Delmore T, Roscoe J et al:A randomized controlled trail of prednisolne in patients with idiopathic membranous nephropathy, New Engl J Med 320:210-215,1989

• 14) Falk RJ, Hogan SL, Muller KE et al:Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network, Ann Intern Med 116:438-45,1992
  pubmed

• 15) Ponticelli C, Zucchelli P, Passerini P et al:A 10-year-follow-up of a randomized study wih methylprednisolome and chlorambucil in membranous nephropathy, Kidney Int 48:1600-1604,1995

• 16) Reichert LJ, Huysmans FT, Assmann K et al:Pre-serving renal function in patients with membranous nephropathy:daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide, Ann Intern Med 121:328-33,1994

• 17) Ponticelli C, Altieri P, Scolari F et al:Ar andomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy, J Am Soc Nephrol 9:444-50,1998

• 18) Cattran DC, Appel GB, Hebert LA et al:Cyclosporine in patients with steroid-resistant membranous nephropathy:A ramdomized trial, Kidney Int 59:1484-1490, 2001

• 19) Muirhead N:Management of idiopathic membranous nephropathy:evidence-based recommendations, Kidney lnt Suppl 70:S 47-55, 1999

• 20) Geddes CC, Cattran DC:The treatment of idiopathic membranous nephropathy Semin Nephrol 20:299-308,2000
  pubmed

第5章 続発性腎疾患の最新治療

P.131 掲載の参考文献

• 1) 槙野博史:現在なぜ糖尿病性腎症が問題になっているのか.槙野博史編著,糖尿病性腎症-発症進展機序と治療-,診断と治療社,東京,p 1-4,1999

• 2) Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M:Reversal of lesions of diabetic nephropathy after pancreas transplantation, N Engl J Med 339:69-75,1998
  pubmed

• 3) 寺岡 慧,谷口 洋,馬場園哲也,伊藤壽記,金澤康徳,出月康夫:我が国における糖尿病患者と膵移植の現況,最新医学 53:2154-2167,1998
  Medical*Online

• 4) 寺岡 慧,馬場園哲也,岩本安彦:膵移植の現況と将来の展望,分子糖尿病学の進歩1999p 133-142,1999

• 5) 寺岡 慧,東間 紘,伊藤克己,二瓶 宏:腎臓 移植(膵腎複合移植も含む) の現況臨床透析 16:1749-1760,2000

• 6) 移植関係学会合同委員会,膵臓移植中央調整委員会編:膵臓移植に関する実施要綱 1999

• 7) Shapiro AM, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV:Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, New Engl J Med 343:230-238,2000

• 8) 膵 膵島移植研究会膵島移植ワーキンググループ編:膵島移植の指針 1998

• 9) Rosengard AM, Cary NR, Langford GA, Tucker AW, Wallwork J, White DJ:Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection, Transplantation 59:1325-1333,1995
  pubmed

• 10) Groth CG, Korsgren O, Tibell A, Tollemar J, Moller E, Bolinder J, Ostman J, Reinholt FP, Hellerstrom C, Andersson A:Transplatation of porcine fetal pancreas to diabetic patients, Lancet 344:1402-1404,1994

• 11) Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, Chapman LE, Lockey C, Onions D, Otto E:Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue, Science 285:1236-1241,1999
  pubmed

• 12) Heneine W, Tibell A, Switzer WM, Sandstrom P, Rosales GV, Mathews A, Korsgren O, Chapman LE, Folks TM, Groth CG:No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts, Lancet 352:695-699,1998
  pubmed

• 13) Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Moloney MK, Schmehl M, Harris M:Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation, Lancet 343:950-951, 1994

• 14) Sun Y, Ma X, Zhou D, Vacek I, Sun AM:Normalization of diabetes in apontaneously diabetic cynomologous monkeys by xenografts of microencapsulated pocine islets without immunosuppression, J Clin Invest 98:1417-1422,1996

• 15) Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, Yamamura K:Establishment of a pancreatic beta cell line that retains glucose-in-ducible insulin secretion:special refenrece to reference to expression of glucose transporter isoforms, Endocrinology l 27:126-132,1990

• 16) Efrat S, Fusco-DeMane D, Lemberg H, al Emran O, Wang X:Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated onocogene, Proc Natl Acad Sci USA 92:3576-3580,1995

• 17) Fleischer N, Chen C, Surana M, Leiser M, Rossetti L, Pralong W, Efrat S:Functional analysis of a conditionally transformed pancreatic beta-cell line, Diabetes 47:1419-1425,1998
  pubmed

• 18) Jonsson J, Carlsson L, Edlund T, Edlund H:Insulin-promotor-factor is required for pancreas development in mice, Nature 371:607-610, 1994

• 19) Watanabe T, Yonemura Y, Yonekura H, Suzuki Y, Miyashita H, Sugiyama K, Moriizumi S, Unno M, Tanaka O, Kondo H:Pancreatic beta-cell replication and amelioration of surgical diabetes by Reg protein, Proc Natl Acad Sci USA 91:3589-3592, 1994
  pubmed

• 20) Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Comelius JG:Reversal of insulin-dependent diabetes using islet generated in vitro from pancreatic stem cells, Nature Medicine 6:278-282,2000

• 21) Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seijffers R, Kopolovic J, Kaiser N, Karasik A:Pancreatic and duodenal homeobox gene 1 induced expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia, Nature Medicne 6:568-572,2000

P.139 掲載の参考文献

• 1) Klag MJ, Whelton PK, Randall BL et al:Blood pressure and end-stage renal disease in men, N Engl J Med 334:13-18,1996

• 2) 後藤淳郎,山田 薫,藤田敏郎:本態性高血圧, 腎実質性高血圧における腎障害予防のための血圧コントロール,循環器専門医 9:印刷中, 2001

• 3) Peterson JC, Adler S, Burkart JM et al:Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann lnt Med 123:754-762, 1995

• 4) Jafar TH, Schmid CH, Stark PC et al:The optimal level of blood pressure and urine protein excretion for the prevention of progression of chronic renal disease, J Am Soc Nephrol l l:AO345,2000

• 5) Ruilope LM, Salvetti A, Jamerson K et al:Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension optimal treatment study(HOT) ,J Am Soc Nephrol 12:218-228, 2001

• 6) Schllaci G, Reboldi G, Verdecchia P:High-nomal serum creatinine concentration is a predictor of cardiovascular risk in essential hyperension, Arch Int Med 161:886-891,2001

• 7) Wang J-G, Staessen JA, Fagard RH et al:Prognostic significance of serum creatinine and uric acid in older patients with isolated systolic hypertension, Hypertension 37:1069-1074, 2001
  pubmed

• 8) Mann JFE, Gerstein HC, Pogue J et al:Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril:The HOPE randomized trial, Ann Int Med 134:629-636, 2001

• 9) Floley RN, Parfrey PS, Sarnak MJ:Clinical epidemiology of cardiovascular disease in chronic renal disease, Am J Kidney Dis 32(Suppl 3) :S 112-S 119, 1998

• 10) Lazarus JM et al:Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group, Hypertension 29:641-650, 1997

• 11) Schwenger V, Ritz E:Audit of antihypertensive treatment in patients with renal failure, Nephrol Dial Transplant 13:3091-3095, 1998
  pubmed

• 12) Maschi G:How good are nephrologists at controlling blood pressure in renal patients? Nephrol Dial Transplant 14:2075-2077,1999

• 13) Charra B, Bergstrom J, Scribner BH:Blood pressure control in dialysis patients:importance of the lag phenomenon, Am J Kidney Dis 32:720-724,1998
  pubmed

• 14) Gunal AI, Duman S, Ozkahya M et al:Strict volume control normalizes hypertension in peritoneal dialysis patients, Am J Kidney Dis 37:588-593,2001
  pubmed

• 15) Bakris GL, Williams M, Dworkin L et al:Preserving renal function in adults with hypertension and diabetes:a concensus approach, Am J Kidney Dis 36:646-661, 2000

• 16) Remuzzi G, Bertani T:Mechanisms of disease:pathophysiology of progressive nephropathies, N Engl J Med 339:1448-1456, 1998

• 17) Mann JFE, for the HOPE investigators:Should the results of the HOPE study affect nephrological practice? Nephrol Dial Transplant 15:453-454,2000

• 18) Bakris GL, Weir MR:Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine, Arch Int Med 160:685-693, 2000

• 19) Hebert LA, Wilmer WA, Falkenhain ME et al:Renoprotection:One or many therapies? Kidney Int 59:1211-1226,2001
  pubmed

• 20) Ruggenenti P, Schieppati A, Remuzzi G:Progression, remission, regression of chronic renal disease, Lancet 357:1601-1608, 2001
  pubmed

第6章 腎不全・透析療法

P.145 掲載の参考文献

• 1) Lieberthal W, Levine JS:Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury, Am J Physiol 271:F 477-F 488, 1996

• 2) Woolfson RC, Hillman K:C auses of acute renal failure, in Johnson RJ, Freehally J eds:Comprehensive Clinical Nephrology. Mosby, London, p 16.116.6, 2000

• 3) Miller TR et al:Urinary diagnostic indices in acute renal failure:A prospective study, Ann Intern Med 89:47-50, 1978
  pubmed

• 4) Nath KA, Norby SM:Reactive oxygen species and acute renal failure, Am J Med 109:665-678,2000
  pubmed

• 5) Molitoris BA, Marrs J:The role of cell adhesion molecules in ischemic acute renal failure, Am J Med 106:583-592, 1999
  pubmed

• 6) Chatterjee PK, Cuzzocrea S, Brown PA et al:Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in rat, Kidney Int 58:658-673,2000
  pubmed

• 7) Linas SL, Whittenburg D, Parsons PE et al:Ischemia increases neutrophil retention and worsens acute renal failure:Role of oxygen metabolites and ICAM-1, Kidney Int 48:1584-1591, 1995
  pubmed

• 8) Garcia-Criado FJ, Eleno N, Santos-Benito F et al:Protective effect of exogenous nitric oxide on the renal function and inflammatory response in a model of ischemia-reperfusion, Transplantation 66:982-990, 1998

• 9) Noiri E, Peresleni T, Miller F et al:In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia, J Clin Invest 97:2377-2383, 1996
  pubmed

• 10) Conger JD:Interventions in clinical acute renal failure:W hat are the data? Am J Kidney Dis 26:565-576, 1995

• 11) Matsushima H, Yonemura K, Ohishi K et al:The role of oxygen free radicals in cisplatin-induced acute renal failure, J Lab Clin Med 131:518-526, 1998
  pubmed

• 12) Nakajima T, Hishida A, Kato A:Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats, Am J Physiol 266:F 425-F 431, 1994

• 13) Kelly KJ, Meehan SM, Colvin RB et al:Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody, Kidney Int 56:922-931,1999
  pubmed

• 14) Ghielli M, Verstrepen WA, De Greef KEJ et al:Anti-bodies to both ICAM-1 and LFA-1 do not protect the kidney against toxic (HgCl2) iroury, Kidney lnt 58:1121-1134,2000

• 15) Bakris GL, Lass N, Gaber AO et al:Radiocontrast medium-induced declines in renal function:A role for oxygen free radicals, Am J Physiol 258:F 115-F 120,1990

• 16) Tepel M, van der Giet M, Schwarzfeld C et al:Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine, N Engl J Med 343:180-184,2 000

• 17) Cigarroa RG, lange RA, Williams Rh et al:Dosing of contrast material to prevent contrast nephropathy in patients with renal disease, Am J Med 86:649-652, 1989
  pubmed

• 18) Rangel-Frausto MS, Pittet D, Costigan M et al:The natural history of the systemic inflammatory response syndrome(SIRS) :A prospective study, JAMA 273:117-123, 1995
  pubmed

• 19) 平澤博之,菅井桂雄,織田成人:外科的侵襲と臓器不全:腎臓,日外会誌 97:765-770,1996

• 20) Demko TM, Diamond JR, Groff J:Obstructive nephropathy as a result of retroperitoneal fibrosis:A re-view of its pathogenesis and associations, J Am Soc Nephrol 8:684-688,1997

P.151 掲載の参考文献

• 1) わが国の慢性透析療法の現況-1999年12月31日現在,日本透析医学会,2000

• 2) Klag MJ et al:Blood pressure and end-stage renal disease in men, N Engl J Med 334:13-18,1996.

• 3) Peterson JC et al:The Modification of Diet in Re-nal Disease Study Group:B lood pressure control, proteinuria, and the progression of renal disease, Am Intem Med 123:754-762,1995.

• 4) 高血圧治療ガイドライン 2000年版 日本高血圧学会高血圧治療ガイドライン作成委員会

P.156 掲載の参考文献

• 1) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況,1999 年12月31日現在,日本透析医学会 2000

• 2) 平沢由平ほか:rHuEPO使用ガイドライン作成に関する研究,平成2年度厚生科学研究腎不全医療研究事業研究報告書,三村信英編:87-89, 1991

• 3) National Kidney Foundation-Dialysis Outcomes Quality Initiative:NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure, Am J Kidney Dis 30:S 192-S 240,1997

• 4) Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure, European best practice guidelines for the management of anaemia in patients with chronic renal failure, Nephrol Dial Transplant 14(Suppl 5) :1-50, 1999

• 5) Ma JZ et al:Hematocrit level and associated mortality in hemodialysis patients, J Am Soc Nephrol 10:610-619,1999
  pubmed

• 6) Madore F et al:Anemia in hemodialysis patients:variables affecting this outcome predictor, J Am Soc Nephrol 8:1921-1929, 1997
  pubmed

• 7) Akiba T et al:W hy has the gross mortality of dialysis patients increased in Japan? Kidney Int 57(Suppl 74) :60-65, 2000

• 8) 椿原美治:保存期慢性腎不全患者に対するエリスロポエチン(rHuEPO) 療法の透析導入後の予後に及ぼす影響,腎不全11:13-17,1999

• 9) Macdougall IC et al:Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients, J Am Soc Nephrol 10:2392-2395,1999
  pubmed

• 10) Wrighton NC et al:Increased potency of an erythropoietin peptide mimetic through covalent dimerization, Nature Biotech 15:1261-1265,1997

• 11) Qureshi SA et al:Mimicry of erythropoietin by a nonpeptide molecule, Proc Natl Acad Sci USA 96:12156-12161,1999
  pubmed

• 12) Ye X Rivera VM et al:Regulated dehvery of thera peutic proteins after in Vivo somatic cell gene transfer, Science 283:88-91,1999

P.160 掲載の参考文献

• 1) Gejyo F, Yamada T, Odani S et al:A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin, Biochem Biophys Res Commun 129:701-706,1985
  pubmed

• 2) Yamaguchi I, Hasegawa K, Naiki H et al:Extension of A beta2M amyloid fibrils with recombinant human beta2-microglobulin, Amyloid 8:30-40,2 001

• 3) Floege J, Ketteler M:beta2-microglobulin-derived amyloidosis:an update, Kidney Int 59 Suppl 78:S 164-171, 2001

• 4) Araki H, Muramoto H, Oda K et al:Severe gastrointestinal complication of dialysis-related amyloidosis in two patients on long-term hemodialysis, Am J Nephrol 16:149-153,1996

• 5) Kazama JJ, Maruyama H, Gejyo F:Reduction of circulating beta2-microglobulin level for the treatment of dialysis related amyloidosis, Nephrol Dial Transp in press

• 6) Jadoul M, Drueke T, Zingraff J et al:Does dialysis-related amyloidosis regress after transplantation? Nephrol Dial Transplant 12:655-657, 1997
  pubmed

• 7) Suda T, Takahashi N, Udagawa N et al:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families, Endocr Rev 1999Jun;20:345-357, 1999
  pubmed

• 8) Homma N, Gejyo E Kobayashi H et al:Cystic radiolucencies of carpal bones, distal radius and ulna as a marker for dialysis-associated amyloid osteoarthropathy, Nephron 62:6-12, 1992

• 9) Maruyama H, Gejyo F, Arakawa M:Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients, Nephron 61:37-44, 1992
  pubmed

• 10) Gejyo F, Maruyama H, Kazama J et al:Role of macrophages inβ 2-microglobulin-related dialysis amyloidosis, Contrib Nephrol 112:97-104, 1995

• 11) Kazama JJ, Maruyama H, Gjyo F:Osteoclastogenesis/activation in dialysis related amyloid osteopathy, Am J Kidney Dis in press

• 12) Ohashi K, Hara M, Kawai R et al:Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column, Kidney Int 41:1646-1652,1992

• 13) Fukagawa M, Kazama JJ, Shigematsu T:Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases, Am J Kidney Dis in press

• 14) Kong YY, Feige U, Sarosi I et al:Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand, Nature 402:304-309, 1999
  pubmed

• 15) Kobayashi K, Takahashi N, Jimi E et al:Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction, J Exp Med 191:275-286,2000
  pubmed

• 16) Fox SW, Fuller K, Chambers TJ:Activation of osteoclasts by interleukin-1:divergent responsiveness in osteoclasts formed in vivo and in vitro, J Cell Physiol 184:334-340, 2000
  pubmed

• 17) Rodan GA, Martin TJ:Therapeutic approaches to bone diseases, Science 289:1508-1514,2000
  pubmed

• 18) Miyata T, Hori O, Zhang J et al:The receptor for advanced glycation end products(RAGE) is a central mediator of the interaction of AGE-β2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis, J Clin Invest 98:1088-1094, 1996

• 19) Niwa T, Miyazaki S, Katsuzaki T et al:Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis, Kidney Int 48:771-778,1 995

• 20) Kazama JJ, Arakawa M, Gejyo F:Synovial inflammatory cells assimilated 131I-β2-microglobulin in patients with dialysis related amyloidosis, Amyloid 5:24-29,1 998

P.164 掲載の参考文献

• 1) Report of the Therapeutics and Technology Assess-ment Subcommittee of the American Academy of Neurology:Assessment of plasmapheresis, Neurology 47:840-843, 1996

• 2) Haupt WF, Rosenow F, van der Ven C et al:Sequential treatment of Guillain-Barre syndrome with extrcorporeal elimination and intravenous immunoglobulin, J Neurol Sci 137:145-149, 1996

• 3) French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome:One year follow-up, Ann Neurol 32:94-97,1992

• 4) Plasma Exchanges/Sandoglobulin Guillain-Barre Syndrome Trial Group:Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome, Lancet 349:225-230, 1997
  pubmed

• 5) Dyck PJ, Daube J, 0'Brien P et al:Plasma exhange in chronic inflammatory demyelinating polyradiculoneuropathy, N Engl J Med 314:461-465, 1986

• 6) Hahn A, Bolton C, Pillay N et al:Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy:a double-blind, sham-controlled, cross-over study, Brain 119:1055-1066,1996
  pubmed

• 7) Dyck PJ, Low PA, Windebank AJ et al:Plasma exchange therapy in polyneuropathy associated with monoclonal gammopathy of undetermined signifcance, N Engl J Med 325:1482-1486, 1991

• 8) Thronton CA, Griggs RC:Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease, Ann Neurol 35:260-268, 1994

• 9) Shibuya N, Sato T, Osamu M et al:Immunoadsorption therapy for myasthenia gravis, J Neurol Neurosurg Psychiatry 57:578-581,1994

• 10) Grob D, Simpson D, Mitsumoto H et al:Treatment of myasthenia gravis by immunoadsorption of plasma, Neurology 45:338-344 1995
  pubmed

• 11) Lewis RA, Selwa JF, Lisak RP, Myasthenia gravis:immunolgical mechanisms and immunotherapy, Ann Neurol 37(S 1) :S 51-S 62,1995

• 12) Sanders DB:Lambert-Eaton myasthenic syndrome; clinical diagnosis, immune-mediated mechanism and update on therapies, Ann Neurol 37(S 1) :S 63-S 73, 1995

• 13) Weiner HL, Dau PC, Kharti BO et al:Double-blind study of true vs sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis, Neurology 39:1143-1149,1 989

• 14) 与芝 真,岩村ゆかり:PMMA膜を用いた血液濾 過透析法,最新医学 42:1625-1629,1987

• 15) Hirasawa H, Sugai T, Ohtake Y et al:Blood purification for prevention and treatment of multiple organ failure, World J Surgery 20:482-486, 1996
  pubmed

• 16) Furlan M, Lammle B:Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpuranew insights into underlying biochemical mechanisms, Nephrol Dail Transplant 15:1112-1114, 2000

• 17) 伊藤和彦:疾患別治療法,E.血液疾患,プラズマフェレシスマニアル 93.中外医学社,東京,p 191-198,1993

• 18) Mabuchi H, Koizumi J, Shimizu M et al:Long-tem efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 82:1489-1495,1998

• 19) 谷 徹,花澤-芳,小玉正智ほか:エンドトキシン吸着器の有効性と限界ICUとCCU 19:797-804, 1995

• 20) Sawada K, Ohnishi K, Fukui S et al:Leukocytaphereisis therapy, perfomed with leukocyte removal filter for inflammatory bowel disease, J Gastroenterol 30:322-329,1995

P.168 掲載の参考文献

• 1) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況(1999年12月31日現在) 日本透析医学会,名古屋,p 60-61,2000

• 2) 斎藤 明:Protein-pemleable hemofiltersの除去性能-糸球体濾過へのアプローチ,人工臓器13:1303-1313,1984

• 3) Gejo F et al:A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin, Biochem Biophys Res Commum 129:701-706, 1985

• 4) Usuda M et al:New stmultaneous HF and HD with no infusion fluid, Trans Am Soc Artif lntern Organs 28:24-27,1982
  pubmed

• 5) Shinzato T et al:Newly developed economical and efficient push/pull hemodiafiltration, Contrib Nephrol,108, Karger, Basel, P 79-86, 1994

• 6) Shinzato T et al:Effectiveness of new push/pull hemodiafiltration for arthralgia in long-term hemodialysis patients, Contrib Nephrol,112, Karger, Basel, p 111-118, 1995

• 7) 山下明泰:HDFの除去理論, HDF療法ハンドブック,南江堂,東京,p 20-33,2000

• 8) 武本佳昭ほか:新しい血液浄化法としての pre&post HFの有効性 第38回日本腎臓学会総会 日腎会誌37(学術総会号) :425,1995

• 9) 柴田 猛ほか:Dialyzerの逆濾過を応用したβ2-MG 除去の検討,腎と透析 36(別冊) :17-21, 1994

• 10) 政金生人,矢吹清-,石崎 充:エンドトキシンフリー透析液透析液で何が変わったか,透析会誌30(supple) :552,1997

• 11) 政金生人ほか:無エンドトキシン透析液は血清β2-MGを低下させ続けたか,腎と透析 44(別冊) :107-110,1998

• 12) 甲田 豊,鈴木正司,平澤由平:HPM が変えた生存率と透析アミロイド症の発症リスク,腎と透析 47(別冊) :28-31,1999

• 13) 金成 泰ほか:セントラルオンラインHDFシステムの安全性と蛋白除去特性,腎と透析 36(別冊) :22-27,1994

• 14) 鈴木 充:濾過速度,透析スタッフのための血液浄化の基礎,アイビーシー,東京,p 57-72,1989

• 15) 小野正孝ほか:Hemofilter の特性とHD,on-line HDF における物質除去性能について,腎と透析 36 (別冊) :28-31,1994

• 16) Lowrie EG, Lew NL:Death risk in hemodialysis patients:the predictive value of commonly measured varialbles and evaluation of death rate differences between facilities, Am J Kid Dis 15:458-482,1990

• 17) Saito A et al:Maintaining low concentrations of Plasma β2-microglobulin through continuous slow haemofiltration, Nephrol Dial Transplant 10(supple 3) :52-56, 1995

• 18) Saito A et al:Separation of an inhibitor of erythropoiesis in "middle molecules" from patients with chronic renal failure, Clin Chem 32:1938-1941, 1986
  pubmed

P.176 掲載の参考文献

• 1) Gotloib L, Shostak A and Wajsbrot V:Functional structure of the peritoneum as a dialysing membrane. Gokal R, Khanna R, Krediet R et al:Textbook of Peritoneal Dialysis. Kluwer Academic Publishers, London, P 38-106,2000

• 2) Popovich RP, Moncrief JW, De cherd JB et al:The definition of novel portable/wearable equilibrium peritoneal dialysis technique, Trans Am Soc Artif Intern Organs 5:64(abstract) ,1976

• 3) Paolo ND and Sacchi G:The normal Peritoneum. Atlas of Peritoneal Histology, Perit Dial Int 20(suppl.3) :S 9-S 36,2000

• 4) Simonescu M and Skmonescu N:Organization of cell junctions in peritoneal mesothelium, J Cell Biol 74:98-110,1977

• 5) Gotloib L, Shostak A, Bar-Sella P et al:Fenestrated capillaries in human peritoneal and rabbit diaphragmatic peritoneum, Nephron 41:200-202,1985

• 6) Tenckhoff H and Schechter H:A bacteriologically safe peritoneal access device, Trans Am Soc Artif Int Organs 14:181-187,1968

• 7) Twardowski M, Prowant BF, Nichols KWet al:Six-year experience with Swan neck catheters, Perit Dial Int 12:384-389,1992

• 8) Tenckhoff H:Chronlc peritoneal daialysis manual, University of Washington School of Medicine, Seattle, p 19-22,1974

• 9) Nakamoto M:Keeping the catheter-surgical and medical tactics, Nephrology 3(Suppl.1) :177,1997

• 10) Rottemburg J, Tacq D, Vonlanthen M et al:Straight or curled Tenckhoff catheter for continuous ambulatory peritoneal dialysis (CAPD) Perit, Dial Bull I:123-124,1981

• 11) Nielsen P, Hemmingsen C, Friis S et al:Comparison of straight and curled Tenckhoff peritoneal dialysis catheters implanted by percutaneous technique:a prospective randomized study, Perit Dial lnt 15:18-21,1995

• 12) 太田和夫:CAPDカテーテルの周辺問題,腎と透析 16:155-160,1984

• 13) Oreopoulos DG, Izatt S, Zellerman G et al:A prospective study of the effectiveness of three permanent peritoneal catheters, Proc Dial Trartsplant Forum:96-100, 1976
  pubmed

• 14) Twardowski ZJ, Nichols WK, Kha【ma Ret al:Swan neck peritoneal dialysis catheters, Design, features, sterilizing, insertion and break-in, Instruction manual published by:A ccurate Surgical lnstruments Corp. Richmond St. W Toronto, Ontario, Canada, p 589-590,1986

• 15) Lye WC, Kour NW, van der Straaten, J C et al:A prospective randomized comparison of the swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD, Perit Dial lnt 16(Suppl.1) :S 333-335,1996

• 16) Rodriguez-Carmona A, Falcon TG, Fontan MP et al:Survival on chronic peritoneal dialysis:have results improved in the 1990s? Perit Dial Int 16 (Suppl.1) :S 410-S 413, 1996

• 17) Twardowski ZJ, Nichols WK, Nolph KD et al:Swan neck presternal("bath tub") catheter for peritoneal dialysis. Khanna R, Nolph K D, Prowant B F et al (eds.) :Advances in peritoneal dialysis. Peritoneal Dialysis Publications Inc. Toronto, Canada, p 316-324,1992

• 18) 窪田 実,石黒 望,濱田千江子ほか:バスタブカテーテル(presternal catheter) の成績,腎と透析別刷アクセス2000:59-63,2000

• 19) Twardowski ZJ, Prowant BF, Nichols WKet al:Six-year experience with Swan neck presternal peritoneal dailysis catheter, Perit Dial Int 18:598-602, 1998

• 20) Warchol S, Roszkowska-Blaim M and Sieniawska M:Swan neck presternal peritoneal dialysis catheter:Five-year experience in children, Perit Dial Int 18:183-187,1998
  pubmed

• 21) 石崎 允:キャップディールコラーゲンカフの1年間の使用経験.太田和夫監修,腹膜透析研究会編:腹膜透析 97東京医学社,東京,p 249-251,1997

• 22) 石崎 允:コラーゲンカフ付きカテーテルの成績腎と透析別刷アクセス2000:65-68,2000

• 23) DiPaolo N, Garosi G, Guarnieri A et al:The self positioning datheter. Proceedings of the Vll Italian Congress on Peritoneal Dialysis, Milan:Wichtig Editore, p 539-542,1993

• 24) DiPaolo N, Petrini G, Garos G et al:Anew self-locating peritoneal catheter, Perit, Dail Int 16:623-627, 1996

• 25) Pommer W, Brauner M, Westphale H-J et al:Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients:Silver ring prophylaxis at the catheter exit study, Am J Kidney Dis 32:752-760,1998

• 26) Buoncristiani U, Bianchi P, Cozzari Met al:A new safe simple connection system for CAPD Int J Nephrol Urol Androl I:50-53, 1980

• 27) Bazzato G, Landini S, Coli Uet al:A new technique of continuous am, bulatory peritoneal dialysis (CAPD) double-bag system for freedom to the patient and significant reduction of peritonitis, Clin Nephrol 13:251,1980

• 28) Feriani M, La Greca G, Kriger FL et al:CAPD systems and solutions. Gokal R and Nolph KD(eds.) :The textbook of peritoneal dialysis. Kluwer Academic Publisher, Dordrecht, p 233-270,1994

• 29) Popovich RP, Moncrief JW, Sorrels-Akar,`PAJ, et al:The ultra-violet germicidal system:t he elimination of distal contamination in CAPD, Maher JF and Winchester JF(eds.) :Frontiers in Peritoneal Dialysis. Field and Rich, New York, p 169-176,1986

• 30) Hamilton R, Charytan C, Kurtz S et al:Reduction in peritonitis frequency by the Dupont sterile connection device, Trans Am Soc Artif Organs 61:651-654, 1985

• 31) Diaz-Buxo JA, Walker PJ, Famer CD et al:Continuous cyclic peritoneal dialysis, Trans Am Soc Artif Inten Organs 27:51-53,1981

• 32) Nakagawa D, Price C, Stinebaugh B et al:Continuous cyclic peritoneal dialysis:aviable option in the treatment of chronic renal failure, Trans Am Soc Artif Intern Organs 27:55-57, 1981

• 33) Stephen RF:Reciprocating peritoneal dialysis with a subcutaneous peritoneal catheter Dial Transplant 7:834-838,1978

• 34) Cruz C, Dumler R, Schmidt R et al:Enhanced peritoneal dialysis delivery with PD-PLUS", Adv Perit Dial 8:288-290,1992

• 35) Diaz-Buxo JA:Automated peritoneal dialysis. A therapy in evolution. Ronco C, Amici G, Feriani M et al(eds.) :Automated Peritoneal Dialysis. Karger, Basel, pl-14,1999

• 36) Ronco C, Brendolan A and Zanella M:Evolution of machines for automated peritoneal dialysis. Ronco C,Amici G, Feriani M et al(eds.) Automated Peritoneal Dialysis. Karger, Basel, p 141-161,1999

• 37) Nilsson-Thorell C B, Muscalu N, Andren AH et al:Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes, Perit Dial Int 13:208-213, 1993
  pubmed

• 38) Wieslander AP, Kjellstrand PT and Rippe B:Heat sterilization of glucose-containing fluids for peritoneal dialysis:Biological consequences of chemical alterations, Perit Dial Int 15:s 52-s 59,1995

• 39) Linden T, Forsback G, Deppisch R et al:3-deoxy-glucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis, Perit Dial Int 18:290-293,1998

• 40) Nakayama M, Kawaguchi Y, Yamada Ket al:Immunohisto-chemical detection of advanced glycosylation end products in the peritoneum and its possible pathophysiological role in CAPD, Kidney Int 51:182-186,1997

• 41) Tzamaloukas AH:Peritoneal toxicities of hypertonic dextrose dialysate, Adv Perit Dial 15:217-Z 21,1999

• 42) Witowski J and Jorres A:Glucose degradation products:Relationship with cell damage, Perit Dial Int 20(Suppl.2) :s 31-s 35,2000

• 43) Brandi L, Nielsen PK, Bro S et al:Long-term effects of intermittent oral alphacalcidol, calcium carbon-ate and low-calcium dialysis(1.25 mmol/L) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis, J Ilt Med 244:121-131,1998

• 44) Yang AH, Chen JY, Lin Yet al:Peritoneal dialysis solution induces apoptosis of mesothelial cells, Kidney Int 51:1280-1288,1997

• 45) 永井志保:培養腹膜中皮細胞繊維芽細胞の障害性と機能に及ぼす腹膜透析排液および培養Ca濃度の影響,透析会誌 32:1011-1019,1999

• 46) Douvdevarti A, Rapoport J, Konforty A et al:Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages, J Am Soc Nephrol 6:207-213,1995
  pubmed

• 47) Horiuchi T, Nagasawa K, Inoue T et al:Effect of glucose degradation and pH in peritoneal dialysis on protiteration of rat peritoneal mesothelial cell and fibroblact, J Am Soc Nephrol 11:209A, 2000

• 48) Witowski J, Topley N, Jorres Aet al:Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cells artd interleukin-6 and prostaglandin synthesis, Kidney Int 47:282-293,1995

• 49) Feriani M, Kirchgessner J, La Greca Get al:Randomized long-term evaluation of bicarbonate-buffered CAPD solution, Kidney Int 54:1731-1738,1998

• 50) Mackenzie RK, Holmes CJ, Moseley Aet al:Bicarbonate/lactate-and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFCY secretion, J Am Soc Nephrol 9:1499-1506,1998

• 51) Frank-Peter F, Machleidt C and Rettenmeier AW:Plasticizers and inhibition of leukocyte function in vitro, Perit Dial Int 18:620-625,1998

• 52) Carossi S, Nasml MG, Schelotte C et al:A biocompatibility study on peritoneal dialysis solution bags for CAPD, Adv Perit Dial 9:138-142,1993

• 53) Mistry C, Gokal R, Peers E et al:A randomized multicenter clinical trial comparing isomolar icodextrin with hyperosmolar solutions in CAPD, Kidney Int 46:496-503,1994

• 54) Ho-Dac-Pannekeet MM, Schouten N, Langendijk MJ et al:Peritoneal transport characteristics with glucose polymer based dialysate, Kidney Int 50:979-986,1996
  pubmed

• 55) Jones M, Hagen T, Boyle CA et al:T reatment of malnutrition with 1.1% amino acid peritoneal dialysis solution:Results of a multicenter out-patient study, Am, J, Kidney Dis 32:761-769,1998

• 56) 野本 保,川口 良,酒井信治ほか:硬化性被嚢性腹膜炎(sderosingencapsulatingpdtonitis, SEP) 診断治療指針(案) -1997年における改訂-, 日本透析医学会会誌 31:303-311,1998

• 57) Shemin D:Gram negative rod peritonitis in peritoneal dialysis. Sem Dialysis 10:38-45,1997

• 58) 樋口千恵子,西村英樹,佐中 孜:腹膜繊維化肥厚に対する透析液の影響〜グルコースの影響, 第44回日本腎臓学会総会予稿集,日本腎臓学会雑誌 43(3) :159,2001

• 59) Rippe B, Simonsen O, Heimburger O et al:Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products, Kidney Int 59:348-357,2001
  pubmed

第7章 腎再生・腎移植

P.183 掲載の参考文献

• 1) Yoder MC, Hiatt K, Dutt P et al:Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac, Immunity 7:335-344, 1997
  pubmed

• 2) Cumano A, Dieterlen-Lievre F & Godin I:Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura, Cll 86:907-916, 1996

• 3) Medivinsky AL & Dzierzak E:Definitive hematopoiesis is autonomously initiated by the AGM region, Cell 86:897-906,1996

• 4) Nishikawa SI, Nishikawa S, Hirashima M et al:Progressive lineages allalysis by cell sorting and culture identifies FLK1+ VE-cadherin+ cells at a diverging point of endothelial and hematopoietic lineages, Development 125:1747-1757,1998

• 5) Jaffredo T, Gautier R, Eichmann A et al:Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny, Development 125:4575-4583,1998
  pubmed

• 6) North T, Gu TL, Stacy T et al:Cbfa2 is required for the formation of intra-aortic hematopoietic clusters, Development 126:2563-2575,1999
  pubmed

• 7) Takakura N, Huang XL, Naruse T et al:Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis, Immunity 9:677-686, 1998
  pubmed

• 8) Crews ST:Control of cell lineage-specifc development and transcription by bHLH-PAS proteins,Genes Dev 12:607-620,1998

• 9) Takakura N, Watanabe T, Suenobu S et al:Arole for hematopoietic stem cells in promoting angiogenesis, Cell 102:199-209,2000

• 10) Janowska-Wieczorek A, Marquez LA, Nabholtz JM et al:Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+cells and their transmigration through reconstituted basement membrane, Blood 93:3379-3390,1999
  pubmed

• 11) Tordljman R, Delaire S, Plouet J et al:Erythroblasts are a source of angiogenic factors, Blood 97:1968-1974, 2001

P.188 掲載の参考文献

• 1) Ikehara S, Kawamura M, Takao F et al:Organ-specificand systemic autoimmune diseases originate from defects in hematopoietic stem cells, Proc Natl Acad Sci USA 87:8341-8344,1990

• 2) Ikehara S, Ohtsuki H, Good RA et al:Prevention of type 1 diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation, Proc Natl Acad Sci USA 82:7743-7747,1985
  pubmed

• 3) Joske DJ et al:Autologous bone-marrow transplantation for rheumatoid arthritis, Lancet 350:337-338,1997
  pubmed

• 4) Krance R, Brenner M:BMT beats autoimmune disease, Nature Med 4:153-155,1998
  pubmed

• 5) Nishimura M, Toki J, Sugiura K et al:Focal segmental glomerular sclerosis, a type of intractable chronic glomerulonephritis, is a stem cell disorder, J Exp Med 179:1053-1058,1994
  pubmed

• 6) 宇都宮保典,宮崎陽一,浅野茂隆ら:骨髄移植後にメサンギウムへのIgA沈着の消失を認めた慢性 骨髄性白血病(CML) 合併IgA腎症の一例,日腎 会誌 39:62,1997

• 7) Imasawa T, Nagasawa R, Ut Sunomiya Y et al:Bone marrow transplantation attenuates murine IgA nephropathy:The role of a stem cell disorder, Kidney Int 56:1809-1817,1999

• 8) Imasawa T, Utsunomiya Y:Bone marrow transplantation for the treatment of IgA nephropathy, Exp Nephrol 2001, in press

• 9) Ikehara S:Bone marrow transplantation as a strategy for the treatment of autoimmune-linked renal disease, Renal Failure 18:1-18,1996
  pubmed

• 10) Gerson S:Mesenchymal stem cells:No longer second class marrow citizens, Nature Med 5:262-264, 1999
  pubmed

• 11) Ferrari G, Cusella-De Angelis G, Coletta M et al:Muscle regeneration by bone narrow-derived myo-genic progenitors, Science 279:1528-1530,1998

• 12) Orlic D, Kajstura J, Chimenti S et al:Bone marrow cells regenerate infarcted myocardium, Nature 410:701-705,2001
  pubmed

• 13) Imasawa T, Utsunomiya Y, Kawamura T et al:The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells, J Am Soc Nephrol 2001, in press

• 14) Harendza S, Lovett DH, Stahl RAK:The hematopoietic transcription factor PU.1 represses gelatinase a transcription in glomerular mesangial cells, J Biol Chem 275:19552-19559,2000

• 15) Fuchs E, Segre JA:Stem cells:A new lease on life, Cell 100:143-155,2000
  pubmed

• 16) Yokoo T, Utsunomiya Y, Ohashi T et al:Inflamed site-speciflc gene delivery using bone marrow-derived CD11bb℃D18 vehicle cells in mice, Hum Gene Ther 9:1731-1738,1998

• 17) Yokoo T, Ohashi T, Utsunomiya Y et al:Prophylaxis of antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells, Hum Gene Ther 10:2673-2678,1999
  pubmed

• 18) Kuncio GS, Neilson EG, Haverty T:Mechanisms of tubulointerstitial fibrosis, Kidney Int 39:550-556, 1991
  pubmed

• 19) Cheng QL, Chen XM, Li F et al:Effects of ICAM-1 antisense oligonucleotide on the tubulointerstitium in mice with unilateral ureteral obstruction, Kidney Int 57:183-190,2000
  pubmed

• 20) Yamagishi H, Yokoo T, Utsunomiya Y et al:Geneti-cally modified bone marrow-derived vehicle cells site specidically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy, J lmmunol 166:609-616,2001

P.191 掲載の参考文献

• 1) Kitamoto Y, Tokunaga H, Tomita K:V ascular endo-thelial growth factor is an essential molecule for mouse kidney developmet:Glomerulogenesis and Nephrogenesis, J Clin Invest 99:2351-2357, 1997

• 2) Iruela-Arispe L, Gordon K, Hugo C et al:Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis, Am J Pathol 147:1715-1727,1995
  pubmed

• 3) Ostendorf T, Kunter U, Eitner F et al:VEGF165 mediates glomerular endothelial repair, J Clin Invest 104:913-923,1999

• 4) Kim Y-G, Suga S-I, Kang D-H et al:Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy, Kidney Int 58:2390-2399,2000
  pubmed

• 5) Miyamoto K, Kitamoto Y, Tokunga H et al:Administration of VEGF165 suppresses endothelial infury and promotes repair of impaired glomeruli in experimental glomerulonephritis, Mol Biol Cell 11(Suppl) :235a,2000

• 6) 北本康則,徳永 寛,冨田公夫:血管内皮細胞増殖因子(VEGF) による糸球体の形成,腎と透析 48:219-225,2000

P.196 掲載の参考文献

• 1) Cavallo T:Tubulointerstitial nephritis, in Jannette J, Olson J, Schwartz M, Silva F(eds) :Heptinstalls Pathology of the Kidney, vol 1. Philadelphia, PA, Lippincott-Raven, pp 667-723,1998

• 2) Covin R, Fang L:Interstitial nephritis, in Tisher C, Brenner B(eds) :Renal Pathology With Clinical and Functional Correlations, vol 1. Philadelphia, PA, Lippincott, pp 728-776,1989

• 3) Cameron JS:Tubular and interstitial factor in the progression of glomerulonephritis, Pediatr Nephrol 6:292-303,1992
  pubmed

• 4) Tobac FG:Regeneration after acute tubular necrosis, Kidney Int 41:226-246,1992

• 5) Humes HD, Cieslinski DA, Ciombra TM et al:Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the ricovery of renal function in postischemic acute renal failure, J Clin Invest 84:1757-1762,1989

• 6) Miller SB, Martin DR, Kissane J et al:Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats, Am J Phisiol 266:F 129-F 134,1994

• 7) Miller SB, Martin DR, Kissane J et al:Insulin-like growth factor accelerates recovery from ischemic acute tubular necrosis in the rat, Proc Natl Acad Sci USA 89:11876-11880,1992
  pubmed

• 8) Mizuno S, Kurosawa T, Matsumoto K et al:Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease, J Clin Invest 101:1827-1834,1998

• 9) Takemura T, Kondo S, Hoinma T et al:T he membrane-bound foml of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells, J Biol Chem 272:31036-31042,1997

• 10) Sakurai H, Nigam SK:In vitro branching tubulogenesis:Implications for developmental and cystic disorders, nephron number, renal repair, and nephron engineering, Kidney Int 54:14-26,1998
  pubmed

• 11) Takemura T, Hino S, Kuwajima H et al:Induction of collecting duct morphogenesis in vitro by heparinbinding epidermal growth factor-like growth factor, J Am Soc Nephrol 12:964-972,2001

• 12) Higashiyama S, Lau K, Besner G et al:Structure of heparin-binding EGF-like growth factor, J Biol Chem 267:6205-6212,1992
  pubmed

• 13) Dluz S, Higashiyama S, Damm D et al:Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mRNA levels and secretion of active mitogen, J Biol Chem 268:18330-18334,1993
  pubmed

• 14) Miyoshi A, Higashiyama S, Nakagawa T et al:Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line, J Biol Chem 272:14349-14355,1997

• 15) Homma T, Sakai M, Yasuda T et al:Heparin-binding epidermal growth factor-like growth factor mRNA increases in response to acute renal injury, J Clin Invest 96:1018-1025,1995

• 16) Kawaida T, Matsumoto K, Shimazu H et al:Hepato-cyte growth factor prevents acute renal failure and accelerates renal regeneration in mice, Proc Natl Acad Sci USA gl:4357-4361,1994

• 17) Takemura T, Hino S, Murata Y et al:Coexpression of CD9 augments the ability of membrane-bound heparin-binding epidemal growth factor-like growth factor(proHB-EGF) to preserve renal epithelial cell viability, Kidney Int 55:71-81,1999

P.200 掲載の参考文献

• 1) Terasaki PI, Cecka JM, Gjertson DW et al:N Eng Med 333:333,1995

• 2) Hoshinaga K, Shiroki R, Naide Y et al:Clinical Transplant 1998:213,1998

• 3) Koostra G:Transplantation, 63:917,1997

• 4) 藤田民夫,平林 聡,名出頼男ほか:移植 25:525

• 5) 日本移植学会.腎移植臨床統計集計報告.移植:33,1998

• 6) 日本臓器ネットワーク:献腎移植統計.Japan Organ Transplant Network, News Letter 5:8,2000

• 7) Nathan HM, Jarrel BE, Bronznic B et al:Transplantation 51:142,1991

• 8) Anaise D, Smith R, Ishimaru M et al:Transplantation 49:290,1990
  pubmed

P.207 掲載の参考文献

• 1) Schwartz RH:A cell culture model for T lymphocyte clonal anergy, Science 248:1349-1356,1990

• 2) Liu Y, Linsley PS:Costimulation of T-cell growth, Curr Opin Immunol 4:265-270,1992
  pubmed

• 3) June CH, Bluestone JA, LM et al:The B7 and CD28 receptor families, Immunol Today 15:321-331,1994

• 4) Steinman RM:The dendritic cell system and its role in immunogenicity, Annu Rev lmmunol 9:271-296, 1991
  pubmed

• 5) Rosenberg S, Spiess PJ, Schwary S:In vivo administration of interleukin-2 enhances specific alloimmune responses, Transplantation 35:631-637,1983

• 6) Heidecke CD, Kupiec-Weglinski JW Lear PA et al:Interactions between T-lymphocyte subsets supported by interleukin 2-rich lymphokines produce acute rejection of vascularized cardiac allografts in T cell deprived rats, J lmmunol 133:532-539,1984

• 7) Kaplan M:Transplant Proc 15:407,1983

• 8) Yoshimura N, Kahan B D:Pharmacodynamic assessment of the in vivo cyclosporine effect on Interleukn-2 production by lymphocytes kidney transplant recipients, Transplantalion, 40:661-666, 1985

• 9) Yoshimura N, Oka T, Kite M et al:Combination therapy of Cycrosporine with steroid Inhibits γ-interferon and Interleukin-1 Gene Expresssion at the level of mRNA Sythesis in Vivo, J Clin lmmunol 9:322-328,1989

• 10) Merker MM et al:K lmmunol 132:3064,1984

• 11) Takahashi N et al:Nature 337:473,1989
  pubmed

• 12) Takahashi N, Hayano T, Suzuki M:Peptidyl prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin, Nature 337:473,1989
  pubmed

• 13) Siekierica JJ, Hung SHY, Poe M et al:A cytosolic binding protein for immunosuppressant FK506 has peptidyl-prolylisomerase activity but is distict from syclophilin, Nature 341:755,1989

• 14) Liu J, Farmer JD Jr, Jane WS et al:C alcineurin is a common target of cyclophilon-cyclosporin A and FKBP-FK506 vomplexes, Cell 66:807,1991

• 15) Milan D, Griffith J, Su M et al:The latch region of calcineurin B in sivolved in both immuno-suppressant-immunophilin complex dockung and phosphatase activation, Cell 79:437,1994

• 16) Oka T, Ohmori Y, Aikawa I et al:The fate of living related donor kidney recipients after conversion from CaS to Az, Transplant Proc 19:2012,1987

• 17) Oka T, Ohmori Y, Aikawa I et al:Combination therapy of CsA and Az in living related kidney transplant recipients compared with patients converted totally from CsA to Az, Transplant Proc 20:143, 1988

• 18) Yoshimura N, Oka T, Yasumura T et al:Combination therapy of tacrolimus with azathioprine and steroid in renal transplant recipients, Transplant Proc 30:33-35,1998
  pubmed

第8章 腎細胞癌・尿路結石治療の最前線

P.211 掲載の参考文献

• 1) MRC Renal cancer collaborators:Interferon-α and survival in metastatic renal carcinoma:early results of a randomized controlled trial, Lancet 353:14-17,1999

• 2) Pyrhonen S, Sakminen E, Rutu M et al:Prospective randomized trial of interferon alpha-2a plus vin-blastine versus vinblastine alone in patients wit advanced renal cell cancer, J Clin Oncol 17:2859-2867,1999

• 3) Motzer RJ, Murphy BA, Bacik J et al:Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma, J Clin Oncol 18:2972-2980,2000
  pubmed

• 4) Negrier S, Escudier B, Lasset C et al:Recombinat human intereukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma, N Engl J Med 338:1272-12781,1998
  pubmed

• 5) Motzer RJ, Rakhit A, Schwartz LH et al:Phase I trial os subcutarteous recombinant human interleuin-12 in patients with advanced renal cell carcinoma, Clin Cancer Res 4:1183-1191,1998

• 6) Rini BI, Stadler WM, Spielberger RT et al:Granulocyte-macrophage-colony stimulating factor metastatic renal cell carcinoma, Cancer 82:1352-1358,1998
  pubmed

• 7) Tepper RI, Mule JJ:Experimental and clinical studies of cytokine gene-modified tumor cells, Hum Gene Ther 5:153-164,1994
  pubmed

• 8) Hara I, Nagai H, Miyake H et al:effectiveness ofcancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration, Cancer gene therapy 7:83-90,2000

• 9) Dranoff G, Jaffee E, Lazenry A et al:Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunitY, Proc Natl Acad Sci USA 90:3539-3543,1993
  pubmed

• 10) Carducci MA, Ayyagari SR, Sanda MG, Simons JW:Gene therapy for human prostate cancer, Translational research in the hormone refractory Dunning prostate cancer model, Cancer 75:2013-20,1995

• 11) Stmons J W, Jaffee E M, Weber C E et al:Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by ex Vivo Granulocyte-Macrophage Colony-stimulatkmg Factor Gene Transfer, Cancer Res 57:1537-1546,1997

• 12) Soiffer R, Lynch T, Mihm M et al:Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma, Proc Natl Acad Sci USA 95:13141-13146,1998
  pubmed

• 13) Simons J W, Mikhak B, Chang J et al:Induction of Imrnunity to Prostate Cancer Antigens:Results of a Clinical Trial of Vaccination with lrradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Using ex Vivo Gene Transfer, Cancer Res 59:5160-5168,1999
  pubmed

• 14) Rini BI, Selk LM, Vogelzang NJ:Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions, Clin Cancer Res 5:2766-2772,1999
  pubmed

• 15) Galanis E, Hersh EM, Stopeck AT et al:Immuno-therapy of advanced malignancy by direct gene transfer of an Interleukin-2 DNA/DMRIE/DOPE lipid complex:Phase I/II experience, J Clin Oncol 17:3313-3323,1999

• 16) Vermorken JB, Claessen AM, van Tinteren H et al:Active specific immunotherapy for stage II and stage III human colon cancer:a randomized tria, Lancet 353:345-350,1999

• 17) Harris JE, Ryan L, Hoover HC et al:Adjuvant active specific immunotherapy for stage II and III colon cancer with art autologous tumor cell vaccine:Eastern Cooperative Oncology Group Study E5823, J Clin Oncol 18:148-167,2000

• 18) Galligioni E, Quaia M, Merlo A et al:Adjuvant im-munotherapy treatment of renal carcinoma patients with autologous tumor cella and Bacillus-Calmette-Guerin l, Cancer 77:2560-2566,1996

• 19) Kugler A, Stuhler G, Walden P et al:Regression of human metastatic renal cell carcinoma after vacciation with tumor cell-dendritic cell hybrids, Na-ture Med 6:332-336,2000

P.218 掲載の参考文献

• 1) Beck Jr. L, DAmore PA:Vascular develop ment;cellular and molecular regulation, FASEB J 11:365-373,1997

• 2) Folkman J:What is the evidence that tumors are an-giogenesis dependent? J Natl Cancer Inst 82:4-6, 1990

• 3) Folkman J:Angiogenesis in cancer, vascular, rheu-matoid and other diseases, Nature Med 1:27-31, 1995

• 4) Folkrman J et al:Induction of angiogenesis during the transition from hyperplasia to neoplasia, Nature 339:58-61,1989

• 5) Boehm T et al:Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature 390:404-407,1997

• 6) Thompson WD et al:The clinical manipulation of angiogenesis:pathology, side-effects, surprizes, and opportunities with novel human therapies, J Pathol 190:330-337,2000
  pubmed

• 7) Lee JS, Feldman AM:Gene therapy for therapeutic myocardial angiogenesis:a promissing synthesis of two emerging thecnologies, Nature Med 4:739-742,1998

• 8) Kong H-L, Crystal RG:Gene therapy strategies for tumor antiangiogenesis, J Natl Cancer Inst 90:273-286,1998
  pubmed

• 9) Goldman Cket al:Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate, Proc Natl Acad Sci USA 95:8795-8800,1998

• 10) Lin P et al:Antiangiogenic gene therapy targeting the endothelium-specific receptor tlyrosine kinase Tie 2, Proc Natl Acad Sci USA 95:8829-8834,1998
  pubmed

• 11) Eguchi J et al:Gene expression and immunolocalization of basic fibroblast growth factor in renal carcinoma, Bioche Biophys Res Commun 183:937-944,1992

• 12) Takahashi A et al:Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal carcinoma associated with angiogenesis, Cancer Res 54:42334237,1994
  pubmed

• 13) Horie S et al:Biological role of HGFI/MET pathway in renal carcinoma, J Urol 161:990-997,1999

• 14) Eliceiri BP et al:Selective requirement for Src kinase during VEGF-induced angiogenesis and vascular permeability, Mol Cell 4:915-924,1999
  pubmed

• 15) Sipkns DA et al:Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonancece imaging, Nature Med 4:623-626,1998

• 16) Spragg DD et al:Immunotargeting of liposomes to activated vascular endothelial cells:A strategy for site-selective dehvery in the cardiovascular system, Proc Natl Acad Sci USA 94:8795-8800,1997
  pubmed

• 17) 神田 滋:FGFとシグナル伝達,医学のあゆみ 194:747-751,2000
  Medical*Online

• 18) Fong TAT et al:SU5416 is a potent and selective inhibitor for the vascular endothelial growth factor receptor(Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res 59:99-106,1999

• 19) Gibbs JB:Anticancer drug targets:growth factors and growth factor signaling, J Clin Invest 105:9-13, 2000
  pubmed

P.223 掲載の参考文献

• 1) Childs R et al:Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant:evidence for a graft-versus-tumor effect, J Clin Oncol 17:2044-2049,1999
  pubmed

• 2) Childs R et al:Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation:full donor T-cell chimerism precedes alloimmune responses, Blood 94:3234-3241, 1999
  pubmed

• 3) Childs R et al:Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation, N Eng J Med 343:750-758, 2000

• 4) Kolb HJ et al:Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients, Blood 76:2462-2465,1990
  pubmed

• 5) 同種末梢血幹細胞移植のための健常人ドナーからの末梢血幹細胞動員採取に関するガイドライン (2000年7月21日第2版) ,日本造血細胞移植学会 日本輸血学会

• 6) Champlin R:Nonmyeloablative chemotherapy with allogeneic hematopoietic transplantation as adoptive immunotherapy for malignancies, in The American Society of Hematology Education Program Book:413416,1999

• 7) 高見昭良:ミニ移植,医薬ジャーナル37:1040-1046, 2001

P.228 掲載の参考文献

• 1) Clayman RV, Kavoussi LR et al:Laparoscopic nephrectomy:initial case report, J Urol 146:278-282,1991
  pubmed

• 2) Robson CJ:Radical nephrectomy for renal cell carcinoma, J Urol 89:37-42,1963
  pubmed

• 3) Go H, Takeda M, Takahashi H et al:Laparoscopic adrenalectomy for primary aldosteronism:a new operative method, J Laparoendosc Surg 3:455459, 1993

• 4) Ono Y,Sahashi M, Yamada S et al:Laparoscopic nephrectomy without morcellation for renal cell carcinoma:report of initial 2 cases, J Urol 150:1222-1224,1993

• 5) Ono Y, Katoh N, Kinukawa T et al:Laparoscopic radical nephrectomy:the Nagoya experience, J Urol 158:719-723,1997
  pubmed

• 6) Ono Y, Hattori R, Ohshima S et al:Laparoscopic radical nephrectomy for renal cell carcinoma:A five-year experience, Urology 53:280-286,1999
  pubmed

• 7) Ono Y, Hattori R, Gotoh M et al:The long-tem outcome of laparoscopic radical nephrectomy for small renal cell carcinoma, J Urol 165:1867-1870, 2001

• 8) Kavoussi LR, McDougall EM, Clayman RV et al:Laparoscopic nephrectomy for renal neoplasma, Urology 42:603-609,1993

• 9) Barrett PH, Fentie DD, Taranger LA:Laparoscopic radical nephrectomy with morcellation for renal cell carcinoma:The Saskatoon experience, Urology 52:23-28,1998
  pubmed

• 10) McDougall EM, Clayman RV, Elashry OM:Laparoscopic radical nephrectomy for renal, tumor:The Washington University experience, J Urol 155:1180-1185,1996 neal laparoscopic versus open radical nephrectomy, J Urol 161:1776-1780,1999

• 12) Gill IS, Schweizer D, Hobart MG, Sung GT, Klein EA, Novick AC:Retroperitoneal laparoscopic radical nephrectomy:the Cleveland clinic experience, J Urol 163:1665-1670,2000

• 13) Janetschek G, Jeschke K, Peschel R et al:Laparoscopic surgery for stage TI renal cell carcinoma:radical nephrectomy and wedge resection, Eur Urol 38:131-138,2000

• 14) Dunn MD, Portis AJ, Shalhav AL, Elbahnasy AM, Heidorn C, McDougall EM and Clayman RV:Laparoscopic versus open radical nephrectomy:9-year experience, J Urol 164:1153-1159,2000
  pubmed

• 15) Cadeddu JA, Ono Y, Clayman RV, Berrett PH, Janetschek G, Fentie DD, McDougall EM, Moore RG, Kinukawa T, Elbahnasy AM, Nelson JB and Ka-voussi LR:Laparoscopic nephrectomy for renal cell cancer:evaluation of efficacy and safety:amul-ticenter experience, Urology 52:773-777,1998

P.234 掲載の参考文献

• 1) Segura JW, Premingr GM, Assimos DG et al:Nephrolithiasis Clinical Guidelines Panel:Report on the management of staghorn calculi. Baltimore:American Urological Association, Inc.,1994

• 2) Segura JW, Premingr GM, Assimos DG et al:Nephrolithiasis clinical guidelines panel summary re-port on the management of staghorn calculi, J Urol 151:1648-1651,1994

• 3) Segura JW, Premingr GM, Assimos DG et al:Ureteral stones clinical guidelnes Panel:Report on the management of ureteral calculi. Baltimore:American Urological Association, Inc.,1997

• 4) Segura JW, Premingr GM, Assimos DG et al:Ureteral Stones Clinical Guidelnes panel summary report on the management of ureteral calculi, J Urol 158:1915-1921,1997

• 5) Tawfiek EB, Bagley DH:Management of upper urinary tract calculi with ureteroscopic techniques,Urology 53:25-31,1999

• 6) Meretyk S, Gofrit ON, Gafni O et al:Complete staghorn calculi:Random prospective comparison between extracorporeal shock wave lithotripsy monotherapy and combined with percutaneous nephrostolithotomy, J Urol 157:780-786,1997
  pubmed

• 7) Aso Y, Ohta N, Nakano M et al:Treatment of staghom calculi by fiberoptic transurethral nephrolithotripsy, J Urol 144:17-19,1990

• 8) Mugiya S, Suzuki K, Ushiyama T et al:Combined treatment of staghom calculi by fiberoptic transurethral nephrolithotripsy and extracorporeal shock wave lithotripsy, Int J Urol 5:129-133,1998

• 9) Martin TV Sosa RE:Shock-wave lithotripsy. In:Campbells Urology. 7 th ed. Edited by Walsh, PC et al:Philadelphia:W. B.Saunders, Co., Vol.3, chapt.92:p 2735-2852,1998

• 10) Clayman, RV, McDougall, EM, Nakada ST:Endourology of upper urinary tract:Percutaneous renal and ureteral procedures. In:Campbells Urology. 7 th ed. Edited by Walsh, PC., et al. Philadelphia:W.B.Saunders, Co., VOl.3, chapt.94:p 2789-2874, 1998

• 11) Lingeman JE, Siegel TI, Steele B et al:Management of lower pole nephrolithiasis:Acritical analysis, J Urol 151:663-667,1994

• 12) Elashery OM, DiMeglio RB, Nakada SY et al:Intracorporeal electrohydraulic lithotripsy of ureteral and renal calculi using small caliber(1.9F) electro-hydraulic lithotripsy probes,J Urol l 56:1581-1585, 1996

• 13) Higashihara E:Endoscopic lithotripsy, Jpn J Endourol ESWL 7:135-140,1994

• 14) Gasso M, Beaghler M, Loisides P:The case for primary endoscopic management of upper urinary tract calculi:II. Cost and outcome assessment of 112prtmiy ureteral calculi, Urology 45:372-376, 1995

第9章 腎疾患画像診断の進歩

P.239 掲載の参考文献

• 1) Schencker B:Drip infusin pyelography, Radiology 83:12-21,1964

• 2) Cattell WR, Fry IK, Spencer AG et al:Excretory urography I. Factors determining the excretion of hypaque, Br J Radiol 40:561-571,1967
  pubmed

• 3) Smith RC, Rosenfield AT, Choe KA et al:Acute flank pain:comparison of non-contrast enhanced CT and intravenous urography, Radiology l 94:789-794,1995

• 4) 山下康行,中山善晴,門田正貴ほか:マルチスライスCTの臨床的有用性と問題点,臨床放射線45:477-486,2000

• 5) Rubin GD, Dake MD, Napel SA et al:Spiral CT of renal artery stenosis:comparison of three-dimentional rendering techniques, Radiology 190:181-189,1994

• 6) Beregi JP, Elkohen M, Deuklunder G et al:HelicalCT angiography compared with arteriography in detection of renal artery stenosis, AJR 167:495-501,1996

• 7) Rubin GD, Alfery EJ, Dake MD et al:Assessment of living renal donors with spiral CT, Radiology 195:457-462,1995

• 8) Dalrymple NC, Casford B, Raiken DP et al:Pearls and pitfalls in the diagnosis of ureterolithiasis with unenhanced Helical CT, Radiographics 20:439-447,2000

• 9) Heneghan JH, Dalrymple NC, Verga M et al:Soft-tissue "rim" sign in the diagnosis of ureteral calculi with use of unenhanced helical CT, Radiology 202:709-711,1997

• 10) Coll DM, Herts BR, Davros WF et al:Prepoerative use of 3D volume rendering to demonstrate renal tumors and renal anatomy, Radiographics 20:431-438,2000

• 11) 大渕真男:腎臓のMR診断,新医療6:55-58,2000

• 12) Prince MR, Schoengerg SO, Ward JS et al:Hemodynamically significant atherosclerotic renal arterystenosis:MR angiographic features, Radiology 205:128-136,1997
  pubmed

• 13) Holland GA, Dougherty L, Carpenter JP et al:Breath-hold ultrafast three-dimentional gadolini-um-enhanced MR angiography of the aorta and the renal and other visceral abdominall arteries, AJR 166:971-998,1996

• 14) Rieumont MJ, Kaufman JA, Geller SC et al:Evaluation of renal artery stenosis with dynamic gadolinium-enhanced MR angiography, AJR 169:39-44,1997
  pubmed

• 15) Hattery RR, King BF:Technique and application of MR urography, Radiology 194:25-27,1995
  pubmed

• 16) 広橋伸治,広橋里奈,星野 亘ほか:MR urography の撮像法と閉塞性尿路疾患への臨床応用,画像診断19:775-781,1999

P.245 掲載の参考文献

• 1) Rubin GD, Alfrey EJ, Dake MD et al:Assessment of living renal donors with spiral CT, Radiology 1 95:457-462,1995

• 2) Platt JF, Ellis JH, Korobkin M et al:Potential renal donors:comparison of conventional imaging with helical CT, Radiology 198:419-423,1996
  pubmed

• 3) Cochran ST, Krasny RM, Danovitch GM et al:Heli-cal CT angiography for examination of living renal donors, AJR 168:1569-1573,1997

• 4) Kim TS, Chung JW, Park JH et al:Renal artery evaluation:comparison of spiral CT artgiography to intra-arterial DSA, J Vasc Interv Radiol 9:553-559, 1998

• 5) Johnson PT, Halpem EJ, Kuszyk BS et al:Renal ar-tery stenosis:CT angiography-comparison of real-time volume-rendering and maximum intensity pro-jection algorithms,Radiology 211:33743,1999

• 6) Rubin GD, Dake MD, Napel S et al:Spiral CT of renal artery stenosis:comparison of three-dimen-sional rendering techniques, Radiology 190:181-189,1994

• 7) Cohan RH, Sherman LS, Korobkin M et al:Renal masses:assessment of corticomedullary-phase and nephrographic-phase CT scans, Radiology 196:445-51,1995
  pubmed

• 8) Szolar DH, Kammerhuber E AItziebler S et al:Multiphasic helical CT of the kidney:increased conspicuity for detection and characterization of small<3cm) renal masses, Radiology 202:211-7,1997

• 9) Jinzaki M, McTavish, JD, Zou KH et al:Small(<3cm) Renal masses:improved detection and characterization with multidetector CT(MDCT) , Radiology 217(P) :580,2000
  pubmed

• 10) Jinzaki M, Tanimoto A, Narimatsu Y et al:Angiomyolipoma:imaging findings in lesions with minimal fat, Radiology 205:497-502,1997
  pubmed

• 11) Jinzaki M, Tanimoto A, Mukai M et al:Double-phase helical CT of small renal parenchymal neo-plasms:correlation With pathologic findings and tu-mor angiogenesis, J Comput Assist Tbmogr 24:835-842,2000

• 12) Bosniak MA, Bimbaum BA, Krinsky GA et al:Small renal parenchymal neoplasms:further observations on growth, Radiology l 97:589-597,1995

• 13) Coll DM, Uzzo RG, Herts BR et al:3-dimensional volume rendered computerized tomography for preoperative evaluation and intraoperative treatment of patients undergoing nephron sparing surgery, J Urol 161:1097-102,1999
  pubmed

• 14) Wunderlich H, Reichelt O, Schubert R et al:Preoperative simulation of partial nephrectomy with three-dimensional computed tomography, BJU Int 86:777-81,2000
  pubmed

• 15) Smith RC, Verga M, McCarthy S et al:Diagnosis of acute flank pain:value of unenhanced helical CT, AJR 166:97-101,1996
  pubmed

• 16) Smith RC, Verga M, Dalrymple N et al:Acute ureteral obstruction:value of secondary signs of helical unenhanced CT, AJR 167:1109-1113,1996
  pubmed

• 17) Takahashi N, Kawashima A, Emst RD et al:Ureterolithiasis:can clinical outcome be predicted with unenhanced helical CT? Radiology 208:97-102, 1998

• 18) Takebayashi S, Hidai H, Chiba T, Takagi H, Koike S:Matsubara S. Using helical CT to evaluate renal cell carcinoma in patients undergokmg hemodialysis:value of early enhanced images, AJR 172:429-33, 1999
  pubmed

P.249 掲載の参考文献

• 1) Marotti M et al:MRI in renal disease, Magn Reson Med 5:160-163,1987
  pubmed

• 2) Leung AW-L et al:Magnetic resonance imaging of the kidneys, AJR l 43:1215-1218,1984

• 3) Weinmann HJ, Brasch RC, Press WR et al:Characteristics of gadolinium-DTPA complex:apotential NMR contrast agent, AJR 142:619-624,1984

• 4) Schuhmann-Giampieri G, Krestin GP:Pharmacokinetics of Gd-DTPA in patients with chronic renal failure, Invest Radiol 26:975-979,1991

• 5) Laub GA, Time-of-flight method of MR angiography, Magn Reson Imaging Clin N Am 3:391-39,1995
  pubmed

• 6) Meyers SP, Talagala SL, Totterman S et al:Evalua-tion of the renal arteries in kidney donors:Value of three dtmensional phase-contrast MR angiography with maximum-intensity-projection or surface rendering,AJR 164:117-121,1995
  pubmed

• 7) De Cobelli E Vanzulli A, Sironi S et al:Renal artery stenosis:evaluation with breath-hold, three-dimensional, dynamic, gadolinium-enhanced versus three-dkmensional, phase-contrast MR angiography, Radiology 205:689-695,1997

• 8) Wilmart AH, Riederer SJ, King BFet al:Fluoroscopically triggered contrast enhanced three-dimensional MR angiography with elliptical centric view order:application to the renal arteries, Radiology 205:137-146,1997

• 9) Namimoto T, Yamashita Y, Mitsuzaki K et al:Measurment of the apparent diffusion coefficient in diffuse renal disease by diffusion-weighted echo-planar MR tmagilg, J Magn Reson lmaging 9:832-837, 199910) McDougall EM, Monk TG, Wolf JS Jr et al:The effect of prolonged pneumoperitoneum on renal function in aii anirnal model, J Am CoU Surg 182:317-328,1996

• 11) Priatna A, Epstein FH, Spokes K et al:Evaluation of changes in intrarenal oxygenation in rats using multiple gradient-recalled echo(mGRE) sequence, JMagn Reson Imaging 9:842-846,1999
  pubmed

• 12) Aerts P, Van Hoe L, Bosmans H et al:Breath-hold MR urography using the HASTE technique, AJR 166:543-545,1996
  pubmed

• 13) Ybshimitsu K, Honda H, Kuroiwa T et al:MR detection of cytoplasmic fat in clear cell renal cell carcinoma utilizing chemical shift gradient-echo imaging, J Magn Reson Imaging 9:579-585,1999

• 14) Sharma RK, Gupta RK, Poptani CM et al:The magnetic resonance renograln in renal transplant evaluation using dynamic contrast-enhanced MR imaging, Transplantation 59:1405-1409,1995

• 15) Lee VS, Rusinek H, Kim S et al:Analysis of dynamic three-dkmensional MR renography:Regional cha acterization by multicompartmental modeling, Abstract of ISMRM annual meeing,2059,2001

• 16) Roberts DA, Detre JA, Bolinger L et al:Renal perfusion in human. MR imaging with spin tagging of arterial water, Radiology 196:281-286,1995
  pubmed

P.255 掲載の参考文献

• 1) 澤村良勝,田島政晴ほか腎臓の超音波計測,日超医論文集 89:183-184,1981

• 2) Miltec D, Fuckar Z, Sustic A et al:Sonographic measurement of absolute and relative renal length in adults, J Clin Ultrasound 26:185,1998

• 3) Emamian SA, Nielsen MB, Pedersen JF et al:Sonographic evaluation of renal appearance in 665 adult volunteers, Acta Radiol 34:482,1993
  pubmed

• 4) Arima M, Takahara S, Ihara H et al:Predictability of renal allograft prognosis during rejection crisis by ultrasonic Doppler flow technique, Urology 19:389-94,1982

• 5) Yura T, Takamitsu Y, Yuasa S et al:Total and split renal function assessed by ultrasound Doppler tech-niques, Nephron 58:37-41,1991

• 6) Handa N, Fukunaga R, Etani H et al:Efficacy of echo-Doppler examination for the evaluation of renovascular disease, Ultrasound in Med & Biol 14:1-5,1988
  pubmed

• 7) Izumi M, Sugiura T, Nakarnura H et al:Differential diagnosis of prerenal azotemia from acute tubular necrosis and prediction of recovery by Doppler utrasound, Am J Kidney Dis 35:713-9,2000

• 8) Claudon M, Plouin PE Baxter GM et al:Renal arteries in patients at risk of renal arterial stenosis:multicenter evaluation of the echo-enhancer SH U508A at color artd spectral Doppler US. Levovist Renal Artery Stenosis Study Group, Radiology 214:739-46,2000

P.260 掲載の参考文献

• 1) O'Reilly P, Aurell M, Britton K et al:Consensus on diuresis renography for investigating the dilated up-per urinary tract. Radionuclides in Nephrourology Group. Consensus Committee on Diuresis Renography, J Nucl Med 37:1872-1876, 1996

• 2) Taylor A:Radionuclide renography:a personal approach, Semin Nucl Med 29:102-127, 1999
  pubmed

• 3) Taylor A, Nally J, Aurell M et al:Consensus report on ACE inhibitor renography for detecting renovascular hypertension. Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography[see columents], J Nucl Med 37:1876-1882, 1996

• 4) Gates GF:Glomerular filtration rate:estimation from fractional renal accumulation of 99mTc-DTPA (stammous) , AJR Am J Roentgenol 138:565-570, 1982
  pubmed

• 5) Diffey BL, Hall FM, Corfield JR:The 99mTc-DTPA dynamic renal scan with deconvolution analysis, J Nucl Med 17:352-355, 1976
  pubmed

• 6) Nakagawa T, Maeda H, Terada N et al:Clinical value of deconvolution analysis in radionuclide renal study, Radiat Med 7:236-242, 1989
  pubmed

• 7) Russell CD, Taylor AT Jr, Dubovsky EV et al:A single-injection, two-sample method for measuring renal 99mTC-MAG3 Clearance in both Children and adults, Nucl Med Biol 22:55-60, 1995
  pubmed

P.263 掲載の参考文献

• 1) 蜂巣 忠:慢性腎不全に伴う上部消化管病変, Pharma Medica 7:135-138, 1996

• 2) 伊東和郎:腎疾患と胃微小循環,G.I. Research 2:320-326, 1994

• 3) 日本透析医学会統計調査委員会(編) :わが国の慢性透析療法の現況,透析医会誌 28:1-30, 1992

• 4) Naga Chalasani,George Costonis, C MedWilcox:Upper gastrointestinal bleeding in patients with chronic renal failure:Role of vascular ectasia,Am J Gastrenterol 91:2329,2332-1996

• 5) Chung-Jyi Tsai, Jyh-chang Hwang:Investigation of upper gastrointestinal hemorrhage in chronic renal failure, J CLIN Gastroenterol 22:2-5,1996

• 6) 松下一之,蜂巣 忠,浜口欣一:上部消化管病変―診断と治療:胃十二指腸の内視鏡所見-,臨床透析 12:15-21, 1996

• 7) 武藤重明:消化性潰瘍薬の投与,臨床と薬物療法 17:640-645,1998

• 8) 伊東和朗,伊東恵美子,松尾 祐ほか:腎疾患と胃の相関,消化器血流の研究 7:57-70, 1991

• 9) 坂口俊文:透析患者における Helicobacter pylori 抗体保有とその特徴,日腎会誌 36:510, 1994

• 10) 大原正志,浅木 茂,加藤勝章ほか:慢性腎不全透析患者と Helicobacter pylori―背景胃粘膜との関係-,Gastroenterol Endosc 36:1969-1975, 1994

• 11) 徳島秀次,村松 治,村川満佐也ほか:慢性腎不全における Helicobacter pylori 感染の意義と治療の実際,Helicobacter Research 3:332-335, 1999

• 12) 佐藤慎一,粒良幸正,蜂巣 忠:慢性腎不全症例における胃十二指腸粘膜血流の検討,Prog Dig Endosc 38:249-252, 1991

• 13) 大井田正人,西元寺克禮:特殊胃炎,びらん性胃炎,最新内科学大系,中山書店,東京,41:323-333, 1993

• 14) 多賀須幸男:パンエンドスコープの12年,Gastroenterol Endosc 30:2351, 1988

• 15) 川本博司,姫野誠一,垂井清一郎:十二指腸炎, 最新内科学大系,中山書店,東京,41:311-321, 1993

• 16) Zuckerman GR,mms BA,Koehler RE:Nodular duodenitis, Pathogenic and clinical characteristics in patients with end-stage renal stage, Dig Dis Sci 28:1018-1022, 1983

• 17) 原田康司,南雲久美子,山崎忠男ほか:上部消化管 Angiodysplasia の内視鏡的検討,Gastroenterol Endosc 33:257-262, 1991

• 18) 高橋 寛:上部消化管合併症,日本臨床(別) ,腎臓症候群(下巻) :39-41, 1997

• 19) 田辺 聡,嶋尾 仁,北村 匡ほか:胃腫瘍および胃前庭部毛細血管拡張症(GAVE) に対するAPC 方による治療,消化器内視鏡10:1603-1608, 1998

• 20) 谷 礼夫:透析患者の消化器病変-胃十二指腸病変を中心に-,透析会誌 26:137-141, 1993

第10章 腎臓病治療薬開発の最新情報

P.268 掲載の参考文献

• 1) 大島久二:副腎皮質ステロイド薬の免疫抑制分子作用機構,炎症と免疫 9:8-15, 2001
  Medical*Online

• 2) Wilckens T and Rijk RD:Glucocorticoids and immune function:Unknown dimensions and new frontiers. Immunol today 18:418-24, 1997

• 3) Yan K et al:Subcellular localization of glucocorticoid receptor protein in the human glomerulus, Kidney Int 56:65-73, 1999
  pubmed

• 4) De Bosscher K et al:Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids:negative interference of activated glucocorticoid recepter with transcription factors, J Neuroimmunol 109(1) :16-22, 2000

• 5) Barnes PJ & Gurevith AW:Nuclear factor-κB-Pivotal transcription factor in chronic inflammatory diseases, N Engl J Med 336:1066-71, 1997

• 6) Moldenhauer I et al:Alteration of structural order of human erythrocyte ghost membrane by glucocorticoids and influence of the glucocorticoid receptor antagonist RU486, In J Tissue React 16:113-9, 1994

• 7) Andreae J et al:Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases, Pediatr Res 49:130-5, 2001

• 8) Sanden S et al:Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patiens with rheumatic diseases, J Rheumatol 27:1265-70, 2000

• 9) Ou ZL et al:Effective methylprednisolone dose in experimental crescentic glomerulonephritis, Am J Kidney Diseas 37:411-7, 2001

• 10) Sakurai H et al:Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats, Biochim Biophys Acta 1316:132-8, 1996
  pubmed

• 11) Wada T et al:A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephntis in Wistar-Kyoto rats, J Am Soc Nephrol 11:1534-41, 2000
  pubmed

• 12) Yokoyama H, et al:Up-regulated MHC-class II expression andγ-IFN and soluble IL-2R in lupus nephritis, Kidney Int 42:755-763, 1992

• 13) Wada T et al:Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis, Kidney Int 49:761-767, 1996
  pubmed

• 14) Wada T et al:MIP-1α and MCP-1 contribute to crescents and interstitial lesions in humam crescentic glomerulonephritis, Kidney Int 56:995-1003, 1999

• 15) Cattran DC et al:Management of glomemlonephritis, Kidney Int 55(suppl 70) :s 1-s 62, 1999.

• 16) Haack D et al:Glucocorticoid receptors in idiopathic nephrotic syndrome, Pediatr Nephrol 13:653-6, 1999
  pubmed

• 17) Ybkoyama H et al:Strategies for treatment of adult nephrotic syndrome by cyclosporin A(cyclosporine) ,Chn Exp Nephrol 3:S 40-S 47, 1999

• 18) 横山 仁,和田隆志,木田 寛:膜性腎症における免疫抑制療法の意義,腎と透析 50:179-183, 2001

• 19) Hirano T et al:Glucocorticoid-resistance in peripheral-blood lymphocytes does not correlate with number of affinity of glucocorticoid-receptors in chronic renal failure, Immunopharmacology 36:57-67, 1997

P.273 掲載の参考文献

• 1) Suthanthiran M, Morris RE, Strom TB:Immunosuppressants:Cellular and molecular mechanisms of action, Am J Kidney Disease 28:159-172, 1996

• 2) Gummert JF, Ikonen T, Morris RE:Newer immunosuppressive drugs:a review, J Am Soc Nephrol 10:1366-1380, 1999
  pubmed

• 3) Niaudet P, Habib R:Cyclosporine in the treatment of idiopathic nephrosis, J Am Soc Nephro 15:1049-1056, 1994

• 4) Cattran DC, Appel GB, Hebert LA et al:Cyclosporine in patients with steroid-resistant memvranous nephropathy:a randomized trial, Kidney Intern 59:1484-1490, 2001

• 5) Mattos AM, Olyaei AJ, Bennett WM:Nephrotoxicity of Immunosuppressive drugs:long-term consequences and challenges for the future, Am J Kidney Disease 35:333-346, 2000

• 6) Jensik SC:Tacrolkmus(FK506) in kidney transplantation:Three year survival results of the US multi-center, randamized, comprehensive trial. FK 506 Kidney Transplant Study Group, Transplant Proc 30:1216-1218, 1998

• 7) Kokado Y, Takahara S, Kyo M et al:Low-dose tacrolimus(FK506) -based immunosuppressive protocol in living donor renal transplalltation, Transpl Int 11:S 61-S 64, 1998 (suppl 1)

• 8) Sclitt HJ, Barkmann A, Broker KHW et al:Replacement of calcineurin inhibitors With mycophenolate mofetil in liver-transplant patients with renal dysfunction:a randomised controlled study, The Lancet 357:587-591, 2001

• 9) Saunders RN, Metcalfe MS, Nicholson ML Rapamycin in transplantation:A review of the evidence, Kidney Intern 59:3-16, 2001

• 10) Mladenovic V, Domljan Z, Rozman B et al:Safety and effectiveness of leflunomide in the treatment of patients with active rheunatoid artritis:Results of a randamized, placebo-controned, phase II study, Arthntis Rheum 38:1595-1603, 1995

P.278 掲載の参考文献

• 1) Hofbauer KG, Mah SC, and Opperman JR:Chronic blockade of vasopressin receptors in rats, J Cardiovasc Pharmacol 8:S 56-S 60, 1986

• 2) Yamamura Y, Ogawa H, Chihara T et al:OPC 21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist, Science 252:572-574, 1991
  pubmed

• 3) Yamamura Y, Ogawa H, Yamashita H et al:Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist, Br J Pharmacol 105:787-791, 1992
  pubmed

• 4) Ohnishi A, Orita Y, Okahara R et al:A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men, J Clin Invest 92:2653-2659, 1993

• 5) Ohnishi A, Oritary, Takagi N et al:A quaretic effect of a potent, orally active, nonpeptide V2 antagonist in men, J Pharmacol Exp Ther 272:546-551, 1995

• 6) Saito T, lshikawa S, Abe K et al:Acute aquaresis by the nonpeptide arginine vasopressin(AVP) antagonist OPC-31260 improves hyponatremia inpatients with syndrome of inappropriate secretion of antidiuretic homone(SIADH) ,J Clin Endocrinol Metab 82:1054-1057, 1997

• 7) Yamarnura Y, Nakamura S, Itoh S et al:OPC-41061, a high potent human vasopressin V2-receptor antagonist:pharmacological profile and aquaretic effect by single and multiple oral dosing in rats, J Pharmacol Exp Ther 287:860-867, 1998

• 8) Hirano T, Yamamura Y, Nakamura S et al:Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats, J Pharmacol Exp Ther 292:288-294, 2000

• 9) Serradeil-Le Gal C, Lacour C, Valette G et al:Characterization of SR121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist, J Clin Invest 98:2729-2738, 1996

• 10) Jimenez W, Claudine Serradeil-Le Gal, Ros J et al:Long-term aquaretic efficacy of a selective nonpep-tide V2-vasopressin receptor antagonist, SR121463, in cirrhotic rats, J Pharmacol Exp Ther 295:83-90, 2000

• 11) Martin PY, Abraham WT, Lieming X et al:Selective V2-receptor vasopressin antagonism decreases urinary aquaporine-2 excretion in patients with chronic heart failure, J Am Soc Nephrol 10:2165-2170, 1999

• 12) Tomura Y, Tahara A, Tsukada J et al:Phamacological profile of orally administered YMO87, a vasopressin antagonist, in conscious rats, Clin Exp Pharmacol Physiol 26:399-403, 1999

• 13) Post JB IV, Frishinan WH:Fenoldopam:A new dopamine agosint for the treatment of hypertension urgencies and emergencies, J Clin Pharmacol 38:2-13, 1998

• 14) Ferrari P, Torielli L, Ferrandi M et al:PST2238:a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain, J Pharmacol Exp Ther 285:83-94, 1998

• 15) Ferrari P, Ferrandi M, Tripodi G et al:PST 2238:a new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension, J Pharmacol Exp Ther 288:1074-1083, 1999
  pubmed

• 16) Richards AM, Wittert GA, Crozier IG et al:Chroniic inhibition of endopeptidase 24.11 in essential hypertension:evidence for enhanced atrial natriuretic peptide and angiotensin II, J Hypertens 11:407-416, 1993
  pubmed

• 17) Quaschning T, d'Uscio LV, Shaw SD et al:Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension, Hypertension 37:1108-1113, 2001

• 18) Majid DSA, Kadowitz PJ, Coy DH et al:Renal response to intra-arterial admmistration of adrenomedullin in dogs, Am J Physiol 270:F 200-F 205, 1996

• 19) Satoh T, Cohen HT, Katz AI:Intracellular signaling in the regulation of renal Na-K-ATPase:II. Role of eicosanoids, J Clin Invest 91:409-415, 1993
  pubmed

• 20) Stec DE, Deng AY, Rapp T et al:Cytochrome P4504A genotype cosegregates with hypertension in Dahl rats, Hypertension 27:564-568, 1996

P.284 掲載の参考文献

• 1) Cunningham MA, Ono T, Hewitson TD et al:Tissue factor pathway inhibitor expression in human crescentic glomerulonephritis, Kidney Int 55:1311-1318, 1999
  pubmed

• 2) Erlich JH, Apostolopoulos J, Wun TC et al:Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits, J Clin lnvest 98:325-335, 1996

• 3) Yamabe H, Osawa H, Inuma H et al:Thrombin stimulates production of transfoming growth factor-beta by cultured human mesangial cells, Nephrol Dial Transplant 12:438-442, 1997

• 4) Glassock RJ, Cohen AH, Adler SG:Primary glomerular diseases. In Brenner BM, Rector FC jr.(eds) :The Kidney, 5th ed. WB Saunder, Philadelphia, p 1432-1434, 1996

• 5) al-Mugeiren MM, Gader AM, al-Rasheed SA et al:Coagulopathy of childhood nepkmotic syndrome-a reappraisal of the role of natural anticoagulants and fibrinolysis, Haemostasis 26:304-310, 1996
  pubmed

• 6) Siddiqi FA, Tepler J, Fantini GA:Acquired protein S and antithrombin III deficiency caused by nephrotic syndrome:an usual cause of graft thrombosis, J Vasc Surg 25:576-580, 1997

• 7) Oikawa T, Murarnatsu Y, Akashi S et al:A coagulation of fibrinolytic study in children with nephrotic syndrome:evaluation of hypercoagulability by measuring with plasmin-alpha 2 plasmin inhibitor complex and FDP D-dimer, Nippon Jinzo Gakkaishi 39:144-149, 1997

• 8) Ariens RA, Moia M, Rivolta E et al:High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria, Thromb Haemost 82:1020-1023, 1999
  pubmed

• 9) Andre E, Voisin P, Andre JL et al:Hemorheological and hemostatic parameters in children with nephrotic syndrome undergoing steroid therapy, Nephron 68:184-191, 1994
  pubmed

• 10) Pierangerli SS, Espinola RG, Liu X et al:Thrombogenic effects of antiphospholipid antibodyies are mediated by intercellular cell adhesion molecular-1,vascular cell adhesion molecule-1 and P-selectin, Circ Res 88:245-250, 2001

• 11) Noris M, Chempharm D, Ruggenenti P et al:Increased nitrix oxide formation in recurrent thrombotic microangiopathies:A possible mediator of microvascular injury, Am J Kidney Dis 27:790, 1996

• 12) Tam-SH et al:Abciximab(Reo Pro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein Ilb/IIIa and alpha(V) beta 3 integrin, Circulation 98:1085-1091, 1998

• 13) Takahashi H, Kashima T, Nomizo Y et al:Metabolism of warfarin enantiomers in Japanease patient with heart disease having different CYP2C9 and CYP2C19 genotypes, Clin Pharmacol Ther 63:519-528, 1998

• 14) Meyer BJ, Badimon JJ, Chesebro JH et al:Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin; comparison with heparin and aspirin, Circulation 97:681-685, 1998

• 15) Taylor FB, Chang AC, Peer G et al:Active site inhibited factor VIIa(DEGR VIIa) attenuates the coaglant and interleukin-6 and-8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli, Blood 91:1609-1615, 1998

• 16) Nutt E, Gasic T, Rodkey J et al:The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure, J Biol Chem 263:10162-10167, 1988
  pubmed

• 17) Taniuchi Y, Sakai Y, Hisamichi N et al:Biochemical and pharmacyological characterization of YM-60828,a newly synthesized and orally active inhibitor of human factor Xa, Thromb Haemost 79:543-548, 1998
  pubmed

P.291 掲載の参考文献

• 1) Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure(JNC VI) ,Arch Intern Med 157:2413-2446, 1997

• 2) Cortes P, Riser BL, Zhao X et al:Glomerular volume expansion and mesangial cell mechanical strain-mediators of glomerular pressure injury-, Kidney Int 45(Suppl) :S 11-S 16, 1994

• 3) Anderson S, Brenner BM:Progressive renal disease:a disorder of adaptation, QJ Med 70:185-189, 19894

• 4) Arendshorst WJ et al:Renal circulation and glomerular hemodynamics, in RW Schrier, CW Gottschalk eds:Texrbook of Diseases of the kidney,4th Ed, Little Brown, Boston, P 65-117, 1998

• 5) de Jong PE, Anderson S, de Zeeuw D:Glomerularpreload and afterload reduction as a tool to lower urinary protein leakage:will such treatments also help to improve renal function outcome? J Am Soc Nephrol 3:1333-1341, 1993
  pubmed

• 6) Nakamura T, Obata J, Kimura H et al:Blocking angiotensin II amehorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis, Kidney Int 55:877-889, 1999
  pubmed

• 7) Klahr S, Levey AS, Beck GJ et al:The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease, N Eng J Med 330:877-884, 1994

• 8) Peterson JC, Adler S, Burkart JM et al:Blood pressure control, proteinuria, and the progression of renal disease, Am Intern Med 123:754-762, 1995

• 9) 木村玄次郎:腎と高血圧-病態生理からのアプローチ―東京医学社,東京,p 127-147, 1998

• 10) Praga M, Hernandez E, Montoyo C et al:Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria, Am J Kidney Dis 20:240-248, 1992
  pubmed

• 11) Gansevoort RT, de Zeeuw D, de Jong PE:Long-telm benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in non-diabetic renal disease, Am J Kidney Dis 22:202-206, 1993

• 12) Gansevoort RT, de Zeeuw D, de Jong PE:Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in non-diabetic renal disease, Am J Kidney Dis 22:202-206, 1993

• 13) Apperloo AJ, de Zeeuw D, de Jong PE:A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function, Kidney Int 51:793-797, 1997

• 14) Chen HH, Bumett JC Jr:C-type natriuretic peptide. The endothelial component of the natriuretic peptide system, J Cardiovasc Pharmacol 32(suppl 3) :S 22-S 28, 1998

• 15) Stein BC, Levin RI:Natriuretic peptides. Physiology, therapeutic potential, and risk stratification in ischemic heart disease, Am Heart J 135:914-923, 1998
  pubmed

• 16) Boland DG, Abraham WT:Natriuretic peptides in heart failure, CHF March/April:23-33, 1998

• 17) Wilkins MR, Redondo J, Brown LA:The natriuretic peptide family, Lancet 349:1307-1310, 1997
  pubmed

• 18) Stingo AJ, Clavell AL, Aarhus LL et al:Cardiovascular and renal actions of C-type natriuretic peptide, Am J Physiol 262:H 308-H 312, 1992

• 19) Grantham JA et al:Natriuretic peptides in cardiovascular disease, in Samson WK, Levin ER eds:Contemporary Endocrinology. Natriuretic Peptides in Health and Disease. Humana Press lnc, Totowa, NJ, p 309-326, 1997

• 20) Maack T, Suzuki M, Almeida FA et al:role of silent receptors of atrial natriuretic factor, Science 238:675-678, 1987
  pubmed

• 21) Ruschitzka E Corti R, Noll G et al:A rationale for treatment of endothelial dysfunction in hypertension, J Hypertens 17(suppl 1) :S 25-S 35, 1999

• 22) Burnett JC Jr:Vasopeptidase inhibiton:a new concept in blood pressure managemant, J Hypertens 17(suppl 1) :S 37-S 43, 1999

• 23) Robl JA, Sun CQ, Stevenson J et al:Dual metalloprotease inhibitors:mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase, J Med Chem 40:1570-1577, 1997
  pubmed

• 24) Saxenhofer H, Raselli A, Weidmann P et al:Urodilantin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men, Am J Physiol 259(Pt 2) :F 832-F 838, 1990

• 25) Margulies KB, Barclay PL, Bumett JC Jr:The role of neutral endopeptidase in dogs with evolving congestive heart failure, Circulation 91:2036-2042, 1995

• 26) Cavero PG, Margulies KB, Winaver J et al:Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure, Circulation 82:196-201, 1990
  pubmed

• 27) Margulies KB, Cavero PG, Seymour AA et al:Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor, Kidney Int 38:67-72, 1990
  pubmed

• 28) Ando S, Rahman MA, Butler GC et al:Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin, Hypertension 26(Pt 2) :1160-1166, 1995
  pubmed

• 29) Richards AM, Crozier IG, Espiner EA et al:Acute inhibition of endopeptidase 24.11 in essential hypertension:SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure, J Cardiovasc Pharmacol 20:735-741, 1992
  pubmed

• 30) Bevan EG, Connell JMC, Doyle J et al:Candoxatril, a neutral endopeptidase inhibitor:efficacy and tolerability in essential hypertension, J Hypertens 10:607-613, 1992

• 31) Robl JA et al:Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme, in van Zwieten PA, Greenlee WJ eds:Antihypertensive Drugs. Australia, Harwood Academic Publishers, p 113-211, 1997

• 32) Stergiou GS, Hannah JA, Bevan EG et al:Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients (abst) ,J Hypertens 12:1310-311, 1994

• 33) Rodeheffer RJ, Lerman A, Heublein DM et al:Increased plasma concentrations of endothelin in congestive heart failure in humans, Mayo Clin Proc 67:719-724, 1992
  pubmed

• 34) Sutsch G, Kiowski W, Yan XW et al:Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure, Circulation 98:2262-2268, 1998
  pubmed

• 35) Krum H, Viskoper RJ, Lacourciere Y et al:The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension, N Engl J Med 338:784-790, 1998
  pubmed

• 36) Packer M:Drugs for heart failure that interfere with the rennin-angiotensin system, in Poole-Wilson PA, Colucci WS et al eds:Heart Failure:Scientific Principles and Clinical Practice. New York, Churchill Livingstone, P 687-690, 1997

• 37) Kaplan NM:Systemic hypertension. Therapy, in Braunwald E eds:Heart Disease. A Textbook of Cardiovascular Medicine, 5th Ed, Philadelphia, WB Saunders Company, p 855-856, 1997

• 38) Gibbons GH:Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance, Drugs 54(suppl 5) :1-11, 1997

• 39) Kelly RA, Smith TW:Drugs used in the treatment of heart failure, in Braunwald E eds:Heart Disease. A textbook of Cardiovascular Medicine, 5th Ed, Philadelphia, WB Saunders Company, p 471-491, 1997

• 40) Susic D, Frohlich ED:Nephroprotective effect of arttihypertensive drugs in essential hypertension, J Hypertens 16:55-567, 1998

• 41) Weber M:Emerging treatments for hypertension:potential role for vasopeptidase inhibition, Am J Hypertens 12:139S-147S, 1999
  pubmed

• 42) Cohen DS, Mathis JE, Dotson RA et al:Protective effects of CGS 30440, a combined angiotennsin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure, J Cardiovasc Pharmacol 32:87-95, 1998

• 43) Fink CA:Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors, Exp Opin Ther Patents 6:1147-1164, 1996

• 44) Wallis EJ, Ramsay LE, Hettiarachchi J:Combined inihibition of neutral endopeptidase and angi-otensin-converting enzyme by sampatrilat in essential hypertension, Clin Pharmacol Ther 64:439-449, 1998

• 45) Norton G, Woodiwiss A, Hartford C et al:Sustained antihypertensive actions of a dual angiotensin-con-verting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects, Am J Hypertense 12:563-571, 1999

• 46) Trippodo NC, Robl JA, Asaad MM et al:Effects of omapatrilat in low, normal, and high renin experimental hypertension, Am J Hypertens 11:363-372, 1998
  pubmed

• 47) French JE Anderson BA, Downs TR et al:Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension, J Cardiovasc Pharmacol 26:107-113, 1995

• 48) Trippodo NC, Robl JA, Asaad MM et al:Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyrne BMC-182657 in experimental hypertension and heart failure, J Pharmacol Exp Ther 275:745-752, 1995

• 49) Vera WG, Fournie-Zaluski MC, Pham I et al:Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats, J Pharmacol Exp Ther 272:343-351, 1995

• 50) Trippodo NC, Fox M, Monticello TM et al:Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition (abst 4095) . Circulation 98:1-781, 1998

• 51) Vesterqvist O, Liao W, Manning JA et al:Effects of BMS-1867, a new dual metalloprotease inhibitor, on phamlacodynamic markers of neutral endopeptidase(NEP) and angiotensin converting enzyme(ACE) activity in healthy man(abstract PrV-46) , Clin Pharmacol Ther 61:230, 1997

• 52) Liao W, Delaney C, Smith R et al:Supine mean arterial blood pressure(MAP) lowwering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme(ACE) and neutral endopeptidase(NEP) in healthy male subjects (abstract PIV-45, Clin Pharmacol Ther 61:229, 1997

• 53) Ruddy M, Guthrie R, Papademetriou V et al:The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat:a pilot study(abst DO59, Am J Hypertens 12(Pt 2) :125A, 1999

• 54) Zusman R, Atlas S, Kochar M et al:Efficacy and safety of omapatrilat, a vasopeptidase inhibitor(abst DO60, Am J Hypertens 12(Pt 2) :125A, 1999

• 55) Weber MA, Chang PI, Reeves RA et al:Antihypertensive dose response of omapatrilat, a vasopeptidase inhibitor, in mild to moderate hypertension(abst DO46, Am J Hypertens 12(Pt 2) :122A, 1999

• 56) Black HR, Chang PI, Reeves RA et al:Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlo-dipine in mild to moderate hypertension(abst) , Am J Hypertens 12(Pt 2) :26A, 1999

• 57) Klag MJ, Whelton PK, Randall BL et al:End-stage renal disease in African-American and white men:16-year MRFIT findings, JAMA 277:1293-1298, 1997
  pubmed

• 58) Hammett JL, Sica DA, Scicli G et al:Omapatrilat increase key vascular/renal markers regardless of renal function(abstract, Clin Pharmacol Ther 65:131, 1999

• 59) Domenic AS, Wei-chi L, Todd WB et al:Disposition and safety of omapatrilat in subj ects with renal impairment, Clin Phamacol Ther 68:261-269, 2000

P.298 掲載の参考文献

• 1) Xie W, Chipman JG, Robertson DL et al:Expression of a mitogen-responsive gene encoding Prostaglandin synthase is regulated by mRNA splicing, Pro Natl Acad Sci 88:2692-2696, 1991

• 2) Kujubu DA, Fletcher BS, Varnurn BC et al:TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue, J Biol Chem 266:12866-12872, 1991

• 3) Fieschi A, Bianchi B:II fenilbutazone. Un farmaco attivo sulla albuminuria, Prog Med Napoli 9:257-263, 1955

• 4) Donker AJ, Brentjens JRH, van der Hem GK et al:Treatment of the nephrotic syndrome with in-domethacin, Nephron 22:374-381, 1978

• 5) Dunn MJ:Prostaglandins, angiotensin II and proteinuria, Nephron 55(suppl) :30-37, 1990
  pubmed

• 6) Arisz L, Donker AJM, Brentjens JRH et al:The effect of indomethacin on proteiluria and kidney function in the nephrotic syndrome, Acta Med Scand 199:121-125, 1976

• 7) Golbetz H, Black V, Shemesh O et al:Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans, Am J Physiol 256:F 44-F 51, 1989

• 8) Niwa T, Maeda K, Shibata M et al:Clinical effects of selective thromboxane A? synthetase inhibitor in patients with nephrotic syndrome, Clin Nephrol 30:276-281, 1988
  pubmed

• 9) Velosa JA, Torres VE:Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome, Am J Kidney Dis 8:345-250, 1986
  pubmed

• 10) Vriesendorp R, Donker AJM, de Zeeuw D et al:Effects of nonsteroidal anti-inflamatory drugs on proteinuria, Am J Med 81(suppl 2B) :84-94, 1986

• 11) Heeg JE, Jong PE, de Zeeuw D et al:Additive anti-proteinuric effect of angiotensin-converting enzylne inhibition and non-steroidal anti-inflammatory drug therapy:A clue to the mechanism of action, Clin Sci 81:367-372, 1991

• 12) Gansevoort RT, Heeg JE, Vriesendorp R et al:Anti-proteinuric drugs in patients with idiopathic membranous glomemlopathy, Nephrol Dial Transplant Suppl 1:91-96, 1992

• 13) Perico N, Remuzzi A, Snagalli F et al:The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin, J Am Soc Nephrol 9:2308-2317, 1998

• 14) Carmichael J, Shankel SW:Effects of nonsteriodal anti-inflammatory drugs on prostaglandins and renal function, Am J Med 78:992-1000, 1985

• 15) Schlondorff D:Renal complications of nonsteroidal anti-inflammnatory drugs, Kidney Int 44:643-653,1993
  pubmed

• 16) Whelton A:Nephrotoxicity of nonsteroidal antiinflammatory drugs:Physiologic foundations and clinical implications, Am J Med 106(5B) :13S-24S, 1999
  pubmed

• 17) Brezin JH, Katz SM, Schwartz AB et al:Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs, N Engl J Med 301:1271-1273, 1979
  pubmed

• 18) Clive DM, Stoff J:Renal syndromes associated with nonsteroidal anti-inflammatory drugs, N Engl J Med 310:563-572, 1984
  pubmed

• 19) Blume C, Heise G, Muhlfeld A et al:Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephntis in the rat, Kidney Int 56:1770-1778, 1999

• 20) Whelton A, Schulman G, Wallemark C et al:Effects of celecoxib and naproxen on renal function in the elderly, Arch Inter Med 160:1465-1470, 2000

• 21) Bevis PJR, Bird HA, Lapham G:An open study to assess the safety and tolerability of meloxicam 15mg in subjects with rheumatic disease and mild renal impairment, Br J Rheumatol 35(suppl 1) :56-60, 1996

• 22) Perazella MA, Eras J:Are selective COX-2 inhibitors nepkmotoxic?, Am J Kidney Dis 35:937-940, 200023) Harris RC, McKanna JA, Akai Y et al:Cyclo-oxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction, J Clin Invest 94:2504-2510, 1994

• 24) Brater DC, Harris C, Redfern JS et al:Renal effects of COX-2-selective inhibitors, Am J Nephrol 21:1-15, 2001
  pubmed

第11章 各種製品の臨床評価

P.301 掲載の参考文献

• 1) 黒山政一,平山武司,矢後和夫,島田慈彦:注射用キット製剤の現状とその有用性,PHARM TECH JAPAN 15(7) :1065-1072, 1999

• 2) 黒山政一,矢後和夫:注射用キット製剤の現状と今後の方向性,医薬ジャーナル 36(4) :1217-1225, 2000

• 3) 黒山政一,平山武司,矢後和夫:新しいプレフィルドシリンジ製剤(エポエチンベータ) の有用性に関する研究-第1報:作業効率-,医学と薬学 45(2) :289-293, 2001
  Medical*Online

• 4) 平山武司,黒山政一,矢後和夫:新しいプレフィルドシリンジ製剤(エポエチンベータ) の有用性に関する研究-第 2報:利便性-,医学と薬学 45(2) :295-301, 2001
  Medical*Online

• 5) 清水博行,黒山政一:海外におけるプレフィル型シリンジの現状と今後の注射用キット製剤の動向, PHARM TECH JAPAN 16(5) :785-792, 2000

P.310 掲載の参考文献

• 1) Calne RY et al:Cyclosporin A initially as the only immunosupressant in 34 recipients of cadaveric organs:32 kidneys,2pancreases, and 2 livers, Lancet 2:1033-1036, 1979

• 2) 岩崎洋治ほか:多施設協同研究による腎移植におけるシクロスポリンの臨床評価に関する研究,移植 20(S) :399-421, 1985

• 3) Lindholm A et al:Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation, Clin Pharmacol Ther 54:205-218, 1993
  pubmed

• 4) 平野哲夫ほか:腎移植におけるモニタリングの実際と問題点,今日の移植 12(6) :679-680, 1999

• 5) 高原史郎ほか:腎移植患者におけるシクロスポリンMEPCの薬物動態試験-現行製剤を対照とした交差比較二重盲検試験-,今日の移植 12(S) :5-24,1999

• 6) 高原史郎ほか:シクロスポリン吸収不良を示す腎移植患者におけるシクロスポリンMEPCの薬物動態学試験-現行シクロスポリン製剤を対照とした無作為化2期2群交差比較試験-,今日の移植12 (S) :25-41,1999

• 7) Mueller EA et al:Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation, Pharm Res 11:151-155, 1994

• 8) Halloran P:Calcineurin inhibition-relationship to cyclosporin blood concentration, Focus on Medicine 13:15-18, 1998

• 9) Bargman JM:Management of minimal lesion glomerulonephritis:evidence-based recommendations, Kidney Int 70(Suppl) :S 3-S 16, 1999

• 10) Burgess E:Management of focal segmental glomerulosclerosis:evidence-based recommendations, Kidney Int 70(Suppl) :S 26-S 32, 1999

• 11) Muirhead N:Management of idiopathic membranous nephropathy:evidence-based recommendations, Kidney Int 70(Suppl) :S 47-S 55, 1999

• 12) Ponticelli C, Edefonti A, Ghio L et al:Cyclosporin versus cylophosphalnide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome:a multicentre randomized controlled trial. Nephrol Dial Transplant 8:1326-1332, 1993
  pubmed

• 13) Ponticelli C, Passerini P:The place of cyclosporin in the management of primary nephrotic syndrome, Bio Drugs 12:327-341, 1999

• 14) Cattran DC, Appel GB, Hebert LA et al:A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis, Kidney Int 56:2220-2226, 1999
  pubmed

• 15) Cattran DC, Appel GB, Hebert LA et al:Cyclosprine in patients with steroid-resistant membranous nephropathy:A randomized trial, Kidney Int 59:1484-1490, 2001

• 16) 小山哲夫,小林正貴,山口直人ほか:シクロスポリンMEPCの頻回再発型およびステロイド抵抗性ネフローゼ症候群に対する使用経験-新規投与試験切り換え投与試験-腎と透析 45:823-836, 1998

• 17) Fritsche L, Budde K, Farber L et al:Treatment of membranous glomerulopathy with cyclosporin A:how much patience is required? Nephrol Dial Transplant 14:1036-1038, 1999
  pubmed

• 18) Kitano Y, Yoshikawa N, Tanaka R, Nakamura H, Ninomiya M, Ito H:Ciclosporin treatment in children with steroid-dependent nephrotic syndrome, Pediatr Nephrol 4:474-477, 1990
  pubmed

• 19) Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H:Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome, Pediatr Nephrol 7:249-252, 1993
  pubmed

• 20) Inoue Y, Iljima K, Nakamura H, Yoshikawa N:Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome, Pediatr Nephrol 13:33-38, 1999

• 21) Iljima K, Hamahira K, Kobayashi A, Nakamura H, Yoshikawa N:Immunohistochemical analysis of renin activity in chronic cyclosporkme nephropathy in childhood nephrotic syndrome, J Am Soc Nephrol 11:2265-2271, 2000

• 22) Hamahira K, Iljisma K, Tanaka R, Nakamura H, Yoshikawa N:Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome, in press

• 23) 池田昌弘,本田雅敬:ステロイド依存性ネフローゼ症候群の治療,腎と透析 50:353-356, 2001

• 24) Report of the Canadian Neoral Renal Transplantation Study Group. A randomized, prospective multi-center pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Transplantation 62:1744-1752, 1996

P.314 掲載の参考文献

• 1) (社) 日本アイソトープ協会医学薬学部会,核医学イメージング規格化専門委員会:標準的なイメージングプロトコール,Radioisotopes 43:81-114, 1994

• 2) 伊藤和夫,油野民雄:臨床腎臓核医学,メディカルレビュー,東京,1997

• 3) 島田憲次,谷澤隆邦:小児腎臓核医学,メディカルレビュー,東京,1998

P.316 掲載の参考文献

• 1) Barker DF et al:Identification of mutations in the COL4A5 collagen genes in Alport syndrome, Science 248:1224-1227, 1990
  pubmed

• 2) Mochizuki T et al:Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in auto-somal recessive Alport syndrome, Nat Genet 8:77-81, 1994

• 3) Ninomiya Y et al:Differential expression of two basement membrane collagen genes, COL4A6 and COIAA5, demonstrated by immunofluorescence staining using Peptide-specific monoclonal anti-bodies, J Cell Biol 130:1219-1229, 1995

• 4) Naito I et al:relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome, Kidney Int 50:304-311, 1996
  pubmed

• 5) Nomura S et al:Molecular genetic and immunohistochemical study of autosomal recessive Alport's syndrome, Am J Kidney Dis 31:E 4, 1998

• 6) Kagawa M et al:Epitope-defined monoclonal anti-bodies against type-IV collagen for diagnosis of Alport's syndrome, Nephrol Dial Transplantation 12:1238-1241, 1997

技術資料編

P.320 掲載の参考文献

• 1) 吉川隆-:糖尿病:診療と研究の進歩,2.糖尿病性腎症,日内会誌 85:546-550, 1996

• 2) 小幡賢一,酒井智恵,大角誠治,丸池 寛, 吉田真一:尿中IV型コラーゲンの酵素免疫測定法,臨床検査機器試薬 18:439-444, 1995

• 3) 厚生省:平成9年度慢性腎不全研究報告書:320

• 4) 家城恭彦,高桜英輔,小幡賢一:2型糖尿病患者における尿中IV型コラーゲン測定の意義, 新薬と臨床 48:1408-1412, 1999
  Medical*Online

P.323 掲載の参考文献

• 1) 古吉重雄,南光聡毅,高田 覚,谷 叙孝:直接血液灌流型β2M吸着器(BM-01) のβ2M 除去性能,人工臓器 23:439-444, 1994

• 2) 中谷勝,古吉重雄,高田 覚,谷敍孝:透析アミロイドーシス治療用直接血液灌流型吸着器「リクセル」の吸着特性,人工臓器 27:571-577, 1998

• 3) 下条文武,本間則行,長谷川伸,荒川正昭, 中澤了一,東仲宣,鈴木満,三村信英:透析アミロイドーシスに対する直接血液灌流型β2-M吸着器(BM-01) の臨床評価,腎と透析 37:749-756, 1994

• 4) 中澤了一,長谷川真二,小林政美,佐々木正明, 浜 成司,渋谷泰史,今井裕二,中村 誠, 松金隆夫,小金沢 修,東 仲宣,鈴木 満:β2-microglobulinの選択的吸着器BM-01の臨床応用,透析会誌 26:1763-1770, 1993

• 5) 中澤了一:β2-ミクログロブリン吸着カラムによる治療,臨床透析 13:1253-1259, 1997

• 6) 下条文武,川口良人,原 茂子,中澤了一, 東 仲宣,小川洋史,甲田 豊,鈴木正司, 金田 浩,岸本秀文,小田瑞枝,恵 京仔, 宮崎良-,丸山弘樹,荒川正昭,原 満:透析アミロイドーシスに対する直接血液灌流型β2-ミクログロブリン吸着器「リクセル(R)」の臨床効果:前向き多施設コントロールβ2-ミクログロブリン吸着器スタディ(βMACS) ,腎と透析 46:547-560, 1999

• 7) 南光聡毅,伊藤普治,古吉重雄,谷 叙孝:小型化した吸着型血液浄化器"リクセル"を使用した透析治療時のBMG除去性能シミュレーション,日本医工学治療学会第15回学術 大会抄録集:58, 2000

• 8) 中澤了一,天野 泉,下条文武:リクセルS-15とS-35の臨床的検討=多施設共同研究=,日本透析医学会雑誌 34:752, 2001

• 9) 小川秋広,冨田俊彦,三田地広和,宇都宮壽 彦,児島勝政,天野 泉:β2ミクログロブリン吸着器の小型化とその臨床評価,日本医工学治療学会第16回学術大会抄録集:86, 2001

• 10) 中澤了一:β2マイクログロブリン吸着療法の現状,日本医工学治療学会第16回学術大会抄 録集:71,2001

• 11) リクセル総合説明書 8副作用について,鐘淵化学工業(株) ,p.18, 1997

P.327 掲載の参考文献

• 1) Tani N:Artificial Orgarts 20:922-929, 1996

• 2) Kutsuki H, Takata S, Yamamoto K and Tani N:Therapeutic Apheresis 2:18-24, 1998
  pubmed

• 3) Mabuchi H, Michishita I, Takeda M, Fujita H, Koizumi J, Takeda R, Takeda S and Oonishi M:Atherosclerosis 68:19-25, 1987

• 4) Mabuchi H, Koizumi J, Shimizu M, Kajinami K,Miyamoto S, Ueda K and Takegoshi T:Am J Cardiol 82:1489-1495, 1998
  pubmed

• 5) Koga N and Iwata Y Atherosclerosis 90:9-21, 1991
  pubmed

• 6) Matsuzaki M, Hiramori K, Kitabatake A,Hishida H, Fuijii T, Sakuma I, Fukarni K,Honda T,and Ogawa H:Circulation 100:1-82, 1999

• 7) 阿岸鉄三,田辺達三,西村昭男,古川欽一, 宮本 魏,大石喜六,三島好雄:脈管学 32:333-340, 1992

• 8) 土田博光,石丸 新,森島 茂,中尾俊之:組織培養工学 24:41-44, 1998

• 9) 重松 宏,赤羽紀武,石丸 新,岩井武尚, 梅津荘一:Ther Res 21:955-963, 2000
  Medical*Online

• 10) 酒井聡一,宗 正敏,飯野靖彦,大坪 修, 杉野信博:腎と透析 33:321-328, 1992

• 11) Yokoyama K, Sasaki T, Sigematu T, Takemoto F Hara S, Yamada A, Kawaguchi Y, and Hosoya T:Clinical Nephrology 50:1-7, 1998

• 12) Muso E, Mune M, Fuji Y, lmai E, Ueda N, Hatta K,Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T and Tsubakihara Y:56:S-122-S-125, 1999

• 13) Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K and Sasayama S:Nephrol Dial Transplant 9:257-264, 1994
  pubmed

• 14) 鈴木王洋,川越光博,菊池正俊,中野正明, 荒川正明,長沼信治,阿岸鉄三,佐中 孜, 船内正憲,堀内 篤:Prog Med 11:3007-3021, 1991

• 15) Hashimoto H, Tsuda H, Kanai Y, Kobayashi S, Hirose S, Shinoura H, Yokohari R, Kinoshita M, Aotsuka S, Yanada H, Takahashi K, Yoshinoya Sand Miyamoto T:The Journal of Rheumatology 18:545-551, 1991

• 16) Suzuki K, Hara M, Harigai M, Ishizuka T, Hirose T,MatSuki Y, Kawaguchi Y, Kitani A, Kawagoe Mand Nakamura H:Arthritis and Rheumatism 34:1546-1552, 1991

• 17) 大石徹也,長宅芳男,槙野博史,平田教至, 川崎秀考,小倉俊朗,平川秀三,太田善介:腎と透析 36:349-354, 1994

P.336 掲載の参考文献

• 1) 小路久敬,三永昌弘,酒井良忠ほか:エンドトキシン除去カラム(PMX) の設計と開発, およびその臨床への適用,人工臓器 22:204-211, 1993

• 2) Shoji H, Tani T, Hanazawa K et al:Extracorpo-real endotoxin removal by polymyxin B immobilized fiber cartridge:Designing and antiendotoxin efficacy in the clinical application, Therapeutic Apheresis 2:3-12, 1998

• 3) The ACCP/SCCM consensus conference committee:Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Chest 101:1644-1655, 1992

• 4) 前川武男,矢吹清隆,佐藤浩一ほか:大腸穿孔症例に対するエンドトキシン吸着法の有効性について,日臨外会誌 59:2734-2739, 1998

• 5) Rangel-Frausto MS, Pittet D, Costigan M et al:The natural history of the systemic inflammatory response syndrome(SIRS) , JAMA 273:117-123, 1995
  pubmed

• 6) 長沼達史,八木眞太郎,黒田久弥ほか:下部消化管穿孔-予後判定と治療法の選択,特に PMXの適応と効果について,小玉正智編著:エンドトキシン吸着療法,自然科学社,p 69-76, 2000

• 7) Knaus WA, Draper EA, Wagner DP et al:APACHE II:Aseverity of disease classification system, Crit Care Med 13:818-829, 1985
  pubmed

• 8) 轟木秀一,日暮愛一郎,永田貴久ほか:エンドトキシン除去治療の併用が奏功した重症敗血症の2手術例,日消外会誌 29:2319-2323, 1996

• 9) 小野山裕彦,山本正博,山崎 巌ほか:急性閉塞性化膿性胆管炎とSIRS,消外 18:185-191, 1995

• 10) 谷川健次,伊佐地秀司,川原田嘉文:急性胆管炎,小玉正智編著:エンドトキシン吸着療法,自然科学社,p 85-91, 2000

• 11) Montgomery AB, Stager MA, Carrico CJ et al:Causes of mortality in patients with ARDS, Am J Respir Dis 132:485-489, 1985

• 12) 津島健司,久保恵嗣:Acute respiratory distress syndrome(ARDS) ,小玉正智編著:エンドトキシン吸着療法,自然科学社,p 107-114, 2000

• 13) 岡崎由希子,柳 富子,中原康雄ほか:急性白血病の化学療法中に敗血症性ショックを合併し早期のエンドトキシン吸着療法が有効であった2症例,第5回エンドトキシン血症治療研究会プログラム抄録集,p 11, 2001

• 14) Varga K, Wagner JA, Bridgen DT et al:Plateletand macrophage-derived endogenous camabinoids are involved in endotoxin-induced hypotension, FASEB J 12:1035-1044, 1998
  pubmed

• 15) 丸山征郎:ポリミキシンカラム(トレミキシン) の分子標的と作用機序,日本アフェレーシス学会雑誌 20:69-74,2001

• 16) Hoshiai K, Hattan N, Fukuyama N et al:Increased plasma tetrahydrobiopterin in septic shock is a possible therapeutic target, Patho-physiology 7:275-281, 2001

• 17) Bone RC:Sir Issac Newton, sepsis, SIRS, and CARS, Crit Care Med 24:1125-1128, 1996

• 18) 堀田 修:細胞性免疫に対する検討,小玉正 智編著:ンドトキシン吸着療法,自然科学社, p 121-126, 2000

P.339 掲載の参考文献

• 1) F Gejyo et al:A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobuhn, Biochem Biophys Res Commun 129:701-706, 1985

• 2) I Aoike for the Nilgata Research Programme for β2-Microglobuhn Removal Membrane:Long-term clinical experience with PMMA membrane, Contrib Nephrol Basel Karger 125:205-212, 1998

• 3) 吾妻眞幸ら:東レポリスルホン膜(トレスルホンBS) の臨床評価,腎と透析 38 別冊ハイパフォーマンスメンブレン95:129-134, 1995

• 4) 松崎竜児ら:(株) 東レ社製"トレスルホン" 改良型透析器BS-Uタイプの臨床評価,腎と透析 43 別冊ハイパフォーマンスメンブレン97:114-117, 1997

• 5) 森本嘉純ら:大孔径化ポリスルホン膜透析器の性能評価,腎と透析43別冊ハイパフォーマンスメンブレン97:122-124, 1997

• 6) 小川-ら:各社ポリスルホン膜の抗血栓性の違いについて,日本医工学治療学会誌 10:55-58, 1998

• 7) 山崎浩子ら:各種透析器からのビスフェノール Aの溶出に関する検討,腎と透析49別冊ハイパフォーマンスメンブレン2000:28-32, 2000

P.342 掲載の参考文献

• 1) 秋葉 隆ほか:各種血液浄化法の機能と適応-血液浄化器の性能評価法と機能分類,透析会誌 29(8) :1231-1245, 1996

• 2) 斎藤章子ほか:ポリマーアロイPEPA膜透析器の臨床評価,腎と透析32別冊ハイパフォーマンスメンブレン92:62-65, 1992

• 3) 保科 繁ほか:親水化PEPA膜ダイアライザーNXF-15GWの安全性の確認と臨床評価,腎と透析 47 別冊ハイパフォーマンスメンブレン 99:59-63, 1999

P.347 掲載の参考文献

• 1) 中川成之輔:腹膜灌流と CAPD の原理,太田和夫 中川成之輔編:CAPDの臨床,南江堂, 東京,P5-17, 1984

• 2) Nolph K D et al:Equilibration of peritoneal dialysis solutions during long-dwell exchanges. J Lab Clin Med 93:246-256, 1979
  pubmed

• 3) Pyle W K et al:Peritoneal transport evaluation in CAPD. In edited by Moncrief, J W et al:CAPD Update 35-52,Masson Publishing USA, 1981

• 4) 太田和夫ほか:慢性腎不全患者に対するPD-2 を用いた CAPD 療法の臨床効果と安全性についての検討,臨床透析1(8) :1117-1129, 1985

• 5) Twardowski Z J et al:0smotic agent and ultrafiltration in peritoneal dialysis. Nephron 42:93-101, 1986

• 6) Feriani M et al:CAPD systems and solutions. In edited by Gokal, R and Nolph, KD:The Text-book of Peritoneal Dialysis 233-270, The Netherlands, Kluwer Academic Publishers, 1994

• 7) Mactier R A and Khalma R, Peritoneal Lymphatics. In edited by Gokal R and Nolph K D:The Textbook of Peritoneal Dialysis 115-134, The Netherlands, Kluwer Academic Publishers, 1994

• 8) Mistry CD, Gokal R, Peers E, the MIDAS Study Group:A randomized multicenter clinical trial comparing isosmolar icodextrin With hyperos-molar glucose solutions in CAPD, Kidney Int 46:496-503, 1994

• 9) Posthuma N, Wee PMter, Verbrugh HA, Oe PL, Peers E et al:lcodeXtrin instead of glucose during the dayttme dwell in CCPD increase Ultrafiltration and 24-h dialysate creatinine clearance, Nephrol Dial Transplant 12:550-553, 1997
  pubmed

• 10) Ho-dac-Pannekeet MM, Schouten N et al:Peritoneal transport characteristics with glucose polyrner based dialysate, Kidney Int 50:979-986, 1996
  pubmed

P.352 掲載の参考文献

• 1) 土谷太郎,尾鍋 隆ほか:広島医学 22:201-222, 1969

• 2) 北岡建樹,関口 孝ほか:日本臨床 43:361-376, 1985
  Medical*Online

• 3) 三村信英:新内科学大系第 5 巻 A:227-229, 1976

• 4) Kaye M, R Mangel et al:Proc Europ Dial Transpl Ass 3:17-23, 1966

• 5) 小出 輝:新内科学大系第 42 巻:167-179, 1974

• 6) Posen GA, Kaye M:Proc Europ Dial Transpl Ass 4:224-230, 1964

• 7) Mion CM, Hegstrom RM et al:Trans Amer Soc Artif Int Org 10:110-113, 1964

• 8) 澤西謙次,原 晃,川村寿-ほか:泌尿器科紀要 23:509-518, 1977

• 9) 今忠正:新薬と臨床26:189-191,1977

• 10) 平沢由平,大森 伯,鈴木正司:新薬と臨床 26:319-329, 1977
  Medical*Online

• 11) 水谷洋子,山本忠司,野崎寛爾,山川 眞ほか:人工透析研究会会誌 13:539-545, 1980

• 12) 藤見 惺,中本雅彦,執行直行ほか:人工透析研究会会誌 14:231-239, 1981

• 13) 吉田文直:薬理と治療 10:1089-1094, 1982
  Medical*Online

• 14) 阿部富彌,平沢由平,前川正信,前田貞亮ほか:薬理と治療 5:3299-3320, 1987

• 15) 阿部富彌,平沢由平,前川正信,前田貞亮ほか:薬理と治療 15:3787-3812, 1987

• 16) 中山文義,奥山 寛,大友正浩ほか:人工臓器 18:1220-1224, 1989

• 17) 越川昭三,黒川 清,前川正信ほか:薬理と治療 19:1637-1676, 1991
  Medical*Online

• 18) 丸茂文昭,浅野泰,平澤由平ほか:薬理と治療 23:139-157, 1995
  Medical*Online

• 19) 丸茂文昭,浅野泰,平澤由平ほか:薬理と治療 23:159-178, 1995
  Medical*Online

• 20) 越川昭三,三村信英,平澤由平:腎と透析 11:665-675, 1981

• 21) 越川昭三,前川正信,平澤由平ほか:薬理と治療 21:843-889, 1993
  Medical*Online

• 22) 児島弘臣ほか:人工臓器 14:144-148, 1985

P.354 掲載の参考文献

• 1) Maggiore Q, Pizzarelli F, Zoccali C et al:Effect of extra-corooreal blood coohng on dialytic arterial hypotension, Proc Eur Dial Transplant Assoc 18:597-602, 1981

• 2) Gotch FA, Keen ML, Yarian SR et al:An analysis of thermal regulation in hemodialysis With one and three compartment models, ASAIO Trans 35:622-4, 1989
  pubmed

P.356 掲載の参考文献

• 1) Kaplow LS, Goffint JA:Profound neutropenia during the early phase of haemodialysis, JAMA 203:1135-1137, 1968

• 2) Craddock PR, Fehr J Dalmasso AB et al:Haemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membrane, J Clin Invest 59:879-888, 1977

• 3) 池田 裕,中村藤夫,鈴木正司ほか:ポリスルホン膜透析器PS-1.6UWおよびPS-1.6Nの性能評価,腎と透析vol. 36:78-83, 1994

• 4) Tielemans C, Madhoun P, Lenaers M et al:Aanphylactoid reactions during hemodialysis on AN 69 membranes in patients receiving ACE inhibitors, Kidney Int 38:982-984, 1990

• 5) Schaefer RM, Fink E, Schaefer L et al:Role of Bradykinin in Anaphyactoid reaction durinh haemodialysis with AN 69 dialyzers, Am J Nephro 113:473-477, 1993

• 6) 小久保謙一,薬師寺大二,酒井清孝:膜構造の異なるポリスルホン膜の透水性および溶質透過性,腎と透析 38:86-88, 1995

• 7) Schaefer RM, Horl WH, Gilge U et al:Biocompatibility profile of the polysulfone 400 membrane, Contrib Nephrol 74:43-51, 1989
  pubmed

• 8) Horl WH, Riegel W, Steinhauer HB et al:Granulocyte activation during hemodialysis, Clin Nephrol 26 Suppl 1:S 30-4, 1986

• 9) Jadoul M, Saitoh A, Kurokawa K et al:Influence of hemodialysis membrane type on pentosidine plasma level, a marker of"carbonyl stress", Kidney Int 55:2487-2492, 1999

• 10) Kuchle C, Fricke H, Held E et al:High-flux hemodialysis postpones clinical manifestation of dialysis-related amy-loidosis, Am J Nephrol 16:484-488, 1996

• 11) 田中 寛,西川 治,湯川 進ほか:透析膜が維持透析患者の血清脂質プロフィールに与える影響,日腎誌 41:1-7, 1999

• 12) McCarthy JT, Jenson BM, Squillace DP et al:Improved preservation of residual renal function in chronic hemo-dialysis patients using Polysulfone dialyzers, Am J Kidney Dis 29:576-583, 1997

P.358 掲載の参考文献

• 1) Nassberger L, Arbin A, Ostelius J:Exposure of patients to phthalates from polyvinyl chloride tubes and bags during dialysis, Nephron 45:286-90, 1987
  pubmed

• 2) Mettang T, Thomas S, Kiefer T et al:The fate of leached di(2-ethylhexyl) phthalate in patients undergoing CAPD treatment, Peritoneal Dialysis lnternational 16:58-62, 1996

• 3) Mettang T, Escher FP, Dunst R et al:Plasticizers in renal failure:aspects of metabohsm and toxicity, Peritoneal Dialysis International 17 Suppl 2:S 31-6, 1997

• 4) Kluwe WM, Haseman JK, Douglas JF et al:The carckmogenicity of dietary di(2-ethylhexyl) phthalate(DEHP) in Fischer 344 rats and B6C3FI mice, J Toxicol Environmen Health 10:797-815, 1982

• 5) Sjoberg P, Bondesson U, Gray TJ et al:Effects of di-(2-ethylhexyl) phthalate and five of its metabolites on rat testis in vivo andd in in vitro Acta Pharmacol Toxicol 58:225-33, 1986

• 6) Labow RS, Barry YA, Tocchi M et als:The effect of mono(2-ethylhexyl) phthalate on an isolated perfused rat heart-lung Preparation, Environmen Health Perspect 89:189-93, 1990

• 7) Fracasso A, Coli U, Landini S et al:Peritoneal sclerosis. Role of plasticizers, ASAIO Transactions 33:676-82, 1987
  pubmed

• 8) Woodward KN:Phthalate esters, cystic kidney disease in animals and possible effects on human health:a review, Human Experiment Toxicol 9:397-401, s 1990

P.366 掲載の参考文献

• 1) 木野 亨免疫抑制剤FK506の発見と開発バイオサイエンスとインダストリー:52,No. 10:801-804(1994)

• 2) 奥原正国,後藤俊男,木野 亨,細田 純而:免疫抑制剤タクロリムス(FK506) の発見と開発:日本農芸化学会誌70,No.1:1-8(1996)

• 3) Liu J et al:Calcineurin ia a common target of cyclophilin-cyclosporirll A and FKBP-FK506 complexes, Cell 66:807-815, 1991

• 4) Fruman DA et al:Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A, Proc Natl Acad Sci USA 89:3686-3690, 1992

• 5) 0'Keefe DA et al:FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calci-neurin, Nature 357:692-694, 1992

• 6) Tocci MJ et al:The imlnunosuppressant FK506 selectively inhibits expression of early T cell activation genes, J Immunol 143:718-726, 1989

• 7) Shibasaki F et al:Role of kinases and the phosphatase calcineurin in the nuclear shuttling of trartscription factor NF-AT4, Nature 382,370-373, 1996
  pubmed

• 8) Laskow DA et al:An open-label, concentrationranging trial of FK506 in prirnary kidney transplantation:a report of the United State Multi-center FK506 Kidney Transplant Group, Transplantation 15,62:900-905, 1996

• 9) Vincenti F et al:Tacrolimus(FK506) in Kidney Transplantation:Five-Year Survival Results of the U.S. Multicenter, Randomized, Comparative Trial, Transplant Proc 33:1019-1020, 2001
  pubmed

• 10) Dumont Fj et al:Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes, J Pharmacol Exp Ther 268, 1:32-41, 1994

• 11) Halloran p:Calcineurin inhibition-relationship to cyclosporin blood concentration.:Foucus on Medicine 13:15-18, 1998

• 12) Pernille B et al:Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation.:AST 2001 Abstract No.1076.

P.371 掲載の参考文献

• 1) 大道雄一郎ほか:Ho:YAGレーザーの泌尿器科領域経の応用,第16回日本レーザー医学会大会 大会論文集p 135-138,1996

P.376 掲載の参考文献

• 1) 小室勢津子ほか:活性型ビタミンD3のフッ素誘導体 ST-630 の体内動態(第2報) ,薬物動態 11:518, 1996
  Medical*Online

• 2) 勝又隆ほか:ファレカルシトリオールの主要代謝物 ST-232 の生物活性に関する検討,基礎と臨床 30:2991, 1996
  Medical*Online

• 3) 小室勢津子ほか:活性型ビタミンD3のフッ素誘導体 ST-630 の体内動態(第1報) ,薬物動態 11:505, 1996
  Medical*Online

• 4) 小室勢津子ほか:活性型ビタミンD3のフッ素誘導体 ST-630 の体内動態(第3報) ,薬物動態 11:530, 1996
  Medical*Online

• 5) 小室勢津子ほか:活性型ビタミンD3のフッ素誘導体 Falecalcitriol の体内動態(第11報) ,基礎と臨床 30:2915, 1996

• 6) 津島直美ほか:5/6 腎摘除ラットの二次性副甲状腺機能亢進症および骨病変に対するファレカルシトリオールの改善効果,基礎と臨床 30:2963, 1996
  Medical*Online

• 7) 勝又 隆ほか:ファレカルシトリオールの生物活性に関する検討,基礎と臨床 30:2955, 1996

• 8) Miyahara T et al:Effects on cultured neonatal mouse calvaria of 1α,25-dihydroxy Vitamin D3, 26,26,26,27,27,27-hexafluoro-1α,25-dihydroxyvitamin D3 and 26,26,26,27,27,27-hexafluoro-1α, 23S,25-tnhydroxyvitamin D3, Bone and Mineral 18:41, 1992

• 9) Morii H et al:Efficacy and safety of oral falecalcitriol in reducing Parathyroid hormone in hemodialysis patients with secondary hyperpara-thyroidism, J Bone Miner Metab 16:34, 1998

• 10) Moni H et al:Efficacy and safety of long-term oral falecalcitriol treatment in patients with renal osteodystrophy, J Bone Miner Metab 16:44, 1998

P.380 掲載の参考文献

• 1) 武永美津子,北川晴雄,平井愛山ほか:Dilazep のヒト血小板膜リン脂質代謝およびアラキドン酸カスケードに及ぼす作用,動脈硬化 12:363-370, 1984

• 2) Inage H, Koyama A, Narita M et al:Effects of the antiplatelet agents, dipyridamole and dilazep dihydrochloride, on in vivo platelet function and proteinuria, Jpn J Nephrol 27:1261-1270, 1985

• 3) 松山公彦,長瀬光昌,本田西男:糸球体腎炎における Dilazep Dihydrochloride の血小板機能に及ぼす影響,基礎と臨床 18:6427-6436, 1984
  Medical*Online

• 4) Nagase M, Kobayashi S, Sakakibara K et al:Amelioration of albuminuria induced by dilazep a(lministration in aminonucleoside nephrosis of rats, Jpn J Nephrol 27:385-391, 1985

• 5) Yukimura T, Miura K, Ito K et al:Renal vascular effects of dilazep antagonized by 3-isobutyl-1-methyl-xanthine:J Cardiovas Pharmacol 8:649-655, 1986

• 6) Inage H, Koyama A, Narita M et al:Effects of dilazep dihydrochloride(Dilazep) and its dosedependent influence on rabbit acute serum sickness nephritis, Jpn J Nephrol 27:1253-1260, 1985

• 7) Hayashi T, Kaneko S, Thang NT et al:Effect of Dilazep Hydrochloride on the lmmunohistopa-thology of IgA Nephropathy in ddY Mice, Nephron 86:327-332, 2000

• 8) Gohda T, Makita Y, Shike T et al:Dilazep Hydrochloride, an Antiplateret Drug, Inhibits Lipopolysaccharide-lnduced Mouse Mesangial Cell IL-6 Secretion and Prohferation, Kidney Blood Press Res 24:33-38, 2001

• 9) 東條静夫,本田西男,柴田昌雄ほか:慢性糸球体腎炎に対する AS-05(Dilazep) の臨床評価-全国多施設協同二重盲検試験-,腎と透析 20:289-313, 1986

P.385 掲載の参考文献

• 1) 尾形悦郎,須田立雄,小椋陽介編:ビタミン Dのすべて,講談社サイエンティフィック,p 1, 1993

• 2) 森井浩世編:透析医学の文化と技術,医薬ジャーナル社:p 106, 1999

• 3) 石村栄治:Clinical Calcium 10(11) :1450, 2000

• 4) 黒川清監修:腎と骨代謝ハンドブック,日本メディカルセンター,2000

• 5) 田畑 勉,西沢良記:Prog Med 16:1991, 1996
  Medical*Online

• 6) 渡邊有三ら:腎と透析48(4) :485, 2000

• 7) 黒川清監修:透析骨病変―新しい考え方,日本メディカルセンター,p 203, 1999

• 8) 中澤了一:腎と透析 48(4) :490, 2000

• 9) 尾形悦郎,須田立雄,小椋陽介編:ビタミン Dのすべて,講談社サイエンティフィック p 19, 1993

• 10) M Fukushima et al:Biochemistry 170:495, 1978

• 11) Y Seino et al:Bone and Mineral 2:479, 1987

• 12) 久保俊英,清野佳紀:ホルモンと臨床 43:43, 1995

• 13) D P McDomell et al:Science 235:1214, 1987

• 14) A R Baker et al:Proc Natl Acad Sci USA 85:3294, 1988

• 15) J R Bumester, N Maeda:H F DeLuca Proc Natl Acad Sci USA 85:1005, 1988

• 16) Marj a Ala-Houhala et al:Pediatr Nephro 9:737, 1995

• 17) Slatopolsky E, Weerts C, Thielan J et al:J Clin Invest 74(6) :2136, 1984
  pubmed

• 18) 渡邊有三ほか:腎と骨代謝 8(2) :149, 1995

• 19) 岡島英五郎ほか:日腎誌 37(10) :1117, 1990

• 20) Tsukarnoto Y et al:Nephron 57:23, 1991
  pubmed

• 21) Tilman B Brueke:Am J of Kid Dis 37(Supp 12) :S 58, 2001

• 22) Christiansen C et al:Lancet 30:700, 1978

• 23) 小川良雄ほか:西日泌尿 60:92, 1998

• 24) Hamdy NA et al:Brit Med J 310:358, 1995
  pubmed

• 25) Coen G et al:Miner Electrolyte Metab 12:375, 1986
  pubmed

• 26) Baker LRI et al:Kidney lnt 35:661, 1989

• 27) 栗原怜:Clinical Calcium 9(6) :734, 1999

• 28) Monier-Faugere MC et al:Kidney Int 55:821, 1999
  pubmed

• 29) Okumura H et al:Bone Mineral 9(2) :101, 1990
  pubmed

• 30) H FIeisch:Bisphophonates in Bone Disease From the Laboratory to the Patient, Fourth Edition, Academic Press, 2000

P.389 掲載の参考文献

• 1) 中井 滋ら:わが国の慢性透析療法の現況 (1999年12月31日現在) ,透析会誌 34:1, 2001

• 2) Evans et al:Ion-exchange resins in the treatment of anuria, Lancet 17:791, 1953

• 3) Berlyne et al:Dangers of resonium a in the treatment of hyperkalemia in renal failure, Lancet 1:167, 1966

• 4) Berlyne et al:Treatment of hyperkalemia with a calcium-resin, Lartcet 1:170, 1966

• 5) Payne et al:Uptake of small resins particles(1-5μ diameter) by the alimentary canal of the calf, Nature 188:586, 1960

• 6) Rashid et al:Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate(kayexalate) in sorbitol, Am Surg Pathol 21:60, 1997
  pubmed

• 7) Gerstman et al:Intestinal necrosis associated With postoperative orally admmistered sodium polystyrene sulfonate in sorbitol, Ann J Kidney Dis 20:159, 1992

• 8) Lillemoe et al:Intestinal necrosis due to sodium polystyrene(kayexalate) in sorbitol enemas:clinical and experimental support for the hypothesis, Surgery 101:267, 1987
  pubmed

• 9) Wootton et al:Colonic necrosis with kaye-xalate-sorbitol enemas after renal transplantation, Am Intem Med 111:947, 1989

• 10) Thomas et al:Colonic necrosis following sodium polystyrene sulfonate(kayexalate-sorbi-tol enema in a renal transplant patient, Dis Colon Rectum 36:607, 1993

• 11) Frohnert et al:Resin treatment of hyperkalemia 1. exchange properties of a cation exchange resin(calcium cycle) ,J Lab Clin Med 71:840, 1968

• 12) 星 猛ら:9.大腸における吸収,本郷利憲編集:標準生理学第2版,医学書院,東京,p 643-645, 1989

• 13) 鈴木好夫ら:ポリスチレンスルホン酸カルシウム(カリメート) の腎不全に伴う高カリウム血症に対する血清カリウム値の抑制効果, 診療と保険15:1794,1973

• 14) 厚生省薬務局安全課:(3) ポリスチレンスルホン酸カルシウム,医薬品副作用情報 40:9, 1979

• 15) 大林誠-ら:高P血症と高K血症を合併した腎不全患者におけるCa型レジン(カリメート) の使用経験(第2報) ,診療と新薬 35:308, 1998

P.395 掲載の参考文献

• 1) ローディアル75製品説明書

• 2) AN69 膜関係文献集 No.6 Biofiltration

• 3) AN69 膜関係文献集 No.10 Acetate Free Biofiltration

• 4) AN69 膜関係文献集 No.13「血液容量をコントロールする透析療法―血行動体への作用―」

P.398 掲載の参考文献

• 1) Chatenoud L et al:Antigenic modulation-a major mechanism of antibody action, Immunol Today 5:20-25, 1984

• 2) 太田和夫ほか:腎移植後の急性拒絶反応に対する muromonab CD3 の治療効果,腎と透析 27:143-156, 1989

• 3) 伊藤克己ほか:小児腎移植後の急性拒絶反応に対するmuromonab CD3の治療効果,小児科臨床42:1551-1560, 1989